US20050003986A1 - Useful mutations of bacterial alkaline protease - Google Patents
Useful mutations of bacterial alkaline protease Download PDFInfo
- Publication number
- US20050003986A1 US20050003986A1 US10/896,177 US89617704A US2005003986A1 US 20050003986 A1 US20050003986 A1 US 20050003986A1 US 89617704 A US89617704 A US 89617704A US 2005003986 A1 US2005003986 A1 US 2005003986A1
- Authority
- US
- United States
- Prior art keywords
- subtilisin
- substitution
- modified subtilisin
- gene
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/38—Products with no well-defined composition, e.g. natural products
- C11D3/386—Preparations containing enzymes, e.g. protease or amylase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
- C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
Definitions
- the present invention relates to mutations of the subtilisin gene which result in changes in the chemical characteristics of subtilisin enzyme. Mutations at specific nucleic acids of the subtilisin gene result in amino acid substitutions and consequently, altered enzyme function. Some of these mutant enzymes exhibit physical properties advantageous to industrial applications, particularly in the detergent industry, providing subtilisins which are more stable to oxidation, possess greater protease activity, and exhibit improved washability.
- Enzymes cleaving the amide linkages in protein substrates are classified as proteases, or (interchangeably) peptidases (See Walsh, 1979, Enzymatic Reaction Mechanisms, W. H. Freeman and Company, San Francisco, Chapter 3).
- Bacteria of the Bacillus species secrete two extracellular species of protease, a neutral, or metalloprotease, and an alkaline protease which is functionally a serine endopeptidase, referred to as subtilisin. Secretion of these proteases has been linked to the bacterial growth cycle, with greatest expression of protease during the stationary phase, when sporulation also occurs. Joliffe et al. (1980, J. Bacterial. 141:1199-1208) has suggested that Bacillus proteases function in cell wall turnover.
- a serine protease is an enzyme which catalyzes the hydrolysis of peptide bonds, in which there is an essential serine residue at the active site (White, Handler, and Smith, 1973, “Principles of Biochemistry,” Fifth Edition, McGraw-Hill Book Company, NY, pp. 271-272).
- the serine proteases have molecular weights in the 25,000 to 30,000 range. They are inhibited by diisopropylfluorophosphate, but in contrast to metalloproteases, are resistant to ethylenediamine-tetra acetic acid (EDTA) (although they are stabilized at high temperatures by calcium ion). They hydrolyze simple terminal esters and are similar in activity to eukaryotic chymotrypsin, also a serine protease.
- EDTA ethylenediamine-tetra acetic acid
- alkaline protease reflects the high pH optimum of the serine proteases, from pH 9.0 to 11.0 (for review, see Priest, 1977, Bacteriological Rev. 41:711-753).
- subtilisin is a serine protease produced by Gram-positive bacteria or fungi.
- subtilisins A wide variety of subtilisins have been identified, and the amino acid sequences of at least eight subtilisins have been determined. These include six subtilisins from Bacillus strains, namely, subtilisin 168, subtilisin BPN′, subtilisin Carlsberg, subtilisin DY, subtilisin amylosacchariticus, and mesentericopeptidase (Kurihara et al., 1972, J. Biol. Chem. 247:29-5631; Stahl and Ferrari, 1984, J. Bacteriol. 158:411-418; Vasantha et al., 1984, J. Bacteriol.
- subtilisins are well-characterized physically and chemically.
- primary structure amino acid sequence
- subtilisin amino acid sequence
- over 50 high resolution X-ray structures of subtilisin have been determined which delineate the binding of substrate, transition state, products, three different protease inhibitors, and define the structural consequences for natural variation (Kraut, 1971, Ann. Rev. Biochem. 46:331-358).
- Random and site-directed mutations of the subtilisin gene have both arisen from knowledge of the physical and chemical properties of the enzyme and contributed information relating to subtilisin's catalytic activity, substrate specificity, tertiary structure, etc. (Wells et al., 1987, Proc. Natl. Acad. Sci. U.S.A.
- subtilisins have found much utility in industry, particularly detergent formulations, as they are useful for removing proteinaceous stains. To be effective, however, these enzymes must not only possess activity under washing conditions, but must also be compatible with other detergent components during storage.
- subtilisin may be used in combination with amylases, which are active against starches; cellulases which will digest cellulosic materials; lipases, which are active against fats; peptidases, which are active on peptides, and ureases, which are effective against urine stains.
- amylases which are active against starches
- cellulases which will digest cellulosic materials
- lipases which are active against fats
- peptidases which are active on peptides, and ureases, which are effective against urine stains.
- subtilisin must be stable with respect to the oxidizing power, calcium binding properties, detergency and high pH of nonenzymatic detergent components. The ability of the enzyme to remain stable in their presence is often referred to
- the present invention relates to mutations of the subtilisin gene, some of which result in changes in the chemical characteristics of subtilisin enzyme. Mutations are created at specific nucleic acids of the subtilisin gene, and, in various specific embodiments, the mutant enzymes possess altered chemical properties including, but not limited to, increased stability to oxidation, augmented proteolytic ability, and improved washability.
- the present invention also relates, but is not limited to the amino acid and DNA sequences for protease mutants derived from Bacillus lentus variants, subtilisin 147 and subtilisin 309, as well as mutations of these genes and the corresponding mutant enzymes.
- Site-directed mutation can efficiently produce mutant subtilisin enzymes which can be tailored to suit a multitude of industrial applications particularly in the areas of detergent and food technology.
- the present invention relates, in part, but is not limited to, mutants of the subtilisin 309 gene which exhibit improved stability to oxidation, augmented protease activity, and/or improved washability.
- FIG. 1 illustrates the insertion of a subset of fragments, ranging from 1.5 kb to 6.5 kb in length, generated by partial digestion of Bacillus lentus strain 309 DNA with Sau 3A restriction endonuclease, into Bam HI cut plasmid pSx50.
- the two resulting plasmids, pSx86 and pSx88, containing the subtilisin 309 gene in opposite orientations, are also shown.
- FIG. 2 illustrates the insertion of Bacillus lentus strain 147 DNA fragments into plasmid pSX56. Partial digestion of strain 147 DNA was performed using Sau 3A restriction endonuclease. Fragments ranging in size from 1.5 to 6.5 kb were then ligated into Bam HI cleaved plasmid pSX56. The product, pSX94, contains the subtilisin 147 gene.
- FIG. 3 illustrates gapped duplex mutagenesis, using the method of Morinaga et al. (1984, Biotechnology 2:636-639). It features two plasmids, pSX93 and pSX119, both derived from puCl3.
- pSX93 contains an XbaI-HindIII fragment of the subtilisin 309 gene
- pSX119 contains the remainder of the subtilisin 309 gene in an EcoRI-XbaI fragment.
- plasmid pSX93 is cleaved with XbaI and ClaI, and the gapped molecules are mixed with pSX93 cut with ScaI, denatured, and allowed to reanneal so as to generate plasmids with a region of single-stranded DNA extending within the subtilisin 309 coding sequence.
- a synthetic oligonucleotide, homologous to the subtilisin 309 gene but containing a mutation, is allowed to anneal to the single stranded gap, which is then filled in using the Klenow fragment of DNA polymerase I and T4 DNA ligase.
- double-stranded mutants of the subtilisin 309 gene are generated.
- the same procedure is performed in (B), using plasmid pSX119 and EcoRI and XbaI enzymes, to create mutations in the corresponding region of the subtilisin 309 gene.
- FIG. 4 illustrates plasmid pSX92, which is a derivative of plasmid pSX62, bearing the subtilisin 309 gene. Mutated fragments (i.e., XbaI - ClaI, XbaI-HindIII, or EcoRI-XbaI), excised from mutation plasmid pSX93 or pSX119 (see FIG. 3 ) using the appropriate restriction endonucleases, were inserted into plasmid pSX92 for expression in B. subtilis strain DN 497.
- Mutated fragments i.e., XbaI - ClaI, XbaI-HindIII, or EcoRI-XbaI
- FIG. 5 illustrates plasmid pSXl43, which contains truncated forms of both subtilisin 309 and subtilisin 147 genes. In vivo recombination between homologous regions of the two genes can result in active protease.
- the invention relates to mutations of the subtilisin gene, some of which result in changes in the chemical characteristics of subtilisin enzyme. Mutations at specific nucleic acids may be generated, and thus, forms of subtilisin can be designed so as to meet the needs of industrial application.
- the invention is based, in part, upon the discovery that nutations of specific nucleic acids in the subtilisin gene can result in enzymes with altered properties.
- enzymes with improved stability to oxidation, augmented protease activity, or improved washing ability can be generated.
- subtilisins for purposes of clarity in description, and not by way of limitation, the invention will be described in four parts: (a) the chemical structure of known subtilisins and subtilisin 147 and 309; (b) methods for producing mutations in the subtilisin gene; (c) expression of mutants of subtilisin and (d) screening of subtilisin mutants for desirable chemical properties.
- subtilisins from various sources can reveal the functional significance of the primary amino acid sequence, and can direct the creation of new mutants with deliberately modified functions. Comparing the amino acid sequence of different forms of subtilisin, while contrasting their physical or chemical properties, may reveal specific target regions which are likely to produce useful mutant enzymes.
- subtilisins The amino acid sequences of at least eight subtilisins are known. These include six subtilisins from Bacillus strains, namely, subtilisin 168, subtilisin BPN′, subtilisin Carlsberg, subtilisin DY, subtilisin amylosacchariticus and mesentericopeptidase (Kurihara et al., 1972, J. Biol. Chem. 247:5629-5631; Stahl and Ferrari, 1984, J. Bacteriol. 158:411-418; Vasantha et al., 1984, J. Bacteriol. 159:811-819; Jacobs et al., 1985, Nucl. Acids Res. 13:8913-8926; Nedkov et al., 1985, Biol.
- subtilisin 147 and 309 the amino acid and DNA sequences for two further serine proteases are revealed.
- proteases were derived from two Bacillus lentus variants, C303 and C360, which have been deposited with NCIB and designated the accession numbers NCIB 10147 and NCIB 10309, respectively.
- the proteases produced by these strains are designated subtilisin 147 and subtilisin 309, respectively, and the genes encoding these proteins are referred to as the subtilisin 147 and 309 genes.
- subtilisin material refers to a proteinaceous material which contains a subtilisin as its active ingredient.
- subtilisin material any serine protease is a subtilisin which has at least 30%, preferably 50%, and more preferably 80% amino acid sequence homology with the sequences referenced above for subtilisin 147, subtilisin 309, subtilisin 168, subtilisin BPN', subtilisin Carlsberg, subtilisin DY, subtilisin amylosacchariticus, mesentericopeptidase, thermitase, proteinase K and thermomycolase.
- subtilisin material refers to a proteinaceous material which contains a subtilisin as its active ingredient.
- any serine protease is a subtilisin which has at least 30%, preferably 50%, and more preferably 80% amino acid sequence homology with the sequences referenced above for subtilisin 147, subtilisin 309, subtilisin 168, subtilisin BPN', subtilisin Carlsberg, subtil
- Table I compares the deduced amino acid sequences of subtilisin 309, subtilisin 147, subtilisin BPN', subtilisin Carlsberg and subtilisin 168 (Spizizen, et al., 1958, Proc. Natl. Acad. Sci. U.S.A. 44:1012-1078).
- Table II presents the nucleic acid sequence of the subtilisin 309 gene
- Table III presents the nucleic acid sequence of the subtilisin 147 gene.
- the sequences of subtilisin 309 or 147, or their functional equivalents, can be used in accordance with the invention.
- subtilisin 309 or 147 depicted in Tables I, II or III can be altered by substitutions, additions or deletions that provide for functionally equivalent molecules.
- other DNA sequences which encode substantially the same amino acid sequence as depicted in Table I may be used in the practice of the present invention. These include but are not limited to nucleotide sequences comprising all or portions of the subtilisin 309 or 147 sequences depicted in Table II or III which are altered by the substitution of different codons that encode the same or a functionally equivalent amino acid residues within the sequence, thus producing a silent change.
- one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity which acts as a functional equivalent.
- Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs.
- the non-polar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine.
- the polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine.
- the positively charged (basic) amino acids include arginine, lysine, and histidine.
- the negatively charged (acidic) amino acids include aspartic and glutamic acid.
- sequences determined for subtilisins 309 and 147 can be compared with sequences of known subtilisins (see Table I) or newly discovered subtilisins in order to deduce sites for desirable mutations. To do this, the closeness of relation of the subtilisins being compared must be determined.
- subtilisins 309 and 147 were compared with one another and with the sequences of other subtilisins (see Table II). Residues that varied between subtilisin 309 or 147 and other subtilisins were identified.
- subtilisin 309 contains a serine residue
- subtilisin 147, subtilisin BPN′, Carlsberg and 168 contain an alanine residue. Therefore, if the serine 153 residue of subtilisin 309 were changed to an alanine residue, the physical properties of subtilisin 309 might be altered in a desired direction.
- subtilisin 147 contains a serine residue at position 218, whereas the other subtilisins expressed an asparagine residue. Because subtilisin 147 has improved thermal stability relative to the other subtilisins, mutating the asparagine 218 of subtilisin 309 to a serine residue might improve the thermal stability of subtilisin 309.
- subtilisin As another example, it was reasoned that, since Thr 71 is close to the active site, the introduction of a negatively charged amino acid, such as aspartic acid, might suppress oxidative attack by electrostatic repulsion.
- the sites that are most likely to be relevant to the physical properties of subtilisin are those in which there is conservation of amino acid residues between most subtilisins, for example Asp-153 and Asn-218 discussed above, and also Trp-6, Arg-170, Pro-168, His-67, Met-175, Gly-219, Arg-275.
- subtilisin substrate specificity The catalytic activities of various subtilisins can differ markedly against selected substrates.
- Wells has shown that only three amino acid substitutions can cause B. amyloliquefaciens subtilisin substrate specificity to approach that of B. licheniformis subtilisin, enzymes that differ by factors of 10-50 in catalytic efficiency in their native state.
- subtilisin 147 and 309 Comparison analysis between subtilisin 147 and 309 and other subtilisins has indicated that mutation of the following sites may alter the physical or chemical properties of subtilisin: 6, 9, 11-12, 19, 25, 36-38, 53-59, 67, 71, 89, 104, 111, 115, 120, 121-122, 124, 128, 131, 140, 153-166, 168, 169-170, 172, 175, 180, 182, 186, 187, 191, 194, 195, 199, 218, 219, 222, 226, 234-238, 241, 260-262, 265, 268, or 275.
- Deletions occur at the following sites in subtilisins 147 and/or 309; insertion of appropriate amino acid residues into these sites might enhance the stability of the parent enzymes: 1, 36, 56, 159, 164-166. According to the method illustrated by these examples, which are not limiting, a number of potential mutation sites become apparent.
- subtilisin genes Many methods for introducing mutations into genes are well known in the art. After a brief discussion of cloning subtilisin genes, methods for generating mutations in both random sites and specific sites within the subtilisin gene will be discussed.
- subtilisin may be cloned from any Gram-positive bacteria or fungus by various methods well known in the art. First a genomic and/or cDNA library of DNA must be constructed using chromosomal DNA or messenger RNA from the organism that produces the subtilisin to be studied. Then, if the amino acid sequence of the subtilisin is known, homologous, labelled oligonucleotide probes may be synthesized and used to identify subtilisin-encoding clones from a genomic library of bacterial DNA, or from a fungal cDNA library.
- a labelled oligonucleotide probe containing sequences homologous to subtilisin from another strain of bacteria or fungus could be used as a probe to identify subtilisin-encoding clones, using hybridization and washing conditions of lower stringency.
- subtilisin-producing clones would involve inserting fragments of genomic DNA into an expression vector, such as a plasmid, transforming protease-negative bacteria with the resulting genomic DNA library, and then plating the transformed bacteria onto agar containing a substrate for subtilisin, such as skim milk. Those bacteria containing subtilisin-bearing plasmid will produce colonies surrounded by a halo of clear agar, due to digestion of the skim milk by excreted subtilisin.
- an expression vector such as a plasmid
- transforming protease-negative bacteria with the resulting genomic DNA library
- subtilisin gene has been cloned into a suitable vector, such as a plasmid, several methods can be used to introduce random mutations into the gene.
- One method would be to incorporate the cloned subtilisin gene, as part of a retrievable vector, into a mutator strain of Eschericia coli.
- Another method would involve generating a single stranded form of the subtilisin gene, and then annealing the fragment of DNA containing the subtilisin gene with another DNA fragment such that a portion of the subtilisin gene remained single stranded.
- This discrete, single stranded region could then be exposed to any of a number of mutagenizing agents, including, but not limited to, sodium bisulfite, hydroxylamine, nitrous acid, formic acid, or hydralazine.
- mutagenizing agents including, but not limited to, sodium bisulfite, hydroxylamine, nitrous acid, formic acid, or hydralazine.
- a specific example of this method for generating random mutations is described by Shortle and Nathans (1978, Proc. Natl. Acad. Sci. U.S.A., 75:2170-2174).
- the plasmid bearing the subtilisin gene would be nicked by a restriction enzyme that cleaves within the gene. This nick would be widened into a gap using the exonuclease action of DNA polymerase I. The resulting single-stranded gap could then be mutagenized using any one of the above mentioned mutagenizing agents.
- subtilisin gene from a Bacillus species including the natural promoter and other control sequences could be cloned into a plasmid vector containing replicons for both E. coli and B. subtilis , a selectable phenotypic marker and the M13 origin of replication for production of single-stranded plasmid DNA upon superinfection with helper phage IR1.
- Single-stranded plasmid DNA containing the cloned subtilisin gene is isolated and annealed with a DNA fragment containing vector sequences but not the coding region of subtilisin, resulting in a gapped duplex molecule.
- Mutations are introduced into the subtilisin gene either with sodium bisulfite, nitrous acid or formic acid or by replication in a mutator strain of E. coli as described above. Since sodium bisulfite reacts exclusively with cytosine in a single-stranded DNA, the mutations created with this mutagen are restricted only to the coding regions. Reaction time and bisulfite concentration are varied in different experiments such that from one to five mutations are created per subtilisin gene on average. Incubation of 10 micrograms of gapped duplex DNA in 4 M Na-bisulfite, pH 6.0, for 9 minutes at 37° C. in a reaction volume of 400 microliters, deaminates about 1% of cytosines in the single-stranded region. The coding region of mature subtilisin contains about 200 cytosines, depending on the DNA strand.
- the reaction time is varied from about 4 minutes (to produce a mutation frequency of about one in 200) to about 20 minutes (about 5 in 200).
- the gapped molecules are treated in vitro with DNA polymerase I (Klenow fragment) to make fully double-stranded molecules and to fix the mutations.
- Competent E. coli are then transformed with the mutagenized DNA to produce an amplified library of mutant subtilisins.
- Amplified mutant libraries can also be made by growing the plasmid DNA in a Mut D strain of E. coli which increases the range of mutations due to its error prone DNA polymerase.
- the mutagens nitrous acid and formic acid may also be used to produce mutant libraries. Because these chemicals are not as specific for single-stranded DNA as sodium bisulfite, the mutagenesis reactions are performed according to the following procedure. The coding portion of the subtilisin gene is cloned in M13 phage by standard methods and single stranded phage DNA prepared. The single-stranded DNA is then reacted with 1 M nitrous acid pH 4.3 for 15-60 minutes at 23° C. or 2.4 M formic acid for 1-5 minutes at 23° C. These ranges of reaction times produce a mutation frequency of from 1 in 1000 to 5 in 1000.
- a universal primer is annealed to the M13 DNA and duplex DNA is synthesized using the mutagenized single stranded DNA as a template so that the coding portion of the subtilisin gene becomes fully double-stranded.
- the coding region can be cut out of the M13 vector with restriction enzymes and ligated into an unmutagenized expression vector so that mutations occur only in the restriction fragment (Myers et al., 1985, Science 229:242-257).
- mutations can be generated by allowing two dissimilar forms of subtilisin to undergo recombination in vivo. According to this method, homologous regions within the two genes lead to a cross-over of corresponding regions resulting in the exchange of genetic information.
- the generation of hybrid amylase molecules according to this technique is fully described in U.S. application Ser. No. 67,992, filed on Jun. 29, 1987, which is fully incorporated herein by reference.
- An example of a plasmid which can generate hybrid forms of subtilisin is depicted in FIG. 5 . Both the subtilisin 309 and 147 genes, incorporated into plasmid pSX143, are truncated, and therefore cannot themselves lead to subtilisin expression.
- subtilisin 309 if recombination occurs between the two genes so as to correct the defect produced by truncation, i.e., the N terminal region of the subtilisin 309 gene becomes linked to the C terminal region of the subtilisin 147 gene, then active, mutant subtilisin can be produced. If pSX143 is incorporated into a protease-negative strain of bacteria, and then bacteria that develop a protease positive phenotype are selected, then various mutants, subtilisin 309/147 chimeras, can be identified.
- subtilisin gene Once the subtilisin gene has been cloned, and desirable sites for mutation identified, these mutations can be introduced using synthetic oligo nucleotides. These oligonucleotides contain nucleotide sequences flanking the desired mutation sites; mutant nucleotides are inserted during oligonucleotide synthesis.
- a single stranded gap of DNA, bridging the subtilisin gene is created in a vector bearing the subtilisin gene.
- the synthetic nucleotide, bearing the desired mutation is annealed to a homologous portion of the single-stranded DNA. The remaining gap is then filled in by DNA polymerase I (Klenow fragment) and the construct is ligated using T4 ligase.
- a fragment within the gene is removed using restriction endonuclease.
- the vector/gene, now containing a gap is then denatured and hybridized to vector/gene which, instead of containing a gap, has been cleaved with another restriction endonuclease at a site outside the area involved in the gap.
- a single-stranded region of the gene is then available for hybridization with mutated oligonucleotides, the remaining gap is filled in by the Klenow fragment of DNA polymerase I, the insertions are ligated with T4 DNA ligase, and, after one cycle of replication, a double-stranded plasmid bearing the desired mutation is produced.
- the Morinaga method obviates the additional manipulation of construction new restriction sites, and therefore facilitates the generation of mutations at multiple sites.
- a mutated subtilisin gene produced by methods described above, or any alternative methods known in the art can be expressed, in enzyme form, using an expression vector.
- An expression vector generally falls under the definition of a cloning vector, since an expression vector usually includes the components of a typical cloning vector, namely, an element that permits autonomous replication of the vector in a microorganism independent of the genome of the microorganism, and one or more phenotypic markers for selection purposes.
- An expression vector includes control sequences encoding a promoter, operator, ribosome binding site, translation initiation signal, and, optionally, a repressor gene.
- nucleotides encoding a “signal sequence” may be inserted prior to the coding sequence of the gene.
- a target gene to be treated according to the invention is operably linked to the control sequences in the proper reading frame.
- Promoter sequences that can be incorporated into plasmid vectors, and which can support the transcription of the mutant subtilisin gene include but are not limited to the prokaryotic beta-lactamase promoter (Villa-Kamaroff, et al., 1978, Proc. Natl. Acad. Sci. U.S.A. 75:3727-3731) and the tac promoter (DeBoer, et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:21-25). Further references can also be found in “Useful proteins from recombinant bacteria” in Scientific American, 1980, 242:74-94.
- B. subtilis is transformed by an expression vector carrying the mutated DNA. If expression is to take place in a secreting microorganism such as B. subtilis a signal sequence may follow the translation initiation signal and precede the DNA sequence of interest. The signal sequence acts to transport the expression product to the cell wall where it is cleaved from the product upon secretion.
- control sequences as defined above is intended to include a signal sequence, when it is present.
- transformed B. subtilis can be cultivated in the presence of a filter material (such as nitrocellulose) to which the secreted expression product (e.g. enzyme) binds.
- a filter material such as nitrocellulose
- the secreted expression product e.g. enzyme
- filter bound expression product is subjected to conditions which distinguish expression product of interest from wild-type expression product.
- the filter-bound expression product can be subjected to conditions which would inactivate a wild-type product.
- Preserved enzyme activity following adverse treatment suggests that the mutation confers enhanced stability on the enzyme, and is therefore a useful mutation.
- screening for stable variants is accomplished using a protease deficient B. subtilis strain transformed with the variant plasmid and plated out as follows: a nitrocellulose filter is placed on a nutrient base in a petri dish, and a cellulose acetate filter is placed on top of the nitrocellulose. Colonies are grown on the cellulose acetate, and protease from individual colonies is secreted through the cellulose acetate onto the nitrocellulose filter where it is stably bound. Protease from hundreds of colonies is bound to a single filter allowing subsequent screening of thousands of different variants by processing multiple filters.
- the filters can be incubated in buffer solutions at temperatures which would inactivate substantially all wild-type activity. Variants of enhanced stability or activity retain activity after this step.
- the suitably treated filter then is soaked in a solution containing Tosyl-L-Arg methyl ester (TAME), Benzoly-Arg-ethyl-ester (BAEE), Acetyl-Tyr-ethyl-ester (ATEE) (Sigma) or similar compounds. Because TAME, BAEE, and ATEE are substrates for the proteases they are cleaved in zones on the filter containing variant subtilisins which remain active after treatment. As cleavage occurs, protons are released in the reaction and cause phenol red to change in color from red to yellow in areas retaining protease activity.
- the filters could be treated at high temperature, at high pH, with denaturants, oxidizing agents, or under other conditions which normally inactivate an enzyme such as a protease to find resistant variants.
- Variants with altered substrate specificity could be screened by replacing TAME, BAEE, or ATEE with other substrates which are normally not cleaved by wild-type subtilisin.
- the colony from which the variant is derived is isolated and the altered subtilisin is purified.
- Experiments can be performed on the purified enzyme to determine conditions of stability towards oxidation, thermal inactivation, denaturation temperature, kinetic parameters as well as other physical measurements.
- the altered gene can also be sequenced to determine the amino acid changes responsible for the enhanced stability. Using this procedure, variants with increased washing abilities have been isolated.
- B. subtilis 309 and 147 are variants of Bacillus lentus , deposited with the NCIB and accorded the accession numbers NCIB 10147 and NCIB 10309, and described in U.S. Pat. No. 3,723,250, issued Mar. 27, 1973, and fully incorporated herein by reference herein.
- B. subtilis DN 497 is described in U.S. application Ser. No. 039,298 filed Apr. 17, 1987, which is also fully incorporated herein by reference, and is an aro + transformant of RUB 200 with chromosomal DNA from SL 438, a sporulation and protease deficient strain obtained from Dr. Kim Hardy of Biogen. E.
- pSX50 (described in U.S. application Ser. No. 039,298, supra) is a derivative of plasmid pDN 1050, comprising the promoter-operator P 1 O 1 the B. pumilus xyn B gene and the B. subtilis xyl R gene.
- pSX65 (described in U.S. application Ser. No. 039,298, supra) is a derivative of plasmid pDN 1050, comprising the promoter-operator P 2 O 2 , the B. pumilus xyn B gene, and the B. subtilis xyl R gene.
- pSX93 shown in FIG. 3A , is puCl3 (Vieira and Messing, 1982, Gene 19:259-268) comprising a 0.7 kb XbaI-Hind III fragment of the subtilisin 309 gene including the terminator inserted in a polylinker sequence.
- pSX119 is pUC13 harboring an EcoRI-XbaI fragment of the subtilisin 309 gene inserted into the polylinker.
- pSX62 (described in U.S. application Ser. No. 039,298, supra) is a derivative of pSX52 (ibid), which comprises a fusion gene between the calf prochymosin gene and the B. pumilus xyn B gene inserted into pSX50 (supra) .
- pSX62 was generated by inserting the E. coli rrn B terminator into pSX52 behind the prochymosin gene.
- pSX92 was produced by cloning the subtilisin 309 gene into plasmid pSX62 (supra) cut at Cla I and Hind III and filled prior to the insertion of the fragments DraI-NheI and NheI-Hind III from the cloned subtilisin 309 gene.
- the procedure relates to a typical purification of a 10 liter scale fermentation of subtilisin 147, subtilisin 309 or mutants thereof.
- the filtrates were concentrated to approximately 400 ml using an Amicon CH2A UF unit equipped with an Amicon S1Y10 UF cartridge.
- the UF concentrate was centrifuged and filtered prior to adsorption on a Bacitracin affinity column at pH 7.
- the protease was eluted from the Bacitracin column using 25% 2-propanol and 1 M sodium chloride in a buffer solution with 0.01 M dimethylglutaric acid, 0.1 M boric acid and 0.002 M calcium chloride adjusted to pH 7.
- the fractions with protease activity from the Bacitracin purification step were combined and applied to a 750 ml Sephadex G25 column (5 cm dia.) equilibrated with a buffer containing 0.01 M dimethylglutaric acid, 0.2 M boric acid and 0.002 M calcium chloride adjusted to pH 6.5.
- protease was eluted using a linear gradient of 0-0.1 M sodium chloride in 2 liters of the same buffer (0-0.2 M sodium chloride in case of subtilisin 147).
- protease containing fractions from the CM Sepharose column were combined and concentrated in an Amicon ultrafiltration cell equipped with a GR81P membrane (from the Danish Sugar Factories Inc.).
- the purified enzyme is diluted to an enzyme content of approximately 0.1 mg/ml in 0.01 M dimethylglutaric acid pH 7 and in the same buffer with 0.01 M peracetic acid (pH 7).
- Both sets of dilutions were heated to 50° C. for 20 minutes. Proteolytic activity was measured in the dilutions before and after the heat treatment.
- Casein Protease Unit CPU
- CPU Casein Protease Unit
- reaction mixtures were kept for 20 minutes in the water bath, whereupon they were filtered through Whatman® 42 paper filters.
- OPA o-phthaldialdehyde
- Disodium tetraborate decahydrate (7.62 g) and sodium dodecylsulfate (2.0 g) was dissolved in 150 ml of water.
- OPA 160 mg
- 4 ml of methanol was then added together with 400 microliters of beta-mercaptoethanol, whereafter the solution was made up to 200 ml with water.
- the OPA test was also performed with a serine standard containing 10 mg of serine in 100 ml of Britton-Robinson buffer (pH 9.5). The buffer was used as a blank.
- CPU /g of enzyme preparation CPU/ml: b wherein OD t , OD b , OD Ser and OD B are the optical density of the test solution, blank, serine standard, and buffer, respectively, C Ser is the concentration of serine in mg/ml in the standard, MW Ser is the molecular weight of serine, Q is the dilution factor (in this instance equal to 8) for the enzyme solution, and t i is the incubation time in minutes.
- Test cloths (7 cm ⁇ 7 cm, approximately 1 g) were produced by passing desized cotton (100% cotton, DS 71) Cloth through the vessel in a Mathis Washing and Drying Unit type TH (Werner Mathis A G, Zurich, Switzerland) containing spinach juice (produced from fresh spinach) and then through the pressure roll of the machine in order to remove excess spinach juice.
- desized cotton 100% cotton, DS 71
- TH Mathis Washing and Drying Unit type TH (Werner Mathis A G, Zurich, Switzerland) containing spinach juice (produced from fresh spinach) and then through the pressure roll of the machine in order to remove excess spinach juice.
- Tests were performed at enzyme concentrations of: 0, 0.05 CPU/1, and 0.1 CPU/l, and two independent sets of tests were performed for each of the mutants.
- Delta R As a measure of the washing ability differential remission, Delta R, was used, Delta R being equal to the remission after wash with enzyme added minus the remission after wash with no enzyme added.
- thermostability of the mutants produced was estimated, by performing the test at temperatures of 40° C. and 60° C., respectively.
- Chromosomal DNA from the “309” strain was isolated by treating a cell suspension with Lysozyme for 30 minutes at 37° C., and then with SDS for 5 minutes at 60° C. Subsequently, the suspension was extracted with phenolchloroform (50:50), precipitated with ethanol, and the precipitate redissolved in TE. This solution was treated with RNase for 1 hour at 37° C.
- chromosomal DNA was partially digested with restriction enzyme Sau 3A (New England Biolabs) and fragments from about 1.5 kb to about 6.5 kb were isolated on DEAE cellulose paper from a 1% agarose gel (the subtilisin gene in other species is approximately 1.2 kb in length).
- the cells were then spread on LB agar plates with 10 mM phosphate pH 7, 6 micrograms/ml chloramphenicol, and 0.2% xylose to induce the xyn-promoter in the plasmid.
- the plates also contained 1% skim milk so the protease producing transformants could be detected by the clear halo where the skim milk had been degraded.
- Protease expressing clones were produced at a frequency of 10 ⁇ 4 . Two clones were found that harbored plasmids carrying the gene for subtilisin 309, pSX86 and pSX88. The gene was then sequenced using the method of Maxam and Gilbert. The deduced nucleotide sequence of subtilisin 309 is presented in Table II.
- subtilisin 147 The same procedure as above was used for the cloning of the subtilisin 147 gene except that the DNA fragments were ligated into the plasmid pSXS6 (also described in U.S. application Ser. No. 039,298 supra), which as indicated in FIG. 2 instead of the xyn promoter harbors the xyl promoter.
- pSXS6 also described in U.S. application Ser. No. 039,298 supra
- One clone was found harboring a plasmid, pSX94, carrying the gene for subtilisin 147. The sequence for this gene is shown in Table III below.
- a 27-mer mismatch primer, Nor-237 which also generates a novel SacI restriction site 5′ CACAGTATGGGCGCAGGGCTTGACATTGTCGCACCA GG 3′ NOR-237 5′ GTATGGCGCA GAGCTCG ACATTTGTCGC 3′ SacI b) Gly-195-Asp:
- a 23-mer mismatch primer, NOR-323 which also generates a novel BglII site AT 5′ CACAGTATGGGCGCAGGGCTTGACATTGTC 3′ 3′ CATACCGCG TCTAGA ACTGTAAC 5′ BglII c) Met-222-Cys:
- a 23-mer mismatch primer, NOR-325 which also generates a novel MspI site TC 5′ TATGCCAGCTTAAACGGTACATCGATG 3′ NOR-324 3′ TACGGTCGAATA GGCC ATGTAGC 5′ MspI g) Thr-71-Asp:
- pSX93 Gapped duplex mutagenesis was performed using the plasmid pSX93 as template.
- pSX93 is shown in FIGS. 3A and 3B, and is pUC13 (Vieira, J. and Messing, J., 1982, Gene 19: 259-268) harboring an 0.7 kb XbaI-HindIII fragment of the subtilisin 309 gene including the terminator inserted in the polylinker. The terminator and the HindIII site are not shown in Table II.
- pSX119 is pUC13 harboring an EcoRI-XbaI fragment of the subtilisin 309 gene inserted into the polylinker.
- the templates pSX93 and pSX119 thus cover the whole of the subtilisin 309 gene.
- the mutations a), b), and e) were performed by cutting pSX93 with XbaI and ClaI as indicated in FIG. 3A ; c), d), f), and h) were performed by cutting pSX93 with XbaI and HindIII as indicated in FIG. 3B .
- Mutation g was performed correspondingly in pSX119 by cutting with EcoRI and XbaI.
- the double mutants i) and j) were produced by cutting the 0.7 kb Xba-HindIII fragment from a) partially with HgiAI (HgiAI also cuts in SacI, which was introduced by the mutation). This 180 bp XbaI-HgiAI fragment and the 0.5 kb HgiAI fragment from the c) and d) mutants, respectively, were ligated to the large HindIII-XbaI fragment from pSX93.
- the double mutant k) was produced as above by combining mutants e) and f).
- Plasmid pSX92 is shown in FIG. 4 and was produced by cloning the subtilisin 309 gene into plasmid pSX62 cut at ClaI, filled in with the Klenow fragment of DNA polymerase I, and cut with HindIII prior to the insertion of the fragments DraI-NheI and NheI-HindIII from the cloned subtilisin 309 gene.
- mutants the mutated fragments (XbaI-ClaI, XbaI-HindIII, or EcoRI-XbaI) were excised from the appropriate mutation plasmid pSX93 or pSX119, respectively, and inserted into pSX92.
- the mutated pSX92 was then used to transform B. subtilis strain DN497, which was then grown in the same medium and under the same conditions as used for the cloning of the parent gene.
- mutants a) and d) were tested for their oxidation stability in 0.01 M peracetic acid after 20 minutes at 50° C. and pH 7.
- the parent strain NCIB 10309 protease was used as reference.
- mutant d (Met 222 to Ala) exhibits superior oxidation stability realtive to the parent enzyme and mutant a.
- mutants c), d), i), and j) (all Met-222) could resist 3-5 times more hypochlorite than the other mutants.
- mutant f When tested in a liquid detergent of the usual built type it was found that mutant f) exhibited superior stability compared to both the other mutants and the “parent” enzyme.
- mutant a exhibits enhanced activity compared to the parent. It is also seen that the Met-222 mutants have lower activity than the parent, but due to their improved oxidation stability their application in detergent compositions containing oxidants is not precluded.
- TABLE V Proteolytic Activity of Mutant Subtilisins Mutant Relative Activity None 100 a) 120 b) 100 c) 30 d) 20 e) 100 f) 100 i) 20 j) 30
- thermostability of mutant f was tested against the wild type enzyme by using the washability test at 40° C. and 60° C., respectively. The results are shown in Table VII.
- mutant f) at 60° C shows a much improved washability compared to the wild type enzyme, whereas at 40° C. the washability of mutant f) is only slightly better than the wild type enzyme.
- Subtilisin genes were cloned from the 147 and 309 variants of the bacterium Bacillus lentus , and the cloned genes were sequenced. By comparing the deduced amino acid sequences of subtilisins 147 and 309 one with the other and with sequences of other subtilisins, sites which, upon mutation, might alter the physical properties of the parent enzyme were identified. Site-directed mutagenesis was used to generate mutations at several of these sites in the subtilisin 309 gene. The resulting mutant enzymes were then expressed in a Bacillus strain, and tested against various physical and chemical parameters. Several of the mutants were shown to have improved stability to oxidation, increased proteolytic ability, or improved washability when compared with subtilisin 309. These mutants exhibit properties desirable in enzymes comprised in detergent compositions.
Abstract
The present invention relates to mutations of a subtilisin gene which result in changes in the chemical characteristics of subtilisin enzymes. Mutations at specific nucleic acids of the subtilisin gene result in amino acid substitutions and consequently, altered enzyme function. Some of these mutant enzymes exhibit physical properties advantageous to industrial applications, particularly in the detergent industry, providing subtilisin which is more stable to oxidation, possesses greater protease activity, and exhibits improved washability.
Description
- This application is a continuation of application Ser. No. 10/306,089 filed Nov. 27, 2002, which is a continuation of application Ser. No. 08/486,846 filed Jun. 7, 1995, now U.S. Pat. No. 6,506,589, which is a division of application Ser. No. 07/294,241 filed Jan. 6, 1989, now abandoned, and claims priority of Danish application no. 64/88 filed Jan. 7, 1988, the contents of which are fully incorporated herein by reference.
- 1. Field of the Invention
- The present invention relates to mutations of the subtilisin gene which result in changes in the chemical characteristics of subtilisin enzyme. Mutations at specific nucleic acids of the subtilisin gene result in amino acid substitutions and consequently, altered enzyme function. Some of these mutant enzymes exhibit physical properties advantageous to industrial applications, particularly in the detergent industry, providing subtilisins which are more stable to oxidation, possess greater protease activity, and exhibit improved washability.
- 2. Description of Related Art
- Bacillus Proteases
- Enzymes cleaving the amide linkages in protein substrates are classified as proteases, or (interchangeably) peptidases (See Walsh, 1979, Enzymatic Reaction Mechanisms, W. H. Freeman and Company, San Francisco, Chapter 3). Bacteria of the Bacillus species secrete two extracellular species of protease, a neutral, or metalloprotease, and an alkaline protease which is functionally a serine endopeptidase, referred to as subtilisin. Secretion of these proteases has been linked to the bacterial growth cycle, with greatest expression of protease during the stationary phase, when sporulation also occurs. Joliffe et al. (1980, J. Bacterial. 141:1199-1208) has suggested that Bacillus proteases function in cell wall turnover.
- Subtilisins
- A serine protease is an enzyme which catalyzes the hydrolysis of peptide bonds, in which there is an essential serine residue at the active site (White, Handler, and Smith, 1973, “Principles of Biochemistry,” Fifth Edition, McGraw-Hill Book Company, NY, pp. 271-272).
- The serine proteases have molecular weights in the 25,000 to 30,000 range. They are inhibited by diisopropylfluorophosphate, but in contrast to metalloproteases, are resistant to ethylenediamine-tetra acetic acid (EDTA) (although they are stabilized at high temperatures by calcium ion). They hydrolyze simple terminal esters and are similar in activity to eukaryotic chymotrypsin, also a serine protease. The alternative term, alkaline protease, reflects the high pH optimum of the serine proteases, from pH 9.0 to 11.0 (for review, see Priest, 1977, Bacteriological Rev. 41:711-753).
- A subtilisin is a serine protease produced by Gram-positive bacteria or fungi. A wide variety of subtilisins have been identified, and the amino acid sequences of at least eight subtilisins have been determined. These include six subtilisins from Bacillus strains, namely, subtilisin 168, subtilisin BPN′, subtilisin Carlsberg, subtilisin DY, subtilisin amylosacchariticus, and mesentericopeptidase (Kurihara et al., 1972, J. Biol. Chem. 247:29-5631; Stahl and Ferrari, 1984, J. Bacteriol. 158:411-418; Vasantha et al., 1984, J. Bacteriol. 159:811-819, Jacobs et al., 1985, Nucl. Acids Res. 13:8913-8926; Nedkov et al., 1985, Biol. Chem. Hoppe-Seyler 366:421-430; Svendsen et al., 1986, FEBS Lett 196:228-232), and two fungal subtilisins, subtilisin thermitase from Thermoactinymyces vulgaris (Meloun et al., 1985, FEBS Lett. 183:195-200) and proteinase K from Tritirachium album (Jany and Mayer, 1985, Biol. Chem. Hoppe-Seyler 366:584-492).
- Subtilisins are well-characterized physically and chemically. In addition to knowledge of the primary structure (amino acid sequence) of these enzymes, over 50 high resolution X-ray structures of subtilisin have been determined which delineate the binding of substrate, transition state, products, three different protease inhibitors, and define the structural consequences for natural variation (Kraut, 1971, Ann. Rev. Biochem. 46:331-358). Random and site-directed mutations of the subtilisin gene have both arisen from knowledge of the physical and chemical properties of the enzyme and contributed information relating to subtilisin's catalytic activity, substrate specificity, tertiary structure, etc. (Wells et al., 1987, Proc. Natl. Acad. Sci. U.S.A. 84:1219-1223; Wells et al., 1986, Phil. Trans. R. Soc. Lond. A. 317:415-423; Hwang and Warshel, 1987, Biochem. 26:2669-2673; Rao et al., 1987, Nature 328:551-554).
- Industrial Applications of Subtilisins
- Subtilisins have found much utility in industry, particularly detergent formulations, as they are useful for removing proteinaceous stains. To be effective, however, these enzymes must not only possess activity under washing conditions, but must also be compatible with other detergent components during storage. For example, subtilisin may be used in combination with amylases, which are active against starches; cellulases which will digest cellulosic materials; lipases, which are active against fats; peptidases, which are active on peptides, and ureases, which are effective against urine stains. Not only must the formulation protect other enzymes from digestion by subtilisin, but subtilisin must be stable with respect to the oxidizing power, calcium binding properties, detergency and high pH of nonenzymatic detergent components. The ability of the enzyme to remain stable in their presence is often referred to as its washing ability or washability.
- The present invention relates to mutations of the subtilisin gene, some of which result in changes in the chemical characteristics of subtilisin enzyme. Mutations are created at specific nucleic acids of the subtilisin gene, and, in various specific embodiments, the mutant enzymes possess altered chemical properties including, but not limited to, increased stability to oxidation, augmented proteolytic ability, and improved washability.
- The present invention also relates, but is not limited to the amino acid and DNA sequences for protease mutants derived from Bacillus lentus variants,
subtilisin 147 andsubtilisin 309, as well as mutations of these genes and the corresponding mutant enzymes. - Site-directed mutation can efficiently produce mutant subtilisin enzymes which can be tailored to suit a multitude of industrial applications particularly in the areas of detergent and food technology. The present invention relates, in part, but is not limited to, mutants of the subtilisin 309 gene which exhibit improved stability to oxidation, augmented protease activity, and/or improved washability.
- Abbreviations
- A=Ala=Alanine
- V=Val=Valine
- L=Leu=Leucine
- I=Ile=Isoleucine
- P=Pro=Proline
- F=Phe=Phenylalanine
- W=Trp=Tryptophan
- M=Met=Methionine
- G=Gly=Glycine
- S=Ser=Serine
- T=Thr=Threonine
- C=Cys=Cysteine
- Y=Tyr=Tyrosine
- N=Asn=Asparagine
- Q=Gln=Glutamine
- D=Asp=Aspartic Acid
- E=Glu=Glutamic Acid
- K=Lys=Lysine
- R=Arg=Arginine
- H=His=Histidine
-
FIG. 1 illustrates the insertion of a subset of fragments, ranging from 1.5 kb to 6.5 kb in length, generated by partial digestion ofBacillus lentus strain 309 DNA withSau 3A restriction endonuclease, into Bam HI cut plasmid pSx50. The two resulting plasmids, pSx86 and pSx88, containing thesubtilisin 309 gene in opposite orientations, are also shown. -
FIG. 2 illustrates the insertion ofBacillus lentus strain 147 DNA fragments into plasmid pSX56. Partial digestion ofstrain 147 DNA was performed usingSau 3A restriction endonuclease. Fragments ranging in size from 1.5 to 6.5 kb were then ligated into Bam HI cleaved plasmid pSX56. The product, pSX94, contains thesubtilisin 147 gene. -
FIG. 3 illustrates gapped duplex mutagenesis, using the method of Morinaga et al. (1984, Biotechnology 2:636-639). It features two plasmids, pSX93 and pSX119, both derived from puCl3. pSX93 contains an XbaI-HindIII fragment of thesubtilisin 309 gene, and pSX119 contains the remainder of thesubtilisin 309 gene in an EcoRI-XbaI fragment. In (A), plasmid pSX93 is cleaved with XbaI and ClaI, and the gapped molecules are mixed with pSX93 cut with ScaI, denatured, and allowed to reanneal so as to generate plasmids with a region of single-stranded DNA extending within thesubtilisin 309 coding sequence. A synthetic oligonucleotide, homologous to thesubtilisin 309 gene but containing a mutation, is allowed to anneal to the single stranded gap, which is then filled in using the Klenow fragment of DNA polymerase I and T4 DNA ligase. Upon replication of the plasmid, double-stranded mutants of thesubtilisin 309 gene are generated. The same procedure is performed in (B), using plasmid pSX119 and EcoRI and XbaI enzymes, to create mutations in the corresponding region of thesubtilisin 309 gene. -
FIG. 4 illustrates plasmid pSX92, which is a derivative of plasmid pSX62, bearing thesubtilisin 309 gene. Mutated fragments (i.e., XbaI - ClaI, XbaI-HindIII, or EcoRI-XbaI), excised from mutation plasmid pSX93 or pSX119 (seeFIG. 3 ) using the appropriate restriction endonucleases, were inserted into plasmid pSX92 for expression in B. subtilis strain DN 497. -
FIG. 5 illustrates plasmid pSXl43, which contains truncated forms of bothsubtilisin 309 andsubtilisin 147 genes. In vivo recombination between homologous regions of the two genes can result in active protease. - The invention relates to mutations of the subtilisin gene, some of which result in changes in the chemical characteristics of subtilisin enzyme. Mutations at specific nucleic acids may be generated, and thus, forms of subtilisin can be designed so as to meet the needs of industrial application.
- The invention is based, in part, upon the discovery that nutations of specific nucleic acids in the subtilisin gene can result in enzymes with altered properties. In various embodiments, enzymes with improved stability to oxidation, augmented protease activity, or improved washing ability can be generated.
- For purposes of clarity in description, and not by way of limitation, the invention will be described in four parts: (a) the chemical structure of known subtilisins and
subtilisin - Chemical Structures of Known Subtilisins and
Subtilisin - Sequence analysis of subtilisins from various sources can reveal the functional significance of the primary amino acid sequence, and can direct the creation of new mutants with deliberately modified functions. Comparing the amino acid sequence of different forms of subtilisin, while contrasting their physical or chemical properties, may reveal specific target regions which are likely to produce useful mutant enzymes.
- The amino acid sequences of at least eight subtilisins are known. These include six subtilisins from Bacillus strains, namely, subtilisin 168, subtilisin BPN′, subtilisin Carlsberg, subtilisin DY, subtilisin amylosacchariticus and mesentericopeptidase (Kurihara et al., 1972, J. Biol. Chem. 247:5629-5631; Stahl and Ferrari, 1984, J. Bacteriol. 158:411-418; Vasantha et al., 1984, J. Bacteriol. 159:811-819; Jacobs et al., 1985, Nucl. Acids Res. 13:8913-8926; Nedkov et al., 1985, Biol. Chem. Hoppe-Seyler 366:421-430; Svendsen et al., 1986, FEBS Lett. 196:228-232), and two fungal subtilisins, subtilisin thermitase from Thermoactinymyces vulgaris (Meloun et al., 1985, FEBS Lett. 183:195-200), and proteinase K from Tritirichium album limber (Janny and Mayer, 1985, Biol. Chem. Hoppe-Seyler 366:485-492).
- In connection with this invention the amino acid and DNA sequences for two further serine proteases are revealed. These proteases were derived from two Bacillus lentus variants, C303 and C360, which have been deposited with NCIB and designated the accession numbers NCIB 10147 and NCIB 10309, respectively. For convenience the proteases produced by these strains are designated
subtilisin 147 andsubtilisin 309, respectively, and the genes encoding these proteins are referred to as thesubtilisin - As used in this invention, the term “subtilisin material” refers to a proteinaceous material which contains a subtilisin as its active ingredient. As used herein, and under the definition of subtilisin material, any serine protease is a subtilisin which has at least 30%, preferably 50%, and more preferably 80% amino acid sequence homology with the sequences referenced above for
subtilisin 147,subtilisin 309, subtilisin 168, subtilisin BPN', subtilisin Carlsberg, subtilisin DY, subtilisin amylosacchariticus, mesentericopeptidase, thermitase, proteinase K and thermomycolase. These serine proteases are also described herein as “homologous serine proteases”. - Table I compares the deduced amino acid sequences of
subtilisin 309,subtilisin 147, subtilisin BPN', subtilisin Carlsberg and subtilisin 168 (Spizizen, et al., 1958, Proc. Natl. Acad. Sci. U.S.A. 44:1012-1078). Table II presents the nucleic acid sequence of thesubtilisin 309 gene, and Table III presents the nucleic acid sequence of thesubtilisin 147 gene. The sequences ofsubtilisin subtilisin subtilisin - Closeness of relation can be measured by comparison of amino acid sequences. There are many methods of aligning protein sequences, but the differences are only manifest when the degree of relatedness is quite small. The methods described in Atlas of Protein Sequence and Structure, Margaret O. Dayhoff editor, vol. 5,
supplement 2, 1976, National Biomedical Research Foundation, Georgetown University Medical Center, Washington, D.C., p. 3 ff., entitled SEARCH and ALIGN, define relatedness. As is well known in the art, related proteins can differ in number of amino acids as well as identity of each amino acid along the chain. That is, there can be deletions or insertions when two structures are aligned for maximum identity. For example, subtilisin Carlsberg has only 274 amino acids while subtilisin BPN' has 275 amino acids. Aligning the two sequences shows that Carlsberg has no residue corresponding to Asn 56 of subtilisin BPN′. Thus the amino acid sequence of Carlsberg would appear very different from subtilisin BPN′ unless a gap is recorded at location 56. Therefore, one can predict with a high degree of confidence that substituting Ser for Asn at location 218 of subtilisin Carlsberg will increase thermal stability provided that the residues in Carlsberg are numbered by homology to subtilisin BPN′. - According to the invention, the sequences determined for
subtilisins - Experiments to determine the relationship between the primary structure of subtilisin and its physical properties have revealed the significance of the methionine-222 residue as well as the amino acids functional in the native site, namely, aspartic acid-32, histidine-64, and serine-221. Asparagine-155 and Serine-221 are within the oxyanion binding site. Mutations at these positions are likely to diminish proteolytic activity. According to the present invention, the amino acid sequences of
subtilisins subtilisin subtilisin 309 contains a serine residue, whereassubtilisin 147, subtilisin BPN′, Carlsberg and 168 contain an alanine residue. Therefore, if the serine 153 residue ofsubtilisin 309 were changed to an alanine residue, the physical properties ofsubtilisin 309 might be altered in a desired direction. Likewise,subtilisin 147 contains a serine residue at position 218, whereas the other subtilisins expressed an asparagine residue. Becausesubtilisin 147 has improved thermal stability relative to the other subtilisins, mutating the asparagine 218 ofsubtilisin 309 to a serine residue might improve the thermal stability ofsubtilisin 309. As another example, it was reasoned that, since Thr 71 is close to the active site, the introduction of a negatively charged amino acid, such as aspartic acid, might suppress oxidative attack by electrostatic repulsion. The sites that are most likely to be relevant to the physical properties of subtilisin are those in which there is conservation of amino acid residues between most subtilisins, for example Asp-153 and Asn-218 discussed above, and also Trp-6, Arg-170, Pro-168, His-67, Met-175, Gly-219, Arg-275. By mutating the nucleic acid sequence such that an amino acid which differs from other subtilisins is substituted with an amino acid that conforms, a more stable form of subtilisin may result. - Wells et al. (1987, Proc. Natl. Acad. Sci. U.S.A. 84:1219-1223) have used comparison of amino acid sequences and site-directed mutation to engineer subtilisin substrate specificity. The catalytic activities of various subtilisins can differ markedly against selected substrates. Wells has shown that only three amino acid substitutions can cause B. amyloliquefaciens subtilisin substrate specificity to approach that of B. licheniformis subtilisin, enzymes that differ by factors of 10-50 in catalytic efficiency in their native state. Comparison analysis between
subtilisin subtilisins 147 and/or 309; insertion of appropriate amino acid residues into these sites might enhance the stability of the parent enzymes: 1, 36, 56, 159, 164-166. According to the method illustrated by these examples, which are not limiting, a number of potential mutation sites become apparent.TABLE I COMPARISON OF AMINO ACID SEQUENCE FOR VARIOUS PROTEASES 10 20 30 a) A-Q-S-V-P-W-G-I-S-R-V-Q-A-P-A-A-H-N-R-G-L-T-G-S-G-V-K-V-A-V- b) *-Q-T-V-P-W-G-I-S-F-I-N-T-Q-Q-A-H-N-R-G-I-F-G-N-G-A-R-V-A-V- c) A-Q-S-V-P-Y-G-V-S-Q-I-K-A-P-A-L-H-S-Q-G-Y-T-G-S-N-V-K-V-A-V- d) A-Q-T-V-P-Y-G-I-P-L-I-K-A-D-K-V-Q-A-Q-G-F-K-G-A-N-V-K-V-A-V- e) A-Q-S-V-P-Y-G-I-S-Q-I-K-A-P-A-L-H-S-Q-G-Y-T-G-S-N-V-K-V-A-V- 40 50 60 a) L-D-T-G-I-*-S-T-H-P-D-L-N-I-R-G-G-A-S-F-V-P-G-E-P-*-S-T-Q-D- b) L-D-T-G-I-*-A-T-H-P-D-L-R-I-A-G-G-A-S-F-I-S-S-E-P-*-S-Y-H-D- c) I-D-S-G-I-D-S-S-H-P-D-L-K-V-A-G-G-A-S-M-V-P-S-E-T-N-P-F-Q-D- d) L-D-T-G-I-Q-A-S-H-P-D-L-N-V-V-G-G-A-S-F-V-A-G-E-A-*-Y-N-T-D- e) L-D-S-G-I-D-S-S-H-P-D-L-N-V-R-G-G-A-S-F-V-A-S-E-T-N-P-Y-Q-D- 70 80 90 a) G-N-G-H-G-T-H-V-A-G-T-I-A-A-L-N-N-S-I-G-V-L-G-V-A-P-S-A-E-L- b) N-N-G-H-G-T-H-V-A-G-T-I-A-A-L-N-N-S-I-G-V-L-G-V-A-P-S-A-D-L- c) N-N-S-H-G-T-H-V-A-G-T-V-A-A-L-N-N-S-I-G-V-L-G-V-A-P-S-A-S-L- d) G-N-G-H-G-T-H-V-A-G-T-V-A-A-L-D-N-T-T-G-V-L-G-V-A-P-S-V-S-L- e) G-S-S-H-G-T-H-V-A-G-T-I-A-A-L-N-N-S-I-G-V-L-G-V-S-P-S-A-S-L- 100 110 120 a) Y-A-V-K-V-L-G-A-S-G-S-G-S-V-S-S-I-A-Q-G-L-E-W-A-G-N-N-G-M-H- b) Y-A-V-K-V-L-D-R-N-G-S-G-S-L-A-S-V-A-Q-G-I-E-W-A-I-N-N-N-M-H- c) Y-A-V-K-V-L-G-A-D-G-S-G-Q-Y-S-W-I-I-N-G-I-E-W-A-I-A-N-N-M-D- d) Y-A-V-K-V-L-N-S-S-G-S-G-T-Y-S-G-I-V-S-G-I-E-W-A-T-T-N-G-M-D- e) Y-A-V-K-V-L-D-S-T-G-S-G-Q-Y-S-W-I-I-N-G-I-E-W-A-I-S-N-N-M-D 130 140 150 a) V-A-N-L-S-L-G-S-P-S-P-S-A-T-L-E-Q-A-V-N-S-A-T-S-R-G-V-L-V-V- b) I-I-N-M-S-L-G-S-T-S-G-S-S-T-L-E-L-A-V-N-R-A-N-N-A-G-I-L-L-V- c) V-I-N-M-S-L-G-G-P-S-P-S-A-A-L-K-A-A-V-D-K-A-V-A-S-G-V-V-V-V- d) V-I-N-M-S-L-G-G-P-S-G-S-T-A-M-K-Q-A-V-D-N-A-Y-A-R-G-V-V-V-V- e) V-I-N-M-S-L-G-G-P-T-G-S-A-A-L-K-T-V-V-D-K-A-V-S-S-G-I-L-V-A- 160 170 180 a) A-A-S-G-N-S-G-A-*-G-S-I-S-*-*-*-Y-P-A-R-Y-A-N-A-M-A-V-G-A-T- b) G-A-A-G-N-T-G-R-*-Q-G-V-N-*-*-*-Y-P-A-R-Y-S-G-V-M-A-V-A-A-V- c) A-A-A-G-N-E-G-T-S-G-S-S-S-T-V-G-Y-P-G-K-Y-P-S-V-I-A-V-G-A-V- d) A-A-A-G-N-S-G-S-S-G-N-T-N-T-I-G-Y-P-A-K-Y-D-S-V-I-A-V-G-A-V- e) A-A-A-G-N-E-G-S-S-G-S-S-S-T-V-G-Y-P-A-K-Y-P-S-T-I-A-V-G-A-V- 190 200 210 a) D-Q-N-N-N-R-A-S-F-S-Q-Y-G-A-G-L-D-I-V-A-P-G-V-N-V-Q-S-T-Y-P- b) D-Q-N-G-Q-P-P-S-F-S-T-Y-G-P-E-I-E-I-S-A-P-G-V-N-V-N-S-T-Y-T- c) D-S-S-N-Q-R-A-S-F-S-S-V-G-P-E-L-D-V-M-A-P-G-V-S-I-Q-S-T-L-P- d) D-S-N-S-N-R-A-S-F-S-S-V-G-A-E-L-E-V-M-A-P-G-A-G-V-Y-S-T-Y-P- e) N-S-S-N-Q-R-A-S-F-S-S-A-G-S-E-L-D-V-M-A-P-G-V-S-I-Q-S-T-L-P- 220 230 240 a) G-S-T-Y-A-S-L-N-G-T-S-M-A-T-P-H-V-A-G-A-A-A-L-V-K-Q-K-N-P-S- b) G-N-R-Y-V-S-L-S-G-T-S-M-A-T-P-H-V-A-G-V-A-A-L-V-K-S-R-Y-P-S- c) G-N-K-Y-G-A-Y-N-G-T-S-M-A-S-P-H-V-A-G-A-A-A-L-I-L-S-K-H-P-N- d) T-S-T-Y-A-T-L-N-G-T-S-M-A-S-P-H-V-A-G-A-A-A-L-I-L-S-K-H-P-N- e) G-G-T-Y-G-A-Y-N-G-T-S-M-A-T-P-H-V-A-G-A-A-A-L-I-L-S-K-H-P-T- 250 260 270 a) W-S-N-V-Q-I-R-N-H-L-K-N-T-A-T-S-L-G-S-T-N-L-Y-G-S-G-L-V-N-A- b) Y-T-N-N-Q-I-R-Q-R-I-N-Q-T-A-T-Y-L-G-S-P-S-L-Y-G-N-G-L-V-H-A- c) W-T-N-T-Q-V-R-S-S-L-E-N-T-T-T-K-L-G-D-S-F-Y-Y-G-K-G-L-I-N-V- d) L-S-A-S-Q-V-R-N-R-L-S-S-T-A-T-Y-L-G-S-S-F-Y-Y-G-K-G-L-I-N-V- e) W-T-N-A-Q-V-R-D-R-L-E-S-T-A-T-Y-L-G-N-S-F-Y-Y-G-K-G-L-I-N-V- a) E-A-A-T-R b) G-R-A-T-Q c) Q-A-A-A-Q d) E-A-A-A-Q e) Q-A-A-A-Q
a =subtilisin 309
b =subtilisin 147
c = subtilisin BPN′
d = subtilisin Carlsberg
e = subtilisin 168
* = assigned deletion
Methods for Producing Mutations in Subtilisin Genes - Many methods for introducing mutations into genes are well known in the art. After a brief discussion of cloning subtilisin genes, methods for generating mutations in both random sites and specific sites within the subtilisin gene will be discussed.
- Cloning a Subtilisin Gene
- The gene encoding subtilisin may be cloned from any Gram-positive bacteria or fungus by various methods well known in the art. First a genomic and/or cDNA library of DNA must be constructed using chromosomal DNA or messenger RNA from the organism that produces the subtilisin to be studied. Then, if the amino acid sequence of the subtilisin is known, homologous, labelled oligonucleotide probes may be synthesized and used to identify subtilisin-encoding clones from a genomic library of bacterial DNA, or from a fungal cDNA library. Alternatively, a labelled oligonucleotide probe containing sequences homologous to subtilisin from another strain of bacteria or fungus could be used as a probe to identify subtilisin-encoding clones, using hybridization and washing conditions of lower stringency.
- Yet another method for identifying subtilisin-producing clones would involve inserting fragments of genomic DNA into an expression vector, such as a plasmid, transforming protease-negative bacteria with the resulting genomic DNA library, and then plating the transformed bacteria onto agar containing a substrate for subtilisin, such as skim milk. Those bacteria containing subtilisin-bearing plasmid will produce colonies surrounded by a halo of clear agar, due to digestion of the skim milk by excreted subtilisin.
- Generation of Random Mutations in the Subtilisin Gene
- Once the subtilisin gene has been cloned into a suitable vector, such as a plasmid, several methods can be used to introduce random mutations into the gene.
- One method would be to incorporate the cloned subtilisin gene, as part of a retrievable vector, into a mutator strain of Eschericia coli.
- Another method would involve generating a single stranded form of the subtilisin gene, and then annealing the fragment of DNA containing the subtilisin gene with another DNA fragment such that a portion of the subtilisin gene remained single stranded. This discrete, single stranded region could then be exposed to any of a number of mutagenizing agents, including, but not limited to, sodium bisulfite, hydroxylamine, nitrous acid, formic acid, or hydralazine. A specific example of this method for generating random mutations is described by Shortle and Nathans (1978, Proc. Natl. Acad. Sci. U.S.A., 75:2170-2174). According to the Shortle and Nathans method, the plasmid bearing the subtilisin gene would be nicked by a restriction enzyme that cleaves within the gene. This nick would be widened into a gap using the exonuclease action of DNA polymerase I. The resulting single-stranded gap could then be mutagenized using any one of the above mentioned mutagenizing agents.
- Alternatively, the subtilisin gene from a Bacillus species including the natural promoter and other control sequences could be cloned into a plasmid vector containing replicons for both E. coli and B. subtilis, a selectable phenotypic marker and the M13 origin of replication for production of single-stranded plasmid DNA upon superinfection with helper phage IR1. Single-stranded plasmid DNA containing the cloned subtilisin gene is isolated and annealed with a DNA fragment containing vector sequences but not the coding region of subtilisin, resulting in a gapped duplex molecule. Mutations are introduced into the subtilisin gene either with sodium bisulfite, nitrous acid or formic acid or by replication in a mutator strain of E. coli as described above. Since sodium bisulfite reacts exclusively with cytosine in a single-stranded DNA, the mutations created with this mutagen are restricted only to the coding regions. Reaction time and bisulfite concentration are varied in different experiments such that from one to five mutations are created per subtilisin gene on average. Incubation of 10 micrograms of gapped duplex DNA in 4 M Na-bisulfite, pH 6.0, for 9 minutes at 37° C. in a reaction volume of 400 microliters, deaminates about 1% of cytosines in the single-stranded region. The coding region of mature subtilisin contains about 200 cytosines, depending on the DNA strand. Advantageously, the reaction time is varied from about 4 minutes (to produce a mutation frequency of about one in 200) to about 20 minutes (about 5 in 200).
- After mutagenesis the gapped molecules are treated in vitro with DNA polymerase I (Klenow fragment) to make fully double-stranded molecules and to fix the mutations. Competent E. coli are then transformed with the mutagenized DNA to produce an amplified library of mutant subtilisins. Amplified mutant libraries can also be made by growing the plasmid DNA in a Mut D strain of E. coli which increases the range of mutations due to its error prone DNA polymerase.
- The mutagens nitrous acid and formic acid may also be used to produce mutant libraries. Because these chemicals are not as specific for single-stranded DNA as sodium bisulfite, the mutagenesis reactions are performed according to the following procedure. The coding portion of the subtilisin gene is cloned in M13 phage by standard methods and single stranded phage DNA prepared. The single-stranded DNA is then reacted with 1 M nitrous acid pH 4.3 for 15-60 minutes at 23° C. or 2.4 M formic acid for 1-5 minutes at 23° C. These ranges of reaction times produce a mutation frequency of from 1 in 1000 to 5 in 1000. After mutagenesis, a universal primer is annealed to the M13 DNA and duplex DNA is synthesized using the mutagenized single stranded DNA as a template so that the coding portion of the subtilisin gene becomes fully double-stranded. At this point the coding region can be cut out of the M13 vector with restriction enzymes and ligated into an unmutagenized expression vector so that mutations occur only in the restriction fragment (Myers et al., 1985, Science 229:242-257).
- By yet another method, mutations can be generated by allowing two dissimilar forms of subtilisin to undergo recombination in vivo. According to this method, homologous regions within the two genes lead to a cross-over of corresponding regions resulting in the exchange of genetic information. The generation of hybrid amylase molecules according to this technique is fully described in U.S. application Ser. No. 67,992, filed on Jun. 29, 1987, which is fully incorporated herein by reference. An example of a plasmid which can generate hybrid forms of subtilisin is depicted in
FIG. 5 . Both thesubtilisin subtilisin 309 gene becomes linked to the C terminal region of thesubtilisin 147 gene, then active, mutant subtilisin can be produced. If pSX143 is incorporated into a protease-negative strain of bacteria, and then bacteria that develop a protease positive phenotype are selected, then various mutants,subtilisin 309/147 chimeras, can be identified. - Generation of Site Directed Mutations in the Subtilisin Gene
- Once the subtilisin gene has been cloned, and desirable sites for mutation identified, these mutations can be introduced using synthetic oligo nucleotides. These oligonucleotides contain nucleotide sequences flanking the desired mutation sites; mutant nucleotides are inserted during oligonucleotide synthesis. In a preferred method, a single stranded gap of DNA, bridging the subtilisin gene, is created in a vector bearing the subtilisin gene. Then the synthetic nucleotide, bearing the desired mutation, is annealed to a homologous portion of the single-stranded DNA. The remaining gap is then filled in by DNA polymerase I (Klenow fragment) and the construct is ligated using T4 ligase. A specific example of this method is described in Morinaga et al. (1984, Biotechnology 2:636-639). According to Morinaga et al., a fragment within the gene is removed using restriction endonuclease. The vector/gene, now containing a gap, is then denatured and hybridized to vector/gene which, instead of containing a gap, has been cleaved with another restriction endonuclease at a site outside the area involved in the gap. A single-stranded region of the gene is then available for hybridization with mutated oligonucleotides, the remaining gap is filled in by the Klenow fragment of DNA polymerase I, the insertions are ligated with T4 DNA ligase, and, after one cycle of replication, a double-stranded plasmid bearing the desired mutation is produced. The Morinaga method obviates the additional manipulation of construction new restriction sites, and therefore facilitates the generation of mutations at multiple sites. U.S. Pat. No. 4,760,025, by Estelle et al., issued Jul. 26, 1988, is able to introduce oligonucleotides bearing multiple mutations by performing minor alterations of the cassette, however, an even greater variety of mutations can be introduced at any one time by the Morinaga method, because a multitude of oligonucleotides, of various lengths, can be introduced.
- Expression of Subtilisin Mutants
- According to the invention, a mutated subtilisin gene produced by methods described above, or any alternative methods known in the art, can be expressed, in enzyme form, using an expression vector. An expression vector generally falls under the definition of a cloning vector, since an expression vector usually includes the components of a typical cloning vector, namely, an element that permits autonomous replication of the vector in a microorganism independent of the genome of the microorganism, and one or more phenotypic markers for selection purposes. An expression vector includes control sequences encoding a promoter, operator, ribosome binding site, translation initiation signal, and, optionally, a repressor gene. To permit the secretion of the expressed protein, nucleotides encoding a “signal sequence” may be inserted prior to the coding sequence of the gene. For expression under the direction of control sequences, a target gene to be treated according to the invention is operably linked to the control sequences in the proper reading frame. Promoter sequences that can be incorporated into plasmid vectors, and which can support the transcription of the mutant subtilisin gene, include but are not limited to the prokaryotic beta-lactamase promoter (Villa-Kamaroff, et al., 1978, Proc. Natl. Acad. Sci. U.S.A. 75:3727-3731) and the tac promoter (DeBoer, et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:21-25). Further references can also be found in “Useful proteins from recombinant bacteria” in Scientific American, 1980, 242:74-94.
- According to one embodiment B. subtilis is transformed by an expression vector carrying the mutated DNA. If expression is to take place in a secreting microorganism such as B. subtilis a signal sequence may follow the translation initiation signal and precede the DNA sequence of interest. The signal sequence acts to transport the expression product to the cell wall where it is cleaved from the product upon secretion. The term “control sequences” as defined above is intended to include a signal sequence, when it is present.
- Screening of Mutant Subtilisins
- For screening mutants, transformed B. subtilis can be cultivated in the presence of a filter material (such as nitrocellulose) to which the secreted expression product (e.g. enzyme) binds. In order to screen for an expression product having a desired characteristic, filter bound expression product is subjected to conditions which distinguish expression product of interest from wild-type expression product. For example, the filter-bound expression product can be subjected to conditions which would inactivate a wild-type product. Preserved enzyme activity following adverse treatment suggests that the mutation confers enhanced stability on the enzyme, and is therefore a useful mutation.
- In one embodiment of the invention, screening for stable variants is accomplished using a protease deficient B. subtilis strain transformed with the variant plasmid and plated out as follows: a nitrocellulose filter is placed on a nutrient base in a petri dish, and a cellulose acetate filter is placed on top of the nitrocellulose. Colonies are grown on the cellulose acetate, and protease from individual colonies is secreted through the cellulose acetate onto the nitrocellulose filter where it is stably bound. Protease from hundreds of colonies is bound to a single filter allowing subsequent screening of thousands of different variants by processing multiple filters.
- To identify colonies producing subtilisin of enhanced thermal stability, the filters can be incubated in buffer solutions at temperatures which would inactivate substantially all wild-type activity. Variants of enhanced stability or activity retain activity after this step. The suitably treated filter then is soaked in a solution containing Tosyl-L-Arg methyl ester (TAME), Benzoly-Arg-ethyl-ester (BAEE), Acetyl-Tyr-ethyl-ester (ATEE) (Sigma) or similar compounds. Because TAME, BAEE, and ATEE are substrates for the proteases they are cleaved in zones on the filter containing variant subtilisins which remain active after treatment. As cleavage occurs, protons are released in the reaction and cause phenol red to change in color from red to yellow in areas retaining protease activity.
- This procedure can be used to screen for different classes of variants with only slight modifications. For example, the filters could be treated at high temperature, at high pH, with denaturants, oxidizing agents, or under other conditions which normally inactivate an enzyme such as a protease to find resistant variants. Variants with altered substrate specificity could be screened by replacing TAME, BAEE, or ATEE with other substrates which are normally not cleaved by wild-type subtilisin.
- Once a variant of enhanced stability is identified by screening, the colony from which the variant is derived is isolated and the altered subtilisin is purified. Experiments can be performed on the purified enzyme to determine conditions of stability towards oxidation, thermal inactivation, denaturation temperature, kinetic parameters as well as other physical measurements. The altered gene can also be sequenced to determine the amino acid changes responsible for the enhanced stability. Using this procedure, variants with increased washing abilities have been isolated.
- Site-Specific Mutation of the Subtilisin Gene Generates Mutants With Useful Chemical Characteristics
- Materials And Methods
- Bacterial Strains
-
B. subtilis - Plasmids
- pSX50 (described in U.S. application Ser. No. 039,298, supra) is a derivative of plasmid pDN 1050, comprising the promoter-operator P1O1the B. pumilus xyn B gene and the B. subtilis xyl R gene.
- pSX65 (described in U.S. application Ser. No. 039,298, supra) is a derivative of plasmid pDN 1050, comprising the promoter-operator P2O2, the B. pumilus xyn B gene, and the B. subtilis xyl R gene.
- pSX93, shown in
FIG. 3A , is puCl3 (Vieira and Messing, 1982, Gene 19:259-268) comprising a 0.7 kb XbaI-Hind III fragment of thesubtilisin 309 gene including the terminator inserted in a polylinker sequence. - pSX119 is pUC13 harboring an EcoRI-XbaI fragment of the
subtilisin 309 gene inserted into the polylinker. - pSX62 (described in U.S. application Ser. No. 039,298, supra) is a derivative of pSX52 (ibid), which comprises a fusion gene between the calf prochymosin gene and the B. pumilus xyn B gene inserted into pSX50 (supra) . pSX62 was generated by inserting the E. coli rrn B terminator into pSX52 behind the prochymosin gene.
- pSX92 was produced by cloning the
subtilisin 309 gene into plasmid pSX62 (supra) cut at Cla I and Hind III and filled prior to the insertion of the fragments DraI-NheI and NheI-Hind III from the clonedsubtilisin 309 gene. - Purification of Subtilisins
- The procedure relates to a typical purification of a 10 liter scale fermentation of
subtilisin 147,subtilisin 309 or mutants thereof. - Approximately 8 liters of fermentation broth were centrifuged at 5000 rpm for 35 minutes in 1 liter beakers. The supernatants were adjusted to pH 6.5 using 10% acetic acid and filtered on Seitz Supra S100 filter plates.
- The filtrates were concentrated to approximately 400 ml using an Amicon CH2A UF unit equipped with an Amicon S1Y10 UF cartridge. The UF concentrate was centrifuged and filtered prior to adsorption on a Bacitracin affinity column at pH 7. The protease was eluted from the Bacitracin column using 25% 2-propanol and 1 M sodium chloride in a buffer solution with 0.01 M dimethylglutaric acid, 0.1 M boric acid and 0.002 M calcium chloride adjusted to pH 7.
- The fractions with protease activity from the Bacitracin purification step were combined and applied to a 750 ml Sephadex G25 column (5 cm dia.) equilibrated with a buffer containing 0.01 M dimethylglutaric acid, 0.2 M boric acid and 0.002 M calcium chloride adjusted to pH 6.5.
- Fractions with proteolytic activity from the Sephadex G25 column were combined and applied to a 150 ml CM Sepharose CL 6B cation exchange column (5 cm dia.) equilibrated with a buffer containing 0.01 M dimethylglutaric acid, 0.2 M boric acid and 0.002 M calcium chloride adjusted to pH 6.5.
- The protease was eluted using a linear gradient of 0-0.1 M sodium chloride in 2 liters of the same buffer (0-0.2 M sodium chloride in case of subtilisin 147).
- In a final purification step protease containing fractions from the CM Sepharose column were combined and concentrated in an Amicon ultrafiltration cell equipped with a GR81P membrane (from the Danish Sugar Factories Inc.).
-
Subtillisin 309 and Mutants -
- Met 222 to Ala
- Gly 195 to Glu
- Asn 218 to Ser
- Arg 170 to Tyr
- Gly 195 to Glu, Arg 170 to Tyr
- Gly 195 to Glu, Met 222 to Ala
were purified by this procedure.
- Oligonucledotide Synthesis
- All mismatch primers were synthesized on an Applied Biosystems 380 A DNA synthesizer and purified by polyacrylamide gel electrophoresis (PAGE).
- Determination of Oxidation Stability
- The purified enzyme is diluted to an enzyme content of approximately 0.1 mg/ml in 0.01 M dimethylglutaric acid pH 7 and in the same buffer with 0.01 M peracetic acid (pH 7).
- Both sets of dilutions were heated to 50° C. for 20 minutes. Proteolytic activity was measured in the dilutions before and after the heat treatment.
- Assay For Proteolytic Activity
- OPA-Casein Method
- Proteolytic activity was determined using casein as the substrate. One Casein Protease Unit (CPU) is defined as the amount of enzyme liberating 1 millimole of primary amino groups (determined by comparison with a serine standard) per minute under standard conditions, i.e. incubation for 30 minutes at 25° C. and pH 9.5.
- A 2% (w/v) solution of casein (Hammarstein, supplied by Merck A. G., West Germany) was prepared with the Universal Buffer described by Britton and Robinson (Journ. Chem. Soc. 1931, p. 1451), adjusted to pH 9.5.
- Two ml of substrate solution was preincubated in a water bath for 10 minutes at 25° C. One ml of enzyme solution containing about 0.2-0.3 CPU/ml of Britton-Robinson buffer (pH 9.5), was added. After 30 minutes of incubation at 25° C. the reaction was terminated by the addition of a stopping agent (5 ml of a solution containing trichloroacetic acid (17.9 g), sodium acetate (29.9 g), and acetic acid (19.8 g), filled up to 500 ml with deionized water). A blank was prepared in the same manner as the test solution, except that the stopping agent was added prior to the enzyme solution.
- The reaction mixtures were kept for 20 minutes in the water bath, whereupon they were filtered through Whatman® 42 paper filters.
- Primary amino groups were determined by their color development with o-phthaldialdehyde (OPA).
- Disodium tetraborate decahydrate (7.62 g) and sodium dodecylsulfate (2.0 g) was dissolved in 150 ml of water. OPA (160 mg) dissolved in 4 ml of methanol was then added together with 400 microliters of beta-mercaptoethanol, whereafter the solution was made up to 200 ml with water.
- To the OPA reagent (3 ml) was added 40 μl of the above-mentioned filtrates with mixing. The optical density (OD) at 340 nm was measured after about 5 minutes.
- The OPA test was also performed with a serine standard containing 10 mg of serine in 100 ml of Britton-Robinson buffer (pH 9.5). The buffer was used as a blank.
- The protease activity was calculated from the optical density measurements by means of the following formula:
CPU/g of enzyme solution=[OD t −OD b)×C Ser ×Q]/[(OD Ser −OD B)×MW Ser ×t i]
CPU/g of enzyme preparation=CPU/ml: b
wherein ODt, ODb, ODSer and ODB are the optical density of the test solution, blank, serine standard, and buffer, respectively, CSer is the concentration of serine in mg/ml in the standard, MWSer is the molecular weight of serine, Q is the dilution factor (in this instance equal to 8) for the enzyme solution, and ti is the incubation time in minutes. - In the following Table V, results from the above assay are shown relative to the parent enzyme.
- Assay for Washability
- Test cloths (7 cm×7 cm, approximately 1 g) were produced by passing desized cotton (100% cotton, DS 71) Cloth through the vessel in a Mathis Washing and Drying Unit type TH (Werner Mathis A G, Zurich, Switzerland) containing spinach juice (produced from fresh spinach) and then through the pressure roll of the machine in order to remove excess spinach juice.
- Finally the cloth was dried in a strong air stream at room temperature, stored at room temperature for 3 weeks, and subsequently kept at −18° C. prior to use.
- The tests were performed in a Terg-O-tometer test washing machine (described in Jay C. Harris −Detergency Evaluation and Testing”, Interscience Publishers Ltd., 1954, p.60-61) isothermally for 10 minutes at 100 rpm. As detergent the following standard powder detergent was used:
Nansa S 80 0.40 g/l AE, Berol 0 65 0.15 g/l Soap 0.15 g/l STPP 1.75 g/l Sodium silicate 0.40 g/l CMC 0.05 g/l EDTA 0.01 g/l Na2SO4 2.10 g/l Perborate 1.00 g/l TAED 0.10 g/l
TAED=N,N,N′,N″-tetraacetyl-ethylene diamine; pH was adjusted with 4 N NAOH to 9.5. The water used was ca. 9° GH (German Hardness). - Tests were performed at enzyme concentrations of: 0, 0.05 CPU/1, and 0.1 CPU/l, and two independent sets of tests were performed for each of the mutants.
- Eight cloths were used for each testing using one beaker (800 ml) of detergent. Of the cloths, four were clean and four were stained with spinach juice. Subsequent to the washing the cloths were flushed in running water for 25 minutes in a bucket.
- The cloths were then air dryed overnight (protected against day light) and the remission, R, determined on a E1REPHO 2000 spectrophotometer from Datacolor S.A., Dietkikon, Switzerland at 460 nm.
- As a measure of the washing ability differential remission, Delta R, was used, Delta R being equal to the remission after wash with enzyme added minus the remission after wash with no enzyme added.
- Assay for Thermostability
- The same procedure as above for washability was used for estimating the thermostability of the mutants produced, by performing the test at temperatures of 40° C. and 60° C., respectively.
- Results
- Cloning of the
Subtilisin - Chromosomal DNA from the “309” strain was isolated by treating a cell suspension with Lysozyme for 30 minutes at 37° C., and then with SDS for 5 minutes at 60° C. Subsequently, the suspension was extracted with phenolchloroform (50:50), precipitated with ethanol, and the precipitate redissolved in TE. This solution was treated with RNase for 1 hour at 37° C.
- Approximately 30 micrograms of the chromosomal DNA was partially digested with
restriction enzyme Sau 3A (New England Biolabs) and fragments from about 1.5 kb to about 6.5 kb were isolated on DEAE cellulose paper from a 1% agarose gel (the subtilisin gene in other species is approximately 1.2 kb in length). - As outlined in
FIG. 1 the fragments were annealed and ligated to BamHI cut plasmid pSX50 (described in U.S. patent application Ser. No. 039,298 filed Apr. 17, 1987, is which is hereby included for reference). The plasmids were then transformed into competent B. subtilis DN 497. - The cells were then spread on LB agar plates with 10 mM phosphate pH 7, 6 micrograms/ml chloramphenicol, and 0.2% xylose to induce the xyn-promoter in the plasmid. The plates also contained 1% skim milk so the protease producing transformants could be detected by the clear halo where the skim milk had been degraded.
- Protease expressing clones were produced at a frequency of 10−4. Two clones were found that harbored plasmids carrying the gene for
subtilisin 309, pSX86 and pSX88. The gene was then sequenced using the method of Maxam and Gilbert. The deduced nucleotide sequence ofsubtilisin 309 is presented in Table II.TABLE II THE SUBTILISIN 309 GENE Signal ATGAAGAAACCG TTGGGGAAAATT GTCGCAAGCACC GCACTACTCATT TCTGTTGCTTTT 1 PRO AGTTCATCGATC GCATCGGCTGCT GAAGAAGCAAAA GAAAAATATTTA ATTGGCTTTAAT 82 GAGCAGGAAGCT GTCAGTGAGTTT GTAGAACAAGTA GAGGCAAATGAC GAGGTCGCCATT CTCTCTGAGGAA GAGGAAGTCGAA ATTGAATTGCTT CATGAATTTGAA ACGATTCCTGTT TTATCCGTTGAG TTAAGCCCAGAA GATGTGGACGCG CTTGAACTCGAT CCAGCGATTTCT Mature TATATTGAAGAG GATGCAGAAGTA ACGACAATGGCG CAATCAGTGCCA TGGGGAATTAGC 334 CGTGTGCAAGCC CCAGCTGCCCAT AACCGTGGATTG ACAGGTTCTGGT GTAAAAGTTGCT GTCCTCGATACA GGTATTTCCACT CATCCAGACTTA AATATTCGTGGT GGCGCTAGCTTT GTACCAGGGGAA CCATCCACTCAA GATGGGAATGGG CATGGCACGCAT GTGGCCGGGACG ATTGCTGCTTTA AACAATTCGATT GGCGTTCTTGGC GTAGCGCCGAGC GCGGAACTATAC GCTGTTAAAGTA TTAGGGGCGAGC GGTTCAGGTTCG GTCAGCTCGATT GCCCAAGGATTG GAATGGGCAGGG AACAATGGCATG CACGTTGCTAAT TTGAGTTTAGGA AGCCCTTCGCCA XbaI AGTGCCACACTT GAGCAAGCTGTT AATAGCGCGACT TCTAGAGGCGTT CTTGTTGTAGCG GCATCTGGGAAT TCAGGTGCAGGC TCAATCAGCTAT CCGGCCCGTTAT GCGAACGCAATG GCAGTCGGAGCT ACTGACCAAAAC AACAACCGCGCC AGCTTTTCACAG TATGGCGCAGGG CTTGACATTGTC GCACCAGGTGTA AACGTGCAGAGC ACATACCCAGGT TCAACGTATGCC ClaI AGCTTAAACGGT ACATCGATGGCT ACTCCTCATGTT GCAGGTGCAGCA GCCCTTGTTAAA CAAAAGAACCCA TCTTGGTCCAAT GTACAAATCCGC AATCATCTAAAG AATACGGCAACG AGCTTAGGAAGC ACGAACTTGTAT GGAAGCGGACTT GTCAATGCAGAA GCGGCAACACGC Stop TAA 1141 - The same procedure as above was used for the cloning of the
subtilisin 147 gene except that the DNA fragments were ligated into the plasmid pSXS6 (also described in U.S. application Ser. No. 039,298 supra), which as indicated inFIG. 2 instead of the xyn promoter harbors the xyl promoter. One clone was found harboring a plasmid, pSX94, carrying the gene forsubtilisin 147. The sequence for this gene is shown in Table III below.TABLE III THE SUBTILISIN 147 GENE Signal ATGAGACAAAGT CTAAAAGTTATG GTTTTGTCAACA GTGGCATTGCTT TTCATGGCAAAC 1 Pro CCAGCAGCAGCA GGCGGGGAGAAA AAGGAATATTTG ATTGTCGTCGAA CCTGAAGAAGTT 73 TCTGCTCAGAGT GTCGAAGAAAGT TATGATGTGGAC GTCATCCATGAA TTTGAAGAGATT CCAGTCATTCAT GCAGAACTAACT AAAAAAGAATTG AAAAAATTAAAG AAAGATCCGAAC Mature GTAAAAGCCATC GAAGAGAATGCA GAAGTAACCATC AGTCAAACGGTT CCTTGGGGAATT 280 TCATTCATTAAT ACGCAGCAAGCG CACAACCGCGGT ATTTTTGGTAAC GGTGCTCGAGTC GCTGTCCTTGAT ACAGGAATTGCT TCACACCCAGAC TTACGAATTGCA GGGGGAGCGAGC TTTATTTCAAGC GAGCCTTCCTAT CATGACAATAAC GGACACGGAACT CACGTGGCTGGT ACAATCGCTGCG TTAAACAATTCA ATCGGTGTGCTT GGTGTACGACCA TCGGCTGACTTG TACGCTCTCAAA GTTCTTGATCGG AATGGAAGTGGT TCGCTTGCTTCT GTAGCTCAAGGA ATCGAATGGGCA ATTAACAACAAC ATGCACATTATT AATATGAGCCTT GGAAGCACGAGT GGTTCTAGCACG TTAGAGTTAGCT GTCAACCGAGCA AACAATGCTGGT ATTCTCTTAGTA GGGGCAGCAGGT AATACGGGTAGA CAAGGAGTTAAC TATCCTGCTAGA TACTCTGGTGTT ATGGCGGTTGCA GCAGTTGATCAA AATGGTCAACGC GCAAGCTTCTCT ACGTATGGCCCA GAAATTGAAATT TCTGCACCTGGT GTCAACGTAAAC AGCACGTACACA GGCAATCGTTAC GTATCGCTTTCT GGAACATCTATG GCAACACCACAC GTTGCTGGAGTT GCTGCACTTGTG AAGAGCAGATAT CCTAGCTATACG AACAACCAAATT CGCCAGCGTATT AATCAAACAGCA ACGTATCTAGGT TCTCCTAGCCTT TATGGCAATGGA TTAGTACATGCT GGACGTGCAACA Stop CAATAA 1084 - Generation of Site-Specific Mutations of the
Subtilisin 309 Gene - Site specific mutations were performed by the method of Morinaga et al. (Biotechnology, supra). The following oligonucleotides were used for introducing the mutations:
- a) Gly-195-Glu:
- A 27-mer mismatch primer, Nor-237, which also generates a novel SacI restriction site
5′ CACAGTATGGGCGCAGGGCTTGACATTGTCGCACCA GG 3′ NOR-237 5′ GTATGGCGCAGAGCTCGACATTTGTCGC 3′ SacI
b) Gly-195-Asp: - A 23-mer mismatch primer, NOR-323, which also generates a novel BglII site
AT 5′ CACAGTATGGGCGCAGGGCTTGACATTGTC 3′ 3′ CATACCGCGTCTAGAACTGTAAC 5′ BglII
c) Met-222-Cys: - A 24-mer mismatch primer, NOR-236
ClaI 5′ AGCTTAA{overscore (ACGGTACA)}TCGATGGCTACTCCTCATGTT 3′ NOR-236 5′ ACGGTACATCGTGCGCTACTCCTC 3′
d) Met-222-Ala: - A 22-mer mismatch primer, NOR-235
ClaI 5′ AGCTTAAACGGTACATCGATGGCTACTCCTCATGTT 3′ NOR-235 5′ CGGTACATCGGCGGCTACTCCT 3′
Both of these primers destroy the unique ClaI site.
e) Ser-153-Ala: - An 18-mer mismatch primer, NOR-324, which also generates a novel PvuII site
G 5′ CTTGTAGCGGCATCTGGGAATTCAGGT 3′ NOR-324 3′ CATCGCCGTCGACCCTTA 5′ PvuII
f) Asn-218-Ser: - A 23-mer mismatch primer, NOR-325, which also generates a novel MspI site
TC 5′ TATGCCAGCTTAAACGGTACATCGATG 3′ NOR-324 3′ TACGGTCGAATAGGCCATGTAGC 5′ MspI
g) Thr-71-Asp: - A 23-mer mismatch primer, NOR-483,
GAC 5′ TGTGGCCCGGGACGATTGCTGCTT 3′ NOR-483 3′ ACACCGGCCCCCTGTAACGACGAA 5′
h) Met-222-Cys and Gly-219-Cys: - A 32-mer mismatch, NOR-484,
T TGT 5′ CAGCTTAAACGGTACATCGATGGCTACTCCTC 3′ 219 222 NOR-484 3′ GTCGAATTTGACATGTAGCACACGATGAGGAG 5′
i+j) Gly-195-Glu and Met-222-Ala or Met-222-Cys: - For these double mutants combinations of NOR-237 and NOR-235 or NOR-236 were performed by joining the single mutant DNA-fragments.
- k) Ser-153-Ala and Asn-218-Ser:
- A combination of NOR-324 and NOR-325 was performed in analogy with the above.
- Gapped duplex mutagenesis was performed using the plasmid pSX93 as template. pSX93 is shown in
FIGS. 3A and 3B, and is pUC13 (Vieira, J. and Messing, J., 1982, Gene 19: 259-268) harboring an 0.7 kb XbaI-HindIII fragment of thesubtilisin 309 gene including the terminator inserted in the polylinker. The terminator and the HindIII site are not shown in Table II. - For the introduction of mutations in the N-terminal part of the enzyme the plasmid pSX119 was used. pSX119 is pUC13 harboring an EcoRI-XbaI fragment of the
subtilisin 309 gene inserted into the polylinker. The templates pSX93 and pSX119 thus cover the whole of thesubtilisin 309 gene. - The mutations a), b), and e) were performed by cutting pSX93 with XbaI and ClaI as indicated in
FIG. 3A ; c), d), f), and h) were performed by cutting pSX93 with XbaI and HindIII as indicated inFIG. 3B . - Mutation g) was performed correspondingly in pSX119 by cutting with EcoRI and XbaI.
- The double mutants i) and j) were produced by cutting the 0.7 kb Xba-HindIII fragment from a) partially with HgiAI (HgiAI also cuts in SacI, which was introduced by the mutation). This 180 bp XbaI-HgiAI fragment and the 0.5 kb HgiAI fragment from the c) and d) mutants, respectively, were ligated to the large HindIII-XbaI fragment from pSX93.
- The double mutant k) was produced as above by combining mutants e) and f).
- Subsequent to annealing, filling and ligation the mixture was used to transform E. coli MC 1000 r−m+. Mutants among the transformants were screened for by colony hybridization as described in Vlasuk et al., 1983, J. Biol. Chem., 258:7141-7148 and in Vlasuk, G. P. and Inouye, S., p. 292-303 in ‘Experimental Manipulation of Gene Expression’ Inouye, M. (ed.) Academic Press, New York. The mutations were confirmed by DNA sequencing.
- Expression of Mutant Subtilisins
- Subsequent to a sequence confirmation of the correct mutation the mutated DNA fragments were inserted into plasmid pSX92, which was used for producing the mutants.
- Plasmid pSX92 is shown in
FIG. 4 and was produced by cloning thesubtilisin 309 gene into plasmid pSX62 cut at ClaI, filled in with the Klenow fragment of DNA polymerase I, and cut with HindIII prior to the insertion of the fragments DraI-NheI and NheI-HindIII from the clonedsubtilisin 309 gene. - To express the mutants the mutated fragments (XbaI-ClaI, XbaI-HindIII, or EcoRI-XbaI) were excised from the appropriate mutation plasmid pSX93 or pSX119, respectively, and inserted into pSX92.
- The mutated pSX92 was then used to transform B. subtilis strain DN497, which was then grown in the same medium and under the same conditions as used for the cloning of the parent gene.
- After appropriate growth the mutated enzymes were recovered and purified.
- Oxidation Stability of Mutant Subtilisins
- The mutants a) and d) were tested for their oxidation stability in 0.01 M peracetic acid after 20 minutes at 50° C. and pH 7. The parent strain NCIB 10309 protease was used as reference.
- The results are indicated in Table IV below, which presents the residual proteolytic activity in the heat treated samples relative to samples untreated by oxidant or heat.
TABLE IV Oxidation Stability Towards Peracetic Acid Residual Activity after 20 min. at 50° C. Enzyme without oxidant with oxidant Subtilisin 309 89% 48% mutant a 83% 45% mutant d 92% 93% - It is concluded that mutant d (Met 222 to Ala) exhibits superior oxidation stability realtive to the parent enzyme and mutant a.
- All the mutants except g) and h) have also been tested qualitatively in 100-500 ppm hypochlorite at room temperature and 35° C., pH 6.5 and 9.0, for from 15 minutes to 2 hours.
- These tests showed that mutants c), d), i), and j) (all Met-222) could resist 3-5 times more hypochlorite than the other mutants.
- When tested in a liquid detergent of the usual built type it was found that mutant f) exhibited superior stability compared to both the other mutants and the “parent” enzyme.
- Proteolytic Activity Of Mutant Subtilisins
- The proteolytic activity of various mutants was tested against casein as protein substrate, according to methods detailed supra. The results are presented in Table V.
- From the table it is seen that mutant a) exhibits enhanced activity compared to the parent. It is also seen that the Met-222 mutants have lower activity than the parent, but due to their improved oxidation stability their application in detergent compositions containing oxidants is not precluded.
TABLE V Proteolytic Activity of Mutant Subtilisins Mutant Relative Activity None 100 a) 120 b) 100 c) 30 d) 20 e) 100 f) 100 i) 20 j) 30 - Washability of Mutant Subtilisins
- The washability of various mutants was tested against spinach juice according to methods detailed supra. The results are presented in Table VI.
- From the table it is seen that all of the tested mutants exhibited an improved washing ability compared to the parent enzyme, and that mutants c), d), i), and j) are markedly superior.
TABLE VI Washability of Mutant Delta R Mutant Concentration (CPU/l) 0.05 0.1 none 14.4 20.4 a) 18.8 21.5 b) 16.9 19.7 c) 21.8 23.8 d 22.2 23.4 e) 15.4 21.8 f) 16.6 19.3 i) 21.6 22.1 j) 20.6 22.6
95% confidence interval: +/−0.9
- Thermostability Of Mutant Subtilisins
- The thermostability of mutant f) was tested against the wild type enzyme by using the washability test at 40° C. and 60° C., respectively. The results are shown in Table VII.
- From the table it is seen that mutant f) at 60° C shows a much improved washability compared to the wild type enzyme, whereas at 40° C. the washability of mutant f) is only slightly better than the wild type enzyme.
TABLE VII Washability at Different Temperatures Delta R Mutant Concentration (CPU/l) 0.05 0.1 none (40° C.) 14.4 20.4 f) (40° C.) 16.6 19.3 none (60° C.) 15.1 24.9 f) (60° C.) 30.4 31.3
95% confidence interval +/−0.9 (40° C.) and +/−0.7 (60° C.)
Discussion - Subtilisin genes were cloned from the 147 and 309 variants of the bacterium Bacillus lentus, and the cloned genes were sequenced. By comparing the deduced amino acid sequences of
subtilisins subtilisin 309 gene. The resulting mutant enzymes were then expressed in a Bacillus strain, and tested against various physical and chemical parameters. Several of the mutants were shown to have improved stability to oxidation, increased proteolytic ability, or improved washability when compared withsubtilisin 309. These mutants exhibit properties desirable in enzymes comprised in detergent compositions.
Claims (43)
1. A modified subtilisin 309, comprising a substitution at one or more of the following positions:
53, 67, 124, 128, 131, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 169, 170, 172, 218, 219, and 222
wherein each position corresponds to the position of the amino acid sequence of the mature subtilisin BPN′ as depicted in Table I(c):
2. The modified subtilisin of claim 1 , which has augmented protease activity or improved washing ability.
3. The modified subtilisin of claim 1 , comprising a substitution at position 53.
4. The modified subtilisin of claim 1 , comprising a substitution at position 67.
5. The modified subtilisin of claim 1 , wherein the substitution is with aspartic acid or glutamic acid.
6. The modified subtilisin of claim 1 , comprising a substitution at position 124.
7. The modified subtilisin of claim 1 , comprising a substitution at position 128.
8. The modified subtilisin of claim 1 , comprising a substitution at position 131.
9. The modified subtilisin of claim 1 , comprising a substitution at position 154.
10. The modified subtilisin of claim 1 , comprising a substitution at position 155.
11. The modified subtilisin of claim 1 , comprising a substitution at position 156.
12. The modified subtilisin of claim 1 , comprising a substitution at position 157.
13. The modified subtilisin of claim 1 , comprising a substitution at position 158.
14. The modified subtilisin of claim 1 , comprising a substitution at position 159.
15. The modified subtilisin of claim 1 , comprising a substitution at position 160.
16. The modified subtilisin of claim 1 , comprising a substitution at position 161.
17. The modified subtilisin of claim 1 , comprising a substitution at position 162.
18. The modified subtilisin of claim 1 , comprising a substitution at position 163.
19. The modified subtilisin of claim 1 , comprising a substitution at position 164.
20. The modified subtilisin of claim 1 , comprising a substitution at position 165.
21. The modified subtilisin of claim 1 , comprising a substitution at position 166.
22. The modified subtilisin of claim 1 , comprising a substitution at position 168.
23. The modified subtilisin of claim 22 , wherein the substitution is with alanine.
24. The modified subtilisin of claim 1 , comprising a substitution at position 169.
25. The modified subtilisin of claim 1 , comprising a substitution at position 170.
26. The modified subtilisin of claim 25 , wherein the substitution is with tyrosine.
27. The modified subtilisin of claim 1 , comprising a substitution at position 172.
28. The modified subtilisin of claim 1 , comprising a substitution at position 218.
29. The modified subtilisin of claim 28 , wherein the substitution is with serine.
30. The modified subtilisin of claim 1 , comprising a substitution at position 219.
31. The modified subtilisin of claim 30 , wherein the substitution is with methionine.
32. The modified subtilisin of claim 1 , comprising a substitution at position 222.
33. The modified subtilisin of claim 32 , wherein the substitution is with cysteine or alanine.
34. A detergent composition comprising a modified subtilisin of claim 1 and a surfactant.
35. A modified subtilisin 309, comprising an insertion at one or more of the following positions:
36, 56, 159, 164, 165 and 166
wherein each position corresponds to the position of the amino acid sequence of the mature subtilisin BPN′ as depicted in Table I(c).
36. The modified subtilisin of claim 35 , which has augmented protease activity or improved washing ability.
37. The modified subtilisin of claim 35 , comprising an insertion at position 6.
38. The modified subtilisin of claim 35 , comprising an insertion at position 56.
39. The modified subtilisin of claim 35 , comprising an insertion at position 159.
40. The modified subtilisin of claim 35 , comprising an insertion at position 164.
41. The modified subtilisin of claim 35 , comprising an insertion at position 165.
42. The modified subtilisin of claim 35 , comprising an insertion at position 166.
43. A detergent composition comprising a modified subtilisin of claim 35 and a surfactant.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/896,177 US20050003986A1 (en) | 1988-01-07 | 2004-07-21 | Useful mutations of bacterial alkaline protease |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK006488A DK6488D0 (en) | 1988-01-07 | 1988-01-07 | ENZYMES |
DK64/88 | 1988-01-07 | ||
US29424189A | 1989-01-06 | 1989-01-06 | |
US08/486,846 US6506589B1 (en) | 1988-01-07 | 1995-06-07 | Useful mutations of bacterial alkaline protease |
US10/306,089 US6808913B2 (en) | 1988-01-07 | 2002-11-27 | Useful mutations of bacterial alkaline protease |
US10/896,177 US20050003986A1 (en) | 1988-01-07 | 2004-07-21 | Useful mutations of bacterial alkaline protease |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/306,089 Continuation US6808913B2 (en) | 1988-01-07 | 2002-11-27 | Useful mutations of bacterial alkaline protease |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050003986A1 true US20050003986A1 (en) | 2005-01-06 |
Family
ID=8089323
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/486,415 Expired - Lifetime US5741694A (en) | 1988-01-07 | 1995-06-07 | Useful mutations of bacterial alkaline protease |
US08/486,846 Expired - Lifetime US6506589B1 (en) | 1988-01-07 | 1995-06-07 | Useful mutations of bacterial alkaline protease |
US10/306,089 Expired - Fee Related US6808913B2 (en) | 1988-01-07 | 2002-11-27 | Useful mutations of bacterial alkaline protease |
US10/310,730 Expired - Fee Related US6835821B2 (en) | 1988-01-07 | 2002-12-05 | Useful mutations of bacterial alkaline protease |
US10/313,853 Expired - Fee Related US6908991B2 (en) | 1988-01-07 | 2002-12-06 | Useful mutations of bacterial alkaline protease |
US10/896,177 Abandoned US20050003986A1 (en) | 1988-01-07 | 2004-07-21 | Useful mutations of bacterial alkaline protease |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/486,415 Expired - Lifetime US5741694A (en) | 1988-01-07 | 1995-06-07 | Useful mutations of bacterial alkaline protease |
US08/486,846 Expired - Lifetime US6506589B1 (en) | 1988-01-07 | 1995-06-07 | Useful mutations of bacterial alkaline protease |
US10/306,089 Expired - Fee Related US6808913B2 (en) | 1988-01-07 | 2002-11-27 | Useful mutations of bacterial alkaline protease |
US10/310,730 Expired - Fee Related US6835821B2 (en) | 1988-01-07 | 2002-12-05 | Useful mutations of bacterial alkaline protease |
US10/313,853 Expired - Fee Related US6908991B2 (en) | 1988-01-07 | 2002-12-06 | Useful mutations of bacterial alkaline protease |
Country Status (7)
Country | Link |
---|---|
US (6) | US5741694A (en) |
EP (4) | EP0675196A3 (en) |
JP (3) | JPH0675504B2 (en) |
AT (1) | ATE136329T1 (en) |
DE (1) | DE68926163T2 (en) |
DK (3) | DK6488D0 (en) |
WO (1) | WO1989006279A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040248273A1 (en) * | 2000-10-13 | 2004-12-09 | Novozymes A/S | Subtilase variants |
US20070270574A1 (en) * | 2000-04-03 | 2007-11-22 | Novozymes A/S | Subtilisin variants |
WO2013138288A1 (en) | 2012-03-16 | 2013-09-19 | Monosol, Llc. | Water soluble compositions incorporating enzymes, and method of making same |
WO2013158364A1 (en) | 2012-04-16 | 2013-10-24 | Monosol, Llc | Powdered pouch and method of making same |
US11104497B2 (en) | 2014-10-03 | 2021-08-31 | Monosol, Llc | Degradable materials and packaging made from same |
Families Citing this family (678)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5185258A (en) | 1984-05-29 | 1993-02-09 | Genencor International, Inc. | Subtilisin mutants |
DK6488D0 (en) * | 1988-01-07 | 1988-01-07 | Novo Industri As | ENZYMES |
US6287841B1 (en) | 1988-02-11 | 2001-09-11 | Genencor International, Inc. | High alkaline serine protease |
US5324653A (en) * | 1988-02-11 | 1994-06-28 | Gist-Brocades N.V. | Recombinant genetic means for the production of serine protease muteins |
PT89702B (en) * | 1988-02-11 | 1994-04-29 | Gist Brocades Nv | PROCESS FOR PREPARING NEW PROTEOLITIC ENZYMES AND DETERGENTS THAT CONTAINS THEM |
US5116741A (en) * | 1988-04-12 | 1992-05-26 | Genex Corporation | Biosynthetic uses of thermostable proteases |
BR9006827A (en) * | 1989-06-26 | 1991-08-06 | Unilever Nv | ENZYMATIC DETERGENT COMPOSITES |
US5665587A (en) * | 1989-06-26 | 1997-09-09 | Novo Nordisk A/S | Modified subtilisins and detergent compositions containing same |
DK316989D0 (en) * | 1989-06-26 | 1989-06-26 | Novo Nordisk As | ENZYMES |
BR9006832A (en) * | 1989-06-26 | 1991-08-06 | Unilever Nv | ENZYMATIC DETERGENT COMPOSITION |
US5658871A (en) * | 1989-07-07 | 1997-08-19 | Lever Brothers Company, Division Of Conopco, Inc. | Microbial lipase muteins and detergent compositions comprising same |
DK0493398T3 (en) * | 1989-08-25 | 2000-05-22 | Henkel Research Corp | Alkaline, proteolytic enzyme and process for its preparation |
DE4023458A1 (en) * | 1989-08-31 | 1991-03-07 | Kali Chemie Ag | NEW HIGH ALKALINE PROTEASES |
US5352603A (en) * | 1989-08-31 | 1994-10-04 | Kali-Chemie Ag | Highly alkaline proteases |
US6271012B1 (en) * | 1989-10-11 | 2001-08-07 | Genencor International, Inc. | Protease muteins and their use in detergents |
US5541062A (en) * | 1990-02-23 | 1996-07-30 | Arch Development Corporation | Methods and compositions for preparing protein processing enzymes |
DK97190D0 (en) * | 1990-04-19 | 1990-04-19 | Novo Nordisk As | OXIDATION STABLE DETERGENT ENZYMER |
US5733473A (en) * | 1990-11-14 | 1998-03-31 | The Procter & Gamble Company | Liquid detergent composition containing lipase and protease |
DK271490D0 (en) * | 1990-11-14 | 1990-11-14 | Novo Nordisk As | detergent composition |
US5766898A (en) * | 1990-12-05 | 1998-06-16 | Novo Nordisk A/S | Proteins with changed epitopes and methods for the production thereof |
US6967080B1 (en) * | 1990-12-05 | 2005-11-22 | Novozymes A/S | Proteins with changed epitopes and methods for the production thereof |
EP0561907B1 (en) * | 1990-12-05 | 1998-09-02 | Novo Nordisk A/S | Proteins with changed epitopes and methods for the production thereof |
US5482849A (en) * | 1990-12-21 | 1996-01-09 | Novo Nordisk A/S | Subtilisin mutants |
ATE159757T1 (en) * | 1990-12-21 | 1997-11-15 | Novo Nordisk As | ENZYME MUTANTS WITH SMALL MOLECULAR CHARGE VARIATION OVER A PH RANGE |
GB9027836D0 (en) * | 1990-12-21 | 1991-02-13 | Unilever Plc | Enzymes and enzymatic detergent compositions |
US5340735A (en) * | 1991-05-29 | 1994-08-23 | Cognis, Inc. | Bacillus lentus alkaline protease variants with increased stability |
US5646028A (en) * | 1991-06-18 | 1997-07-08 | The Clorox Company | Alkaline serine protease streptomyces griseus var. alkaliphus having enhanced stability against urea or guanidine |
EP0525610A3 (en) * | 1991-07-27 | 1993-03-24 | Solvay Enzymes Gmbh & Co. Kg | Process for increasing the stability of enzymes and stabilized enzymes |
US5275945A (en) * | 1991-10-08 | 1994-01-04 | Vista Chemical Company | Alkaline proteases stable in heavy-duty detergent liquids |
SK43094A3 (en) * | 1991-10-16 | 1994-09-07 | Unilever Nv | Aqueous enzymatic detergent compositions |
US5371198A (en) * | 1991-12-16 | 1994-12-06 | Novo Nordisk A/S | Method for protection of proteolysis-susceptible protein during protein production in a fluid medium |
US5623059A (en) * | 1992-03-09 | 1997-04-22 | Novo Nordisk A/S | Method for protection of proteolysis-susceptible protein during protein production in a fluid medium |
DE69333463D1 (en) * | 1992-05-18 | 2004-05-06 | Genencor Int | Bacteria producing alkaline proteases, and process for producing these alkaline proteases |
KR950702633A (en) * | 1992-07-17 | 1995-07-29 | 한스 발터 라벤 | HIGH ALKALINE SERINE PROTEASES |
JPH0763377B2 (en) * | 1992-09-03 | 1995-07-12 | 大阪府 | Heat-resistant alkaline protease gene, recombinant plasmid pABT17, Bacillus subtilis plasmid vector pABTts14 and transformant of the Bacillus subtilis plasmid vector pABTts14 |
DE4231726A1 (en) * | 1992-09-23 | 1994-03-24 | Cognis Bio Umwelt | Mutated subtilisin-like serine proteases |
GB9220669D0 (en) * | 1992-09-30 | 1992-11-11 | Unilever Plc | Detergent composition |
US6440717B1 (en) | 1993-09-15 | 2002-08-27 | The Procter & Gamble Company | BPN′ variants having decreased adsorption and increased hydrolysis |
US6436690B1 (en) | 1993-09-15 | 2002-08-20 | The Procter & Gamble Company | BPN′ variants having decreased adsorption and increased hydrolysis wherein one or more loop regions are substituted |
ES2287931T3 (en) * | 1993-10-14 | 2007-12-16 | THE PROCTER & GAMBLE COMPANY | CLEANING COMPOSITIONS CONTAINING PROTEASE. |
MA23346A1 (en) | 1993-10-14 | 1995-04-01 | Genencor Int | VARIANTS OF THE SUB-USE |
US5677272A (en) * | 1993-10-14 | 1997-10-14 | The Procter & Gamble Company | Bleaching compositions comprising protease enzymes |
US6406855B1 (en) | 1994-02-17 | 2002-06-18 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US5837458A (en) * | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US6599730B1 (en) | 1994-05-02 | 2003-07-29 | Procter & Gamble Company | Subtilisin 309 variants having decreased adsorption and increased hydrolysis |
AU703378B2 (en) * | 1994-06-23 | 1999-03-25 | Unilever Plc | Dishwashing compositions |
US6066611A (en) * | 1994-10-13 | 2000-05-23 | The Procter & Gamble Company | Bleaching compositions comprising protease enzymes |
US6455295B1 (en) | 1995-03-08 | 2002-09-24 | The Procter & Gamble Company | Subtilisin Carlsberg variants having decreased adsorption and increased hydrolysis |
IL117350A0 (en) | 1995-03-09 | 1996-07-23 | Procter & Gamble | Proteinase k variants having decreased adsorption and increased hydrolysis |
US6475765B1 (en) | 1995-03-09 | 2002-11-05 | Procter & Gamble Company | Subtilisin DY variants having decreased adsorption and increased hydrolysis |
BR9608149B1 (en) * | 1995-05-05 | 2012-01-24 | processes for effecting mutation in DNA encoding a subtilase enzyme or its pre- or pre-enzyme and for the manufacture of a mutant subtilase enzyme. | |
US6682924B1 (en) * | 1995-05-05 | 2004-01-27 | Novozymes A/S | Protease variants and compositions |
US5837517A (en) | 1995-05-05 | 1998-11-17 | Novo Nordisk A/S | Protease variants and compositions |
US20120165241A1 (en) * | 1995-05-05 | 2012-06-28 | Unilever Plc | Subtilase Variants |
US6936289B2 (en) | 1995-06-07 | 2005-08-30 | Danisco A/S | Method of improving the properties of a flour dough, a flour dough improving composition and improved food products |
AU4773197A (en) | 1996-11-04 | 1998-05-29 | Novo Nordisk A/S | Subtilase variants and compositions |
KR100561826B1 (en) | 1996-11-04 | 2006-03-16 | 노보자임스 에이/에스 | Subtilase variants and compositions |
US6077662A (en) * | 1996-11-27 | 2000-06-20 | Emory University | Virus-like particles, methods and immunogenic compositions |
ATE220502T1 (en) * | 1997-04-09 | 2002-08-15 | Danisco | IMPROVED METHOD FOR PRODUCING FLOUR PASTA AND PRODUCTS MADE FROM SUCH PASTA USING GLYCERINE OXIDASE |
US6140475A (en) | 1997-04-11 | 2000-10-31 | Altus Biologics Inc. | Controlled dissolution crosslinked protein crystals |
KR20010023468A (en) | 1997-08-29 | 2001-03-26 | 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 | Protease variants and compositions |
ATE385254T1 (en) | 1997-08-29 | 2008-02-15 | Novozymes As | PROTEASE VARIANTS AND COMPOSITIONS |
EP0913458B1 (en) * | 1997-10-22 | 2004-06-16 | The Procter & Gamble Company | Liquid hard-surface cleaning compositions |
AR016969A1 (en) * | 1997-10-23 | 2001-08-01 | Procter & Gamble | PROTEASE VARIANTE, ADN, EXPRESSION VECTOR, GUEST MICROORGANISM, CLEANING COMPOSITION, ANIMAL FOOD AND COMPOSITION TO TREAT A TEXTILE |
ES2367505T3 (en) | 1997-10-23 | 2011-11-04 | Danisco Us Inc. | PROTEASE VARIANTS WITH MULTIPLE SUBSTITUTIONS WITH ALTERED NET LOAD FOR USE IN DETERGENTS. |
US6780629B2 (en) | 1997-11-21 | 2004-08-24 | Novozymes A/S | Subtilase enzymes |
US6773907B2 (en) | 1997-11-21 | 2004-08-10 | Peter Kamp Hansen | Subtilase enzymes |
EP1032655B1 (en) | 1997-11-21 | 2005-06-29 | Novozymes A/S | Protease variants and compositions |
US6835550B1 (en) | 1998-04-15 | 2004-12-28 | Genencor International, Inc. | Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins |
US6936249B1 (en) | 1998-04-15 | 2005-08-30 | Genencor International, Inc. | Proteins producing an altered immunogenic response and methods of making and using the same |
US6642011B2 (en) | 1998-04-15 | 2003-11-04 | Genencor International, Inc. | Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins |
WO2000005396A1 (en) * | 1998-07-21 | 2000-02-03 | Danisco A/S | Foodstuff |
US6461849B1 (en) * | 1998-10-13 | 2002-10-08 | Novozymes, A/S | Modified polypeptide |
US6831053B1 (en) | 1998-10-23 | 2004-12-14 | The Procter & Gamble Company | Bleaching compositions comprising multiply-substituted protease variants |
US6376450B1 (en) | 1998-10-23 | 2002-04-23 | Chanchal Kumar Ghosh | Cleaning compositions containing multiply-substituted protease variants |
JP4723087B2 (en) | 1998-11-27 | 2011-07-13 | ノボザイムス アクティーゼルスカブ | Lipolytic enzyme mutant |
CA2352534A1 (en) | 1998-12-08 | 2000-06-15 | Children's Hospital And Regional Medical Center | Polymorphic loci that differentiate escherichia coli 0157:h7 from other strains |
ATE504651T1 (en) | 1998-12-18 | 2011-04-15 | Novozymes As | SUBTILASE ENZYMES OF THE I-S1 AND I-S2 SUBGROUPS WITH AN ADDITIONAL AMINO ACID RESIDUE IN AN ACTIVE LOOP REGION |
JP4745503B2 (en) | 1999-03-31 | 2011-08-10 | ノボザイムス アクティーゼルスカブ | Polypeptides having alkaline α-amylase activity and nucleic acids encoding them |
AU3419200A (en) | 1999-03-31 | 2000-10-23 | Novozymes A/S | Polypeptides having alkaline alpha-amylase activity and nucleic acids encoding same |
KR20000065867A (en) | 1999-04-09 | 2000-11-15 | 손경식 | Alkaline Protease Vapk Useful as Washing Detergent, vapk Gene, Recombinant Expression Vector, and Transformed Microorganism |
EP1183340B1 (en) | 1999-05-20 | 2008-09-03 | Novozymes A/S | Subtilase enzymes of the i-s1 and i-s2 sub-groups having at least one additional amino acid residue between positions 126 and 127 |
DE60040284D1 (en) | 1999-05-20 | 2008-10-30 | Novozymes As | SUBTILASE ENZYMES OF I-S1 AND I-S2 SUB-GROUPS WITH AT LEAST ONE ADDITIONAL AMINO ACID BETWEEN POSITIONS 129 AND 130 |
WO2000071689A1 (en) | 1999-05-20 | 2000-11-30 | Novozymes A/S | Subtilase enzymes of the i-s1 and i-s2 sub-groups having at least one additional amino acid residue between positions 127 and 128 |
ATE408676T1 (en) | 1999-05-20 | 2008-10-15 | Novozymes As | SUBTILASE ENZYMES OF THE I-S1 AND I-S2 SUBGROUPS WITH AT LEAST ONE ADDITIONAL AMINO ACID BETWEEN POSITIONS 132 AND 133 |
DE60040287D1 (en) | 1999-05-20 | 2008-10-30 | Novozymes As | SUBTILASE ENZYMS OF I-S1 AND I-S2 SUB-GROUPS WITH AT LEAST ONE ADDITIONAL AMINO ACID BETWEEN POSITIONS 128 AND 129 |
WO2000071691A1 (en) | 1999-05-20 | 2000-11-30 | Novozymes A/S | Subtilase enzymes of the i-s1 and i-s2 sub-groups having at least one additional amino acid residue between positions 125 and 126 |
EP1210415A2 (en) * | 1999-07-22 | 2002-06-05 | The Procter & Gamble Company | Subtilisin protease variants having amino acid substitutions in defined epitope regions |
EP1214426A2 (en) | 1999-08-31 | 2002-06-19 | Novozymes A/S | Novel proteases and variants thereof |
US6727085B2 (en) | 1999-12-15 | 2004-04-27 | Fanoe Tina Sejersgaard | Subtilase variants having an improved wash performance on egg stains |
US6777218B1 (en) | 2000-03-14 | 2004-08-17 | Novozymes A/S | Subtilase enzymes having an improved wash performance on egg stains |
US20020192792A1 (en) * | 2000-04-28 | 2002-12-19 | Palle Schneider | Laccase mutants |
CA2419896C (en) | 2000-08-21 | 2014-12-09 | Novozymes A/S | Subtilase enzymes |
US6541234B1 (en) * | 2000-09-11 | 2003-04-01 | University Of Maryland Biotechnology Institute | Calcium free subtilisin mutants |
US6541235B1 (en) * | 2000-09-29 | 2003-04-01 | University Of Maryland Biotechnology Institute | Calcium free subtilisin mutants |
EP1975229A3 (en) | 2000-10-13 | 2009-03-18 | Novozymes A/S | Alpha-amylase variant with altered properties |
CN100497617C (en) | 2000-10-13 | 2009-06-10 | 诺维信公司 | Subtilase variants |
US6673580B2 (en) | 2000-10-27 | 2004-01-06 | Genentech, Inc. | Identification and modification of immunodominant epitopes in polypeptides |
EP1201753B1 (en) * | 2000-10-31 | 2008-04-23 | Boehringer Mannheim Gmbh | Methods for the analysis of non-proteinaceous components using a protease from a bacillus strain |
AU758744B2 (en) * | 2000-10-31 | 2003-03-27 | F. Hoffmann-La Roche Ag | Methods for the analysis of non-proteinaceous components using a protease from a bacillus strain |
EP1201752A1 (en) * | 2000-10-31 | 2002-05-02 | Roche Diagnostics GmbH | Methods for the analysis of non-proteinaceous components using a protease from a Bacillus strain |
US7303907B2 (en) | 2001-01-08 | 2007-12-04 | Health Protection Agency | Degradation and detection of TSE infectivity |
RU2311458C2 (en) | 2001-03-23 | 2007-11-27 | Джененкор Интернэшнл, Инк. | Proteins causing alternated immunogenic response and methods for their preparing and using |
DE10121463A1 (en) * | 2001-05-02 | 2003-02-27 | Henkel Kgaa | New alkaline protease variants and washing and cleaning agents containing these new alkaline protease variants |
EP3000881A3 (en) | 2001-05-15 | 2016-07-20 | Novozymes A/S | Alpha-amylase variant with altered properties |
BR0209154A (en) | 2001-05-18 | 2004-07-20 | Danisco | Process of preparing a dough with an enzyme |
DK2298868T3 (en) | 2001-06-26 | 2015-04-20 | Novozymes As | Polypeptides with cellobiohydrolase I activity and the same coding polynucleotides |
DK200101090A (en) * | 2001-07-12 | 2001-08-16 | Novozymes As | Subtilase variants |
JP2005535284A (en) | 2001-12-31 | 2005-11-24 | ジェネンコー・インターナショナル・インク | Protease that produces a change in immune response, and method for producing and using the same |
AU2003210552A1 (en) * | 2002-01-16 | 2003-09-02 | Genencor International, Inc. | Multiply-substituted protease variants |
EP1530631B1 (en) * | 2002-01-16 | 2013-08-07 | Genencor International, Inc. | Multiply-substituted protease variants |
CN1703511A (en) | 2002-02-26 | 2005-11-30 | 金克克国际有限公司 | Subtilisin carlsberg proteins with reduced immunogenicity |
JP2005520546A (en) | 2002-03-27 | 2005-07-14 | ノボザイムス アクティーゼルスカブ | Granule with filament coating |
DK1495128T3 (en) | 2002-03-29 | 2014-08-11 | Genencor Int | Enhanced protein expression in Bacillus |
DK1520012T3 (en) | 2002-07-01 | 2009-04-27 | Novozymes As | Monopropylene glycol added to fermentation medium |
JP4694966B2 (en) | 2002-07-30 | 2011-06-08 | ジェネンコー・インターナショナル・インク | Formulations that reduce aerosol production |
EP1549745B1 (en) | 2002-10-01 | 2011-01-05 | Novozymes A/S | Family gh 61 polypeptides |
SG188669A1 (en) * | 2002-10-02 | 2013-04-30 | Catalyst Biosciences Inc | Method of generating and screening for proteases with altered specificity |
US7888093B2 (en) * | 2002-11-06 | 2011-02-15 | Novozymes A/S | Subtilase variants |
TWI319007B (en) | 2002-11-06 | 2010-01-01 | Novozymes As | Subtilase variants |
BRPI0317124B1 (en) | 2002-12-11 | 2016-05-17 | Novozymes As | detergent composition and processes for washing a fabric and a hard surface |
WO2004056981A2 (en) | 2002-12-20 | 2004-07-08 | Novozymes A/S | Polypeptides having cellobiohydrolase ii activity and polynucleotides encoding same |
US7955814B2 (en) | 2003-01-17 | 2011-06-07 | Danisco A/S | Method |
US20050196766A1 (en) * | 2003-12-24 | 2005-09-08 | Soe Jorn B. | Proteins |
DE602004030000D1 (en) | 2003-01-17 | 2010-12-23 | Danisco | PROCESS FOR IN-SITU-PRODUCTION OF AN EMULSIFIER IN A FOODSTUFF |
EP1590455B1 (en) | 2003-01-27 | 2010-03-17 | Novozymes A/S | Stabilization of granules |
US7294499B2 (en) * | 2003-01-30 | 2007-11-13 | Novozymes A/S | Subtilases |
EP1923455A3 (en) | 2003-02-18 | 2009-01-21 | Novozymes A/S | Detergent compositions |
US7413888B2 (en) | 2003-05-02 | 2008-08-19 | Novozymes, Inc. | Variants of beta-glucosidases |
CA2526341C (en) | 2003-05-07 | 2013-02-19 | Novozymes A/S | Variant subtilisin enzymes (subtilases) |
EP1675941B1 (en) | 2003-06-25 | 2013-05-22 | Novozymes A/S | Polypeptides having alpha-amylase activity and polynucleotides encoding same |
EP1660637A4 (en) | 2003-08-25 | 2009-10-21 | Novozymes Inc | Variants of glycoside hydrolases |
JP4880469B2 (en) | 2003-10-23 | 2012-02-22 | ノボザイムス アクティーゼルスカブ | Protease with improved stability in detergents |
CN1902310B (en) | 2003-10-28 | 2011-09-21 | 诺维信股份有限公司 | Polypeptides having beta-glucosidase activity and polynucleotides encoding same |
CN1875098A (en) | 2003-10-30 | 2006-12-06 | 诺和酶股份有限公司 | Carbohydrate-binding modules of a new family |
GB0716126D0 (en) | 2007-08-17 | 2007-09-26 | Danisco | Process |
WO2008090395A1 (en) | 2007-01-25 | 2008-07-31 | Danisco A/S | Production of a lipid acyltransferase from transformed bacillus licheniformis cells |
US7718408B2 (en) * | 2003-12-24 | 2010-05-18 | Danisco A/S | Method |
US7906307B2 (en) | 2003-12-24 | 2011-03-15 | Danisco A/S | Variant lipid acyltransferases and methods of making |
JP5059412B2 (en) | 2004-01-06 | 2012-10-24 | ノボザイムス アクティーゼルスカブ | Alicyclobacillus sp. Polypeptide |
CN104726431B (en) | 2004-01-30 | 2018-06-01 | 诺维信股份有限公司 | Polypeptide and its coded polynucleotide with cellulolytic enhancing activity |
CN1942584B (en) | 2004-02-13 | 2011-07-27 | 诺维信公司 | Protease variants |
GB0405637D0 (en) * | 2004-03-12 | 2004-04-21 | Danisco | Protein |
EP1735433B1 (en) * | 2004-04-02 | 2010-12-08 | Novozymes A/S | Subtilase variants having altered immunogenicity |
EP1735339A2 (en) * | 2004-04-09 | 2006-12-27 | Genencor International, Inc. | Pcka modifications and enhanced protein expression in bacillus |
US7148404B2 (en) | 2004-05-04 | 2006-12-12 | Novozymes A/S | Antimicrobial polypeptides |
AU2005245516A1 (en) * | 2004-05-20 | 2005-12-01 | Warnex Research Inc. | Polynucleotides for the detection of escherichia coli 0157:h7 and escherichia coli 0157:nm verotoxin producers |
US20090060933A1 (en) * | 2004-06-14 | 2009-03-05 | Estell David A | Proteases producing an altered immunogenic response and methods of making and using the same |
BRPI0512776A (en) | 2004-07-05 | 2008-04-08 | Novozymes As | originating termamyl alpha-amylase variant, DNA construct, recombinant expression vector, cell, composition, detergent additive, detergent composition, manual or automatic laundry composition, use of an alpha-amylase variant or composition, and method of producing a variant |
EP2275522A3 (en) * | 2004-07-16 | 2011-09-21 | Danisco A/S | Enzymatic oil-degumming method |
CN101040052A (en) | 2004-09-10 | 2007-09-19 | 诺维信北美公司 | Methods for preventing, removing, reducing, or disrupting biofilm |
ATE533843T1 (en) | 2004-09-21 | 2011-12-15 | Novozymes As | SUBTILATE |
DK1794296T3 (en) | 2004-09-21 | 2012-07-30 | Novozymes As | subtilases |
WO2006032279A1 (en) | 2004-09-21 | 2006-03-30 | Novozymes A/S | Subtilases |
US7666630B2 (en) | 2004-09-30 | 2010-02-23 | Novozymes, Inc. | Polypeptides having lipase activity and polynucleotides encoding same |
DK1877551T4 (en) | 2005-04-27 | 2014-03-31 | Novozymes Inc | Polypeptides having endoglucanase activity and polynucleotides encoding the same |
EP2385111B1 (en) | 2005-07-08 | 2016-09-07 | Novozymes A/S | Subtilase variants |
EP1967584B1 (en) | 2005-08-16 | 2011-03-23 | Novozymes A/S | Polypeptides of strain bacillus SP. P203 |
ATE530642T1 (en) | 2005-08-16 | 2011-11-15 | Novozymes As | SUBTILATE |
NZ589570A (en) | 2005-09-30 | 2012-06-29 | Novozymes Inc | Methods for enhancing the degradation or conversion of cellulosic material |
WO2007036235A1 (en) | 2005-09-30 | 2007-04-05 | Novozymes A/S | Immobilization of enzymes |
WO2007107573A1 (en) | 2006-03-22 | 2007-09-27 | Novozymes A/S | Use of polypeptides having antimicrobial activity |
WO2007113241A1 (en) | 2006-03-31 | 2007-10-11 | Novozymes A/S | A stabilized liquid enzyme composition |
CA2649267C (en) | 2006-04-14 | 2014-08-12 | Genencor International, Inc. | One-step treatment of textiles |
US20090215663A1 (en) | 2006-04-20 | 2009-08-27 | Novozymes A/S | Savinase variants having an improved wash performance on egg stains |
CN101473032B (en) | 2006-06-21 | 2013-08-21 | 诺维信北美公司 | Desizing and scouring process |
DK2046819T3 (en) | 2006-07-21 | 2015-06-22 | Novozymes Inc | Methods for enhancing the secretion of polypeptides with biological activity |
AU2007284126B2 (en) | 2006-08-11 | 2013-12-19 | Novozymes Biologicals, Inc. | Bacteria cultures and compositions comprising bacteria cultures |
US20080057528A1 (en) * | 2006-08-30 | 2008-03-06 | Kimberly-Clark Worldwide, Inc. | Detection of hydrogen peroxide released by enzyme-catalyzed oxidation of an analyte |
US20080221008A1 (en) | 2006-10-06 | 2008-09-11 | Novozymes A/S | Detergent compositions and the use of enzyme combinations therein |
US20080090745A1 (en) * | 2006-10-13 | 2008-04-17 | Fox Bryan P | Expression of Streptomyces subtilism inhibitor (SSI) proteins in Bacillus and Streptomyces sp. |
US8034766B2 (en) | 2006-10-27 | 2011-10-11 | E I Du Pont De Nemours And Company | Compositions and methods for prion decontamination |
RU2459867C2 (en) | 2006-12-21 | 2012-08-27 | ДАНИСКО ЮЭс, ИНК., ДЖЕНЕНКОР ДИВИЖН | COMPOSITIONS BASED ON α-AMYLASE POLYPEPTIDE FROM BACILLUS, TYPE 195, AND USE THEREOF |
CN101617035A (en) | 2007-02-20 | 2009-12-30 | 诺维信公司 | The enzyme foam that is used to do washing is handled |
BRPI0808513A2 (en) | 2007-03-09 | 2014-08-19 | Danisco Us Inc Genencor Div | ALPHA-AMILASE VARIANTS OF ALKALIFYL BACILLUS SPECIES, COMPOSITIONS UNDERSTANDING ALPHA-AMYLASE VARIANTS AND METHODS OF USE |
AU2008226792B2 (en) | 2007-03-12 | 2013-06-06 | Danisco Us Inc. | Modified proteases |
AU2008231038B2 (en) | 2007-03-23 | 2013-07-11 | Novozymes Biologicals, Inc. | Preventing and reducing biofilm formation and planktonic proliferation |
DE102007016139A1 (en) | 2007-03-30 | 2008-10-02 | Jenabios Gmbh | Method for regioselective oxygenation of N-heterocycles |
US20100190682A1 (en) | 2007-04-30 | 2010-07-29 | Sang-Kyu Lee | Use of protein hydrolysates to stabilize metalloprotease detergent formulations |
WO2008141281A1 (en) | 2007-05-10 | 2008-11-20 | Danisco Us Inc., Genencor Division | A modified secretion system to increase expression of polypeptides in bacteria |
SG148934A1 (en) | 2007-06-11 | 2009-01-29 | Novozymes As | A process for combined biopolishing and bleach clean-up |
DE102007047433A1 (en) * | 2007-10-04 | 2009-04-09 | Lanxess Deutschland Gmbh | Liquid washing and liquid cleaning agents |
KR20100088675A (en) | 2007-11-05 | 2010-08-10 | 다니스코 유에스 인크. | Variants of bacillis sp. ts-23 alpha-amylase with altered properties |
AR069168A1 (en) | 2007-11-05 | 2010-01-06 | Danisco Us Inc Genencor Div | ALFA VARIANTS -AMILASES WITH ALTERED PROPERTIES |
CN101903519B (en) | 2007-12-21 | 2013-07-31 | 丹尼斯科美国公司 | Enhanced protein production in bacillus |
US20110034367A1 (en) | 2008-02-01 | 2011-02-10 | Novozymes A/S | Liquid Enzyme Composition |
CA2713582C (en) | 2008-02-04 | 2017-02-21 | Danisco Us Inc. | Ts23 alpha-amylase variants with altered properties |
US20090217463A1 (en) * | 2008-02-29 | 2009-09-03 | Philip Frank Souter | Detergent composition comprising lipase |
WO2009111258A2 (en) * | 2008-02-29 | 2009-09-11 | The Procter & Gamble Company | Detergent composition comprising lipase |
RU2510662C2 (en) | 2008-03-26 | 2014-04-10 | Новозимс А/С | Stabilised liquid enzyme compositions |
US9528114B2 (en) | 2008-03-28 | 2016-12-27 | Danisco Us Inc. | Method for amplifying locus in bacterial cell |
CA2722889A1 (en) | 2008-04-30 | 2009-11-05 | Danisco Us Inc. | New chimeric alpha-amylase variants |
US8691743B2 (en) | 2008-05-14 | 2014-04-08 | Novozymes A/S | Liquid detergent compositions |
EP2698434A1 (en) | 2008-06-06 | 2014-02-19 | Danisco US Inc. | Uses of an alpha-amylase from Bacillus subtilis |
MX2010013123A (en) | 2008-06-06 | 2011-01-14 | Danisco Inc | Variant alpha-amylases from bacillus subtilis and methods of use, thereof. |
JP5492879B2 (en) | 2008-06-06 | 2014-05-14 | ダニスコ・ユーエス・インク | Geobacillus stearothermophilus alpha amylase (AmyS) variant with improved properties |
DK2291526T3 (en) | 2008-06-06 | 2014-10-06 | Danisco Us Inc | SACCHARIFICATION OF ENZYME COMPOSITION WITH BACILLUS SUBTILIS ALPHA AMYLASE |
JP5661621B2 (en) | 2008-07-07 | 2015-01-28 | ビーエーエスエフ ソシエタス・ヨーロピアBasf Se | Enzyme composition comprising enzyme-containing polymer particles |
EP2149786A1 (en) | 2008-08-01 | 2010-02-03 | Unilever PLC | Improvements relating to detergent analysis |
WO2010028941A1 (en) | 2008-09-12 | 2010-03-18 | Unilever Plc | Dispenser and pretreater for viscous liquids |
BRPI0920891B1 (en) | 2008-09-25 | 2023-01-10 | Danisco Us Inc | ALPHA-AMYLASE MIXTURE AND METHOD FOR PRODUCING A FERMENTABLE SUGAR |
EP2358878B1 (en) | 2008-11-20 | 2014-10-15 | Novozymes Inc. | Polypeptides having amylolytic enhancing activity and polynucleotides encoding same |
US7771983B2 (en) | 2008-12-04 | 2010-08-10 | Novozymos, Inc. | Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same |
EP2376527A1 (en) | 2008-12-12 | 2011-10-19 | Novozymes Inc. | Polypeptides having lipase activity and polynucleotides encoding same |
EP2202290A1 (en) | 2008-12-23 | 2010-06-30 | Unilever PLC | A flowable laundry composition and packaging therefor |
EP2213723A1 (en) | 2009-01-30 | 2010-08-04 | Novozymes A/S | Isomaltose for fungus fermentation |
EP2401371A1 (en) | 2009-02-27 | 2012-01-04 | Novozymes A/S | Mutant cells having reduced expression of metallopeptidase, suitable for recombinant polypeptide production |
CN102341495A (en) | 2009-03-10 | 2012-02-01 | 丹尼斯科美国公司 | ALPHA-AMYLASES ASSOCIATED with BACILLUS MEGATERIUM DSM90, and method for using same |
MX2011010041A (en) | 2009-04-01 | 2011-11-18 | Danisco Us Inc | Compositions and methods comprising alpha-amylase variants with altered properties. |
WO2010117511A1 (en) | 2009-04-08 | 2010-10-14 | Danisco Us Inc. | Halomonas strain wdg195-related alpha-amylases, and methods of use, thereof |
AR076941A1 (en) | 2009-06-11 | 2011-07-20 | Danisco Us Inc | BACILLUS CEPA FOR A GREATER PROTEIN PRODUCTION |
EP2478096B1 (en) | 2009-09-17 | 2017-05-24 | Novozymes, Inc. | Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same |
MX2012003387A (en) | 2009-09-25 | 2012-04-10 | Novozymes As | Use of protease variants. |
AU2010299799B2 (en) | 2009-09-25 | 2015-10-29 | Novozymes A/S | Subtilase variants |
MX2012003473A (en) | 2009-09-29 | 2012-05-22 | Novozymes Inc | Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same. |
DK2483296T3 (en) | 2009-09-30 | 2015-11-02 | Novozymes Inc | Polypeptides having cellulolytic enhancing activity and polynucleotides encoding them |
BR112012007390A2 (en) | 2009-09-30 | 2015-09-15 | Novozymes As | isolated polypeptide having cellulolytic enhancing activity, isolated polynucleotide, methods for making the polypeptide, for producing a precursor cell mutant, for inhibiting expression of a polypeptide, for producing a protein, for degrading or converting a cellulosic material, for producing a product fermentation, and to ferment a cellulosic material, transgenic plant, plant part or plant cell transformed with a polynucleotide, double stranded inhibitor molecule, and detergent composition |
CA2778471A1 (en) | 2009-10-23 | 2011-04-28 | Danisco Us Inc. | Methods for reducing blue saccharide |
US20120220513A1 (en) | 2009-12-29 | 2012-08-30 | Novozymes A/S | Polypeptides Having Detergency Enhancing Effect |
US9045514B2 (en) | 2010-01-22 | 2015-06-02 | Dupont Nutrition Biosciences Aps | Methods for producing amino-substituted glycolipid compounds |
CN102884197A (en) | 2010-01-29 | 2013-01-16 | 诺维信公司 | Biogas production process with enzymatic pre-treatment |
WO2011100667A1 (en) | 2010-02-14 | 2011-08-18 | Ls9, Inc. | Surfactant and cleaning compositions comprising microbially produced branched fatty alcohols |
WO2011102933A1 (en) | 2010-02-18 | 2011-08-25 | Danisco Us Inc. | Amylase from nesterenkonia and methods of use, thereof |
CN102858968B (en) | 2010-02-25 | 2015-07-01 | 诺维信公司 | Variants of a lysozyme and polynucleotides encoding same |
KR101904484B1 (en) | 2010-04-26 | 2018-11-30 | 노보자임스 에이/에스 | Enzyme granules |
BR112012028033B1 (en) | 2010-06-22 | 2021-04-27 | Novozymes A/S | METHOD TO UNLEASH SKIN FROM RAW LEATHER OR SKIN, PROCESSES FOR DEPILATION OF RAW LEATHER OR SKIN, AND TO PREPARE A WET BLUE |
CN103154263A (en) | 2010-08-19 | 2013-06-12 | 诺维信公司 | Induced sporulation screening method |
US20130111677A1 (en) | 2010-08-30 | 2013-05-09 | Novozymes A/S | Concentrated Soak Wash |
KR20130102537A (en) | 2010-08-30 | 2013-09-17 | 노보자임스 에이/에스 | A two-soak wash |
US20130266554A1 (en) | 2010-09-16 | 2013-10-10 | Novozymes A/S | Lysozymes |
GB201015672D0 (en) | 2010-09-20 | 2010-10-27 | Unilever Plc | Improvements relating to fabric treatment compositions comprising targeted benefit agents |
EP2622070B1 (en) | 2010-09-30 | 2016-08-03 | Novozymes, Inc. | Variants of polypeptides having cellulolytic enhancing activity and polynucleotides encoding same |
MX2013003236A (en) | 2010-09-30 | 2013-05-30 | Novozymes Inc | Variants of polypeptides having cellulolytic enhancing activity and polynucleotides encoding same. |
DK2640833T3 (en) | 2010-11-18 | 2016-11-28 | Novozymes Inc | Chimeric polypeptides having cellulolytic enhancing ACTIVITY AND POLYNUCLEOTIDES ENCODING THEM |
CN103339260A (en) | 2011-01-04 | 2013-10-02 | 诺维信公司 | Process for producing biogas from pectin and lignocellulose containing material |
WO2012101149A1 (en) | 2011-01-26 | 2012-08-02 | Novozymes A/S | Storage-stable enzyme granules |
WO2012104176A1 (en) | 2011-01-31 | 2012-08-09 | Novozymes A/S | Use of browned glucose as a feed substrate |
ES2686944T3 (en) | 2011-02-15 | 2018-10-22 | Novozymes North America, Inc. | Odor mitigation in cleaning machines and cleaning processes |
WO2012110563A1 (en) | 2011-02-16 | 2012-08-23 | Novozymes A/S | Detergent compositions comprising metalloproteases |
WO2012110562A2 (en) | 2011-02-16 | 2012-08-23 | Novozymes A/S | Detergent compositions comprising metalloproteases |
US20140038876A1 (en) | 2011-02-16 | 2014-02-06 | Novozymes A/S | Detergent Compositions Comprising Mettaloproteases |
GB201102865D0 (en) | 2011-02-18 | 2011-04-06 | Danisco | Feed additive composition |
GB201102857D0 (en) | 2011-02-18 | 2011-04-06 | Danisco | Feed additive composition |
BR112013016830A2 (en) | 2011-02-23 | 2017-03-01 | Novozymes Inc | isolated polypeptide, isolated polynucleotide, method of producing the polypeptide, producing a parent cell mutant, inhibiting expression of a polypeptide, producing a protein, degrading or converting a cellulosic material, producing a fermentation product and ferment a cellulosic material, transgenic plant, plant part or plant cell transformed with a polynucleotide, double-stranded rna molecule, composition, and full broth formulation or cell culture composition |
WO2012135659A2 (en) | 2011-03-31 | 2012-10-04 | Novozymes A/S | Methods for enhancing the degradation or conversion of cellulosic material |
MX2013011617A (en) | 2011-04-08 | 2013-11-21 | Danisco Us Inc | Compositions. |
DE102011007313A1 (en) | 2011-04-13 | 2012-10-18 | Henkel Ag & Co. Kgaa | expression methods |
DK2702162T3 (en) | 2011-04-29 | 2020-05-18 | Novozymes Inc | PROCEDURES FOR IMPROVING THE DEGRADATION OR CONVERSION OF CELLULOSE SUBSTANCES |
EP2537918A1 (en) | 2011-06-20 | 2012-12-26 | The Procter & Gamble Company | Consumer products with lipase comprising coated particles |
WO2012175401A2 (en) | 2011-06-20 | 2012-12-27 | Novozymes A/S | Particulate composition |
MX349517B (en) | 2011-06-24 | 2017-08-02 | Novozymes As | Polypeptides having protease activity and polynucleotides encoding same. |
US20140106427A1 (en) | 2011-06-28 | 2014-04-17 | Novozymes A/S | Biogas From Enzyme-Treated Bagasse |
KR20140056237A (en) | 2011-06-30 | 2014-05-09 | 노보자임스 에이/에스 | Alpha-amylase variants |
CN112662734A (en) | 2011-06-30 | 2021-04-16 | 诺维信公司 | Method for screening alpha-amylase |
JP6306504B2 (en) | 2011-07-01 | 2018-04-04 | ノボザイムス アクティーゼルスカブ | Liquid detergent composition |
MX346246B (en) | 2011-07-01 | 2017-03-13 | Novozymes As | Stabilized subtilisin composition. |
US10711262B2 (en) | 2011-07-12 | 2020-07-14 | Novozymes A/S | Storage-stable enzyme granules |
CN109022518A (en) | 2011-07-22 | 2018-12-18 | 诺维信北美公司 | For pre-treating cellulosic material and the method for improving its hydrolysis |
EP2744898A1 (en) | 2011-08-15 | 2014-06-25 | Novozymes A/S | Polypeptides having cellulase activity and polynucleotides encoding same |
JP2014530598A (en) | 2011-09-22 | 2014-11-20 | ノボザイムスアクティーゼルスカブ | Polypeptide having protease activity and polynucleotide encoding the same |
TR201909896T4 (en) | 2011-09-23 | 2019-07-22 | Novozymes As | Changing color in textiles. |
EP3246404B1 (en) | 2011-10-28 | 2019-02-27 | Danisco US Inc. | Variant maltohexaose-forming alpha-amylase variants |
US10351834B2 (en) | 2011-11-21 | 2019-07-16 | Novozymes, Inc. | GH61 polypeptide variants and polynucleotides encoding same |
US9701952B2 (en) | 2011-11-25 | 2017-07-11 | Novozymes A/S | Polypeptides having lysozyme activity and polynucleotides encoding same |
WO2013076269A1 (en) | 2011-11-25 | 2013-05-30 | Novozymes A/S | Subtilase variants and polynucleotides encoding same |
WO2013083801A2 (en) | 2011-12-09 | 2013-06-13 | Novozymes A/S | Biogas from substrates comprising animal manure and enzymes |
EP3272862A1 (en) | 2011-12-16 | 2018-01-24 | Novozymes, Inc. | Polypeptides having laccase activity and polynucleotides encoding same |
CN104105403B (en) | 2011-12-19 | 2017-11-14 | 诺维信生物农业公司 | Biological insecticides method and composition |
EP2607468A1 (en) | 2011-12-20 | 2013-06-26 | Henkel AG & Co. KGaA | Detergent compositions comprising subtilase variants |
JP2015504660A (en) | 2011-12-20 | 2015-02-16 | ノボザイムス アクティーゼルスカブ | Subtilase variant and polynucleotide encoding the same |
BR112014014410A2 (en) | 2011-12-22 | 2019-09-24 | Danisco Us Inc | compositions and methods comprising a lipolytic enzyme variant |
IN2014DN03298A (en) | 2011-12-22 | 2015-06-26 | Danisco Us Inc | |
DK3382003T3 (en) | 2011-12-29 | 2021-09-06 | Novozymes As | DETERGENT COMPOSITIONS WITH LIPASE VARIANTS |
ES2644007T3 (en) | 2012-01-26 | 2017-11-27 | Novozymes A/S | Use of polypeptides with protease activity in animal feed and in detergents |
US10093911B2 (en) | 2012-02-17 | 2018-10-09 | Novozymes A/S | Subtilisin variants and polynucleotides encoding same |
ES2582608T3 (en) | 2012-02-17 | 2016-09-14 | Henkel Ag & Co. Kgaa | Detergent compositions comprising subthylase variants |
EP2823026A1 (en) | 2012-03-07 | 2015-01-14 | Novozymes A/S | Detergent composition and substitution of optical brighteners in detergent compositions |
US20150291922A1 (en) | 2012-03-29 | 2015-10-15 | Novozymes A/S | Use of Enzymes For Preparing Water Soluble Films |
CA2868308A1 (en) | 2012-04-27 | 2013-10-31 | Novozymes, Inc. | Gh61 polypeptide variants and polynucleotides encoding same |
CN104271723B (en) | 2012-05-07 | 2021-04-06 | 诺维信公司 | Polypeptides having xanthan degrading activity and nucleotides encoding same |
CA2870830A1 (en) | 2012-05-11 | 2013-11-14 | Danisco Us Inc. | Use of alpha-amylase from aspergillus clavatus for saccharification |
CN104302753A (en) | 2012-05-16 | 2015-01-21 | 诺维信公司 | Compositions comprising lipase and methods of use thereof |
EP4026902A1 (en) | 2012-06-08 | 2022-07-13 | Danisco US Inc. | Variant alpha amylases with enhanced activity on starch polymers |
EP2861749A1 (en) | 2012-06-19 | 2015-04-22 | Novozymes Bioag A/S | Enzymatic reduction of hydroperoxides |
BR112014031882A2 (en) | 2012-06-20 | 2017-08-01 | Novozymes As | use of an isolated polypeptide, polypeptide, composition, isolated polynucleotide, nucleic acid construct or expression vector, recombinant expression host cell, methods for producing a polypeptide, for enhancing the nutritional value of an animal feed, and for the treatment of protein, use of at least one polypeptide, animal feed additive, animal feed, and detergent composition |
KR101380740B1 (en) | 2012-06-29 | 2014-04-11 | 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 | Purification of iduronate-2-sulfatase |
US9150841B2 (en) | 2012-06-29 | 2015-10-06 | Shire Human Genetic Therapies, Inc. | Cells for producing recombinant iduronate-2-sulfatase |
FI3553172T3 (en) | 2012-08-16 | 2023-03-21 | Novozymes As | Method for treating textile with endoglucanase |
CN104583412A (en) | 2012-08-16 | 2015-04-29 | 丹尼斯科美国公司 | Process for producing glucose from starch employing the aspergillus clavatus alpha-amylase and a pullulanase |
CN104619838A (en) | 2012-08-22 | 2015-05-13 | 诺维信公司 | Metalloprotease from exiguobacterium |
EP2888360B1 (en) | 2012-08-22 | 2017-10-25 | Novozymes A/S | Metalloproteases from alicyclobacillus sp. |
BR112015003726A2 (en) | 2012-08-22 | 2019-09-24 | Novozymes As | detergent composition, use of a composition and a polypeptide, and method for removing a stain from a surface. |
AR093330A1 (en) | 2012-11-01 | 2015-06-03 | Novozymes As | METHOD FOR DNA REMOVAL |
US20180112203A1 (en) | 2012-11-20 | 2018-04-26 | Danisco Us Inc. | Amylase with maltogenic properties |
BR112015012982A2 (en) | 2012-12-07 | 2017-09-12 | Novozymes As | detergent composition, washing method for textile, washed textile, and use of a deoxyribonuclease |
JP6499081B2 (en) | 2012-12-11 | 2019-04-10 | ダニスコ・ユーエス・インク | Trichoderma reesei host cell expressing glucoamylase from Aspergillus fumigatus and method of use thereof |
EP2931911A1 (en) | 2012-12-14 | 2015-10-21 | Danisco US Inc. | Method of using alpha-amylase from aspergillus fumigatus and isoamylase for saccharification |
WO2014090940A1 (en) | 2012-12-14 | 2014-06-19 | Novozymes A/S | Removal of skin-derived body soils |
CN104903461A (en) | 2012-12-20 | 2015-09-09 | 丹尼斯科美国公司 | Method of using [alpha]-amylase from aspergillus terreus and pullulanase for saccharification |
CN104869841A (en) | 2012-12-21 | 2015-08-26 | 诺维信公司 | Polypeptides having protease activiy and polynucleotides encoding same |
DK3354728T3 (en) | 2012-12-21 | 2020-07-27 | Danisco Us Inc | ALPHA-amylase variants |
WO2014099525A1 (en) | 2012-12-21 | 2014-06-26 | Danisco Us Inc. | Paenibacillus curdlanolyticus amylase, and methods of use, thereof |
WO2014106593A1 (en) | 2013-01-03 | 2014-07-10 | Novozymes A/S | Alpha-amylase variants and polynucleotides encoding same |
WO2014164834A1 (en) | 2013-03-11 | 2014-10-09 | Danisco Us Inc. | Alpha-amylase combinatorial variants |
US20160024440A1 (en) | 2013-03-14 | 2016-01-28 | Novozymes A/S | Enzyme and Inhibitor Containing Water-Soluble Films |
CN111394202B (en) | 2013-04-23 | 2022-04-26 | 诺维信公司 | Liquid automatic dishwashing detergent composition with stabilized subtilisin |
US20160075976A1 (en) | 2013-05-03 | 2016-03-17 | Novozymes A/S | Microencapsulation of Detergent Enzymes |
US10351833B2 (en) | 2013-05-14 | 2019-07-16 | Novozymes A/S | Detergent compositions |
WO2014183921A1 (en) | 2013-05-17 | 2014-11-20 | Novozymes A/S | Polypeptides having alpha amylase activity |
WO2014191170A1 (en) | 2013-05-30 | 2014-12-04 | Novozymes A/S | Particulate enzyme composition |
EP3786269A1 (en) | 2013-06-06 | 2021-03-03 | Novozymes A/S | Alpha-amylase variants and polynucleotides encoding same |
PE20160799A1 (en) | 2013-06-12 | 2016-09-03 | Earth Alive Clean Tech Inc | DUST SUPPRESSOR |
WO2014200656A1 (en) | 2013-06-13 | 2014-12-18 | Danisco Us Inc. | Alpha-amylase from streptomyces umbrinus |
WO2014200657A1 (en) | 2013-06-13 | 2014-12-18 | Danisco Us Inc. | Alpha-amylase from streptomyces xiamenensis |
WO2014200658A1 (en) | 2013-06-13 | 2014-12-18 | Danisco Us Inc. | Alpha-amylase from promicromonospora vindobonensis |
EP3011020A1 (en) | 2013-06-17 | 2016-04-27 | Danisco US Inc. | Alpha-amylase from bacillaceae family member |
FI3013956T3 (en) | 2013-06-27 | 2023-05-23 | Novozymes As | Subtilase variants and polynucleotides encoding same |
US20160145596A1 (en) | 2013-06-27 | 2016-05-26 | Novozymes A/S | Subtilase Variants and Polynucleotides Encoding Same |
WO2015000969A2 (en) | 2013-07-03 | 2015-01-08 | Basf Se | Use of a gel-like polymer composition which can be obtained by polymerizing an acid group-containing monomer in the presence of a polyether compound in formulations for automatic dishwashing |
WO2015001017A2 (en) | 2013-07-04 | 2015-01-08 | Novozymes A/S | Polypeptides having anti-redeposition effect and polynucleotides encoding same |
WO2015004102A1 (en) | 2013-07-09 | 2015-01-15 | Novozymes A/S | Polypeptides with lipase activity and polynucleotides encoding same |
EP3696264B1 (en) | 2013-07-19 | 2023-06-28 | Danisco US Inc. | Compositions and methods comprising a lipolytic enzyme variant |
RU2670946C9 (en) | 2013-07-29 | 2018-11-26 | Новозимс А/С | Protease variants and polynucleotides encoding them |
CN105358684A (en) | 2013-07-29 | 2016-02-24 | 诺维信公司 | Protease variants and polynucleotides encoding same |
EP3339436B1 (en) | 2013-07-29 | 2021-03-31 | Henkel AG & Co. KGaA | Detergent composition comprising protease variants |
WO2015049370A1 (en) | 2013-10-03 | 2015-04-09 | Novozymes A/S | Detergent composition and use of detergent composition |
WO2015050723A1 (en) | 2013-10-03 | 2015-04-09 | Danisco Us Inc. | Alpha-amylases from exiguobacterium, and methods of use, thereof |
US20160186102A1 (en) | 2013-10-03 | 2016-06-30 | Danisco Us Inc. | Alpha-amylases from exiguobacterium, and methods of use, thereof |
UA119331C2 (en) | 2013-11-08 | 2019-06-10 | Новозімес Біоаґ А/С | Compositions and methods for treating pests |
WO2015077278A1 (en) | 2013-11-20 | 2015-05-28 | Novozymes Bioag A/S | Compositions and methods comprising chromobacterium for controlling plant nematode pests and plant insect pests |
MX2016006489A (en) | 2013-11-20 | 2016-08-03 | Danisco Us Inc | Variant alpha-amylases having reduced susceptibility to protease cleavage, and methods of use, thereof. |
WO2015094809A1 (en) | 2013-12-19 | 2015-06-25 | Danisco Us Inc. | Chimeric fungal alpha-amylases comprising carbohydrate binding module and the use thereof |
WO2015091989A1 (en) | 2013-12-20 | 2015-06-25 | Novozymes A/S | Polypeptides having protease activity and polynucleotides encoding same |
US10463701B2 (en) | 2013-12-31 | 2019-11-05 | DuPont Nutrition BioScience ApS | Blends of Bacillus strains and enzymes |
US10287591B2 (en) | 2013-12-31 | 2019-05-14 | Danisco Us Inc | Enhanced protein expression |
CN105849121B (en) | 2014-01-22 | 2020-12-29 | 诺维信公司 | Polypeptides having lipase activity and polynucleotides encoding same |
WO2015134729A1 (en) | 2014-03-05 | 2015-09-11 | Novozymes A/S | Compositions and methods for improving properties of non-cellulosic textile materials with xyloglucan endotransglycosylase |
WO2015134737A1 (en) | 2014-03-05 | 2015-09-11 | Novozymes A/S | Compositions and methods for improving properties of cellulosic textile materials with xyloglucan endotransglycosylase |
CN106103721B (en) | 2014-03-12 | 2020-01-03 | 诺维信公司 | Polypeptides having lipase activity and polynucleotides encoding same |
JP6591998B2 (en) * | 2014-03-28 | 2019-10-16 | ノボザイムス アクティーゼルスカブ | Resolubilization of protein crystals at low pH |
EP3126479A1 (en) | 2014-04-01 | 2017-02-08 | Novozymes A/S | Polypeptides having alpha amylase activity |
DK3129457T3 (en) | 2014-04-11 | 2018-09-17 | Novozymes As | detergent |
EP3131921B1 (en) | 2014-04-15 | 2020-06-10 | Novozymes A/S | Polypeptides with lipase activity and polynucleotides encoding same |
US10023852B2 (en) | 2014-05-27 | 2018-07-17 | Novozymes A/S | Lipase variants and polynucleotides encoding same |
WO2015181118A1 (en) | 2014-05-27 | 2015-12-03 | Novozymes A/S | Methods for producing lipases |
CN106414729A (en) | 2014-06-12 | 2017-02-15 | 诺维信公司 | Alpha-amylase variants and polynucleotides encoding same |
WO2016001319A1 (en) | 2014-07-03 | 2016-01-07 | Novozymes A/S | Improved stabilization of non-protease enzyme |
US10550381B2 (en) | 2014-07-04 | 2020-02-04 | Novozymes A/S | Variant proteases and amylases having enhanced storage stability |
EP3164486B1 (en) | 2014-07-04 | 2020-05-13 | Novozymes A/S | Subtilase variants and polynucleotides encoding same |
EP3172329A1 (en) | 2014-10-24 | 2017-05-31 | Danisco US Inc. | Method for producing alcohol by use of a tripeptidyl peptidase |
WO2016079110A2 (en) | 2014-11-19 | 2016-05-26 | Novozymes A/S | Use of enzyme for cleaning |
US10287562B2 (en) | 2014-11-20 | 2019-05-14 | Novoszymes A/S | Alicyclobacillus variants and polynucleotides encoding same |
US10457921B2 (en) | 2014-12-05 | 2019-10-29 | Novozymes A/S | Lipase variants and polynucleotides encoding same |
WO2016096714A1 (en) | 2014-12-15 | 2016-06-23 | Henkel Ag & Co. Kgaa | Detergent composition comprising subtilase variants |
JP7012533B2 (en) | 2014-12-16 | 2022-02-14 | ダニスコ・ユーエス・インク | Enhanced protein expression |
WO2016096996A1 (en) | 2014-12-16 | 2016-06-23 | Novozymes A/S | Polypeptides having n-acetyl glucosamine oxidase activity |
JP2017538433A (en) | 2014-12-19 | 2017-12-28 | ダニスコ・ユーエス・インク | Increased protein expression |
WO2016097352A1 (en) | 2014-12-19 | 2016-06-23 | Novozymes A/S | Protease variants and polynucleotides encoding same |
ES2813727T3 (en) | 2014-12-19 | 2021-03-24 | Novozymes As | Protease variants and polynucleotides that encode them |
US10798963B2 (en) | 2015-03-30 | 2020-10-13 | Societe Des Produits Nestle S.A. | Milk-based protein hydrolysates and compositions made thereof |
MX2017012515A (en) | 2015-04-06 | 2018-01-30 | Dupont Nutrition Biosci Aps | Proteases for high protein fermented milk products. |
US20180105772A1 (en) | 2015-04-10 | 2018-04-19 | Novozymes A/S | Detergent composition |
WO2016162556A1 (en) | 2015-04-10 | 2016-10-13 | Novozymes A/S | Laundry method, use of dnase and detergent composition |
EP3298121B1 (en) | 2015-05-19 | 2019-03-20 | Novozymes A/S | Odor reduction |
EP3303536B1 (en) | 2015-06-02 | 2019-04-17 | Unilever PLC | Laundry detergent composition |
ES2665989T3 (en) | 2015-06-04 | 2018-04-30 | The Procter & Gamble Company | Liquid detergent composition for dishwashing by hand |
ES2712459T3 (en) | 2015-06-04 | 2019-05-13 | Procter & Gamble | Liquid detergent composition for dishwashing by hand |
ES2666186T3 (en) | 2015-06-05 | 2018-05-03 | The Procter & Gamble Company | Compacted liquid detergent composition for laundry |
EP3101102B2 (en) | 2015-06-05 | 2023-12-13 | The Procter & Gamble Company | Compacted liquid laundry detergent composition |
EP3101107B1 (en) | 2015-06-05 | 2019-04-24 | The Procter and Gamble Company | Compacted liquid laundry detergent composition |
WO2016198262A1 (en) | 2015-06-11 | 2016-12-15 | Unilever Plc | Laundry detergent composition |
EP3310908B1 (en) | 2015-06-16 | 2020-08-05 | Novozymes A/S | Polypeptides with lipase activity and polynucleotides encoding same |
EP3310688A1 (en) | 2015-06-17 | 2018-04-25 | Novozymes A/S | Container |
BR112017027402B1 (en) | 2015-06-26 | 2022-05-10 | Unilever Ip Holdings B.V. | Detergent composition for washing clothes and method of domestic treatment of a fabric |
US20180171271A1 (en) | 2015-06-30 | 2018-06-21 | Novozymes A/S | Laundry detergent composition, method for washing and use of composition |
EP3317407B1 (en) | 2015-07-01 | 2021-05-19 | Novozymes A/S | Methods of reducing odor |
CN114292829A (en) | 2015-07-06 | 2022-04-08 | 诺维信公司 | Lipase variants and polynucleotides encoding same |
EP3350323B1 (en) | 2015-09-17 | 2021-04-14 | Novozymes A/S | Polypeptides having xanthan degrading activity and polynucleotides encoding same |
ES2794837T3 (en) | 2015-09-17 | 2020-11-19 | Henkel Ag & Co Kgaa | Detergent Compositions Comprising Polypeptides Having Xanthan Degrading Activity |
WO2017055205A1 (en) | 2015-10-01 | 2017-04-06 | Unilever Plc | Powder laundry detergent composition |
WO2017060505A1 (en) | 2015-10-07 | 2017-04-13 | Novozymes A/S | Polypeptides |
WO2017066510A1 (en) | 2015-10-14 | 2017-04-20 | Novozymes A/S | Cleaning of water filtration membranes |
WO2017064253A1 (en) | 2015-10-14 | 2017-04-20 | Novozymes A/S | Polypeptides having protease activity and polynucleotides encoding same |
WO2017064269A1 (en) | 2015-10-14 | 2017-04-20 | Novozymes A/S | Polypeptide variants |
CA2996749C (en) | 2015-10-28 | 2023-10-10 | Novozymes A/S | Detergent composition comprising amylase and protease variants |
RU2754276C2 (en) | 2015-11-09 | 2021-08-31 | ДюПон НЬЮТРИШН БАЙОСАЙЕНСИЗ АпС | Feed additive composition |
WO2017089366A1 (en) | 2015-11-24 | 2017-06-01 | Novozymes A/S | Polypeptides having protease activity and polynucleotides encoding same |
US10870838B2 (en) | 2015-12-01 | 2020-12-22 | Novozymes A/S | Methods for producing lipases |
EP3387124B1 (en) | 2015-12-09 | 2021-05-19 | Danisco US Inc. | Alpha-amylase combinatorial variants |
CA3005292A1 (en) | 2015-12-09 | 2017-06-15 | Basf Se | Method of purifying a protein from fermentation solids under desorbing conditions |
US20190002819A1 (en) | 2015-12-28 | 2019-01-03 | Novozymes Bioag A/S | Heat priming of bacterial spores |
MX2018007485A (en) | 2015-12-30 | 2018-08-01 | Novozymes As | Enzyme variants and polynucleotides encoding the same. |
CN108884451A (en) | 2016-01-29 | 2018-11-23 | 诺维信公司 | Beta glucan enzyme variants and the polynucleotides for encoding them |
EP3205392A1 (en) | 2016-02-12 | 2017-08-16 | Basf Se | Microcapsules and process for preparation of microcapsules |
EP3205393A1 (en) | 2016-02-12 | 2017-08-16 | Basf Se | Process for preparation of microcapsules |
BR112018016674B1 (en) | 2016-02-17 | 2022-06-07 | Unilever Ip Holdings B.V. | Detergent composition for washing clothes and domestic method of treating a fabric |
BR112018016129B1 (en) | 2016-02-17 | 2022-06-07 | Unilever Ip Holdings B.V. | Detergent composition for washing clothes and domestic method of treating a fabric |
WO2017162378A1 (en) | 2016-03-21 | 2017-09-28 | Unilever Plc | Laundry detergent composition |
CN109072133B (en) | 2016-03-23 | 2021-06-15 | 诺维信公司 | Use of polypeptides having dnase activity for treating textiles |
WO2017173190A2 (en) | 2016-04-01 | 2017-10-05 | Danisco Us Inc. | Alpha-amylases, compositions & methods |
WO2017173324A2 (en) | 2016-04-01 | 2017-10-05 | Danisco Us Inc. | Alpha-amylases, compositions & methods |
BR112018070468B1 (en) | 2016-04-08 | 2022-07-12 | Unilever Ip Holdings B.V | AQUEOUS LIQUID DETERGENT COMPOSITION FOR WASHING CLOTHES AND DOMESTIC FABRIC TREATMENT METHOD |
CN114480035A (en) | 2016-04-08 | 2022-05-13 | 诺维信公司 | Detergent composition and use thereof |
WO2017182295A1 (en) | 2016-04-18 | 2017-10-26 | Basf Se | Liquid cleaning compositions |
BR112018072282A2 (en) | 2016-04-29 | 2019-02-12 | Novozymes A/S | detergent compositions and uses thereof |
CN109415421B (en) | 2016-05-03 | 2023-02-28 | 诺维信公司 | Alpha-amylase variants and polynucleotides encoding same |
MX2018013556A (en) | 2016-05-09 | 2019-03-14 | Novozymes As | Variant polypeptides with improved performance and use of the same. |
US20190218479A1 (en) | 2016-05-31 | 2019-07-18 | Novozymes A/S | Stabilized Liquid Peroxide Compositions |
WO2017220422A1 (en) | 2016-06-23 | 2017-12-28 | Novozymes A/S | Use of enzymes, composition and method for removing soil |
EP3478827A1 (en) | 2016-06-30 | 2019-05-08 | Novozymes A/S | Lipase variants and compositions comprising surfactant and lipase variant |
WO2018002261A1 (en) | 2016-07-01 | 2018-01-04 | Novozymes A/S | Detergent compositions |
JP2019522988A (en) | 2016-07-05 | 2019-08-22 | ノボザイムス アクティーゼルスカブ | Pectate lyase mutant and polynucleotide encoding the same |
WO2018007573A1 (en) | 2016-07-08 | 2018-01-11 | Novozymes A/S | Detergent compositions with galactanase |
CA3027272C (en) | 2016-07-13 | 2022-06-21 | The Procter & Gamble Company | Bacillus cibi dnase variants and uses thereof |
MX2019000621A (en) | 2016-07-14 | 2019-08-01 | Basf Se | Fermentation medium comprising chelating agent. |
EP4357453A2 (en) | 2016-07-18 | 2024-04-24 | Novozymes A/S | Lipase variants, polynucleotides encoding same and the use thereof |
EP3497199A1 (en) | 2016-08-08 | 2019-06-19 | Basf Se | Liquid laundry formulation |
PL3284805T3 (en) | 2016-08-17 | 2020-07-13 | The Procter & Gamble Company | Cleaning composition comprising enzymes |
CN109844110B (en) | 2016-08-24 | 2023-06-06 | 诺维信公司 | Xanthan gum lyase variants and polynucleotides encoding same |
EP3504331A1 (en) | 2016-08-24 | 2019-07-03 | Henkel AG & Co. KGaA | Detergent compositions comprising xanthan lyase variants i |
WO2018037062A1 (en) | 2016-08-24 | 2018-03-01 | Novozymes A/S | Gh9 endoglucanase variants and polynucleotides encoding same |
CN109563451A (en) | 2016-08-24 | 2019-04-02 | 汉高股份有限及两合公司 | Detergent composition comprising GH9 endo-glucanase enzyme variants I |
CN109790491B (en) | 2016-09-27 | 2021-02-23 | 荷兰联合利华有限公司 | Household washing method |
US20200140786A1 (en) | 2016-09-29 | 2020-05-07 | Novozymes A/S | Use of enzyme for washing, method for washing and warewashing composition |
EP3519547A1 (en) | 2016-09-29 | 2019-08-07 | Novozymes A/S | Spore containing granule |
EP3532592A1 (en) | 2016-10-25 | 2019-09-04 | Novozymes A/S | Detergent compositions |
CN110072986B (en) | 2016-11-01 | 2023-04-04 | 诺维信公司 | Multi-core particles |
WO2018099762A1 (en) | 2016-12-01 | 2018-06-07 | Basf Se | Stabilization of enzymes in compositions |
US20190292493A1 (en) | 2016-12-12 | 2019-09-26 | Novozymes A/S | Use of polypeptides |
CN110023469A (en) | 2016-12-15 | 2019-07-16 | 荷兰联合利华有限公司 | Laundry detergent composition |
JP7231228B2 (en) | 2017-02-24 | 2023-03-01 | ダニスコ・ユーエス・インク | Compositions and methods for increased protein production in Bacillus licheniformis |
US11053483B2 (en) | 2017-03-31 | 2021-07-06 | Novozymes A/S | Polypeptides having DNase activity |
EP3601550A1 (en) | 2017-03-31 | 2020-02-05 | Novozymes A/S | Polypeptides having dnase activity |
JP2020515269A (en) | 2017-03-31 | 2020-05-28 | ダニスコ・ユーエス・インク | α-amylase combination mutant |
CN110651039A (en) | 2017-03-31 | 2020-01-03 | 诺维信公司 | Polypeptides having rnase activity |
US20200109388A1 (en) | 2017-04-03 | 2020-04-09 | Novozymes A/S | Recovery Process |
US20200109352A1 (en) | 2017-04-04 | 2020-04-09 | Novozymes A/S | Polypeptide compositions and uses thereof |
EP3607039A1 (en) | 2017-04-04 | 2020-02-12 | Novozymes A/S | Polypeptides |
CN110651029B (en) | 2017-04-04 | 2022-02-15 | 诺维信公司 | Glycosyl hydrolase |
EP3385362A1 (en) | 2017-04-05 | 2018-10-10 | Henkel AG & Co. KGaA | Detergent compositions comprising fungal mannanases |
ES2728758T3 (en) | 2017-04-05 | 2019-10-28 | Henkel Ag & Co Kgaa | Detergent compositions comprising bacterial mannanas |
WO2018184817A1 (en) | 2017-04-06 | 2018-10-11 | Novozymes A/S | Cleaning compositions and uses thereof |
EP3967756A1 (en) | 2017-04-06 | 2022-03-16 | Novozymes A/S | Detergent compositions and uses thereof |
WO2018184818A1 (en) | 2017-04-06 | 2018-10-11 | Novozymes A/S | Cleaning compositions and uses thereof |
US20200032170A1 (en) | 2017-04-06 | 2020-01-30 | Novozymes A/S | Cleaning compositions and uses thereof |
EP3607043A1 (en) | 2017-04-06 | 2020-02-12 | Novozymes A/S | Cleaning compositions and uses thereof |
CN110709499A (en) | 2017-04-06 | 2020-01-17 | 诺维信公司 | Cleaning composition and use thereof |
WO2018185285A1 (en) | 2017-04-06 | 2018-10-11 | Novozymes A/S | Cleaning compositions and uses thereof |
WO2018184816A1 (en) | 2017-04-06 | 2018-10-11 | Novozymes A/S | Cleaning compositions and uses thereof |
EP3619304A1 (en) | 2017-05-05 | 2020-03-11 | Novozymes A/S | Compositions comprising lipase and sulfite |
EP3401385A1 (en) | 2017-05-08 | 2018-11-14 | Henkel AG & Co. KGaA | Detergent composition comprising polypeptide comprising carbohydrate-binding domain |
WO2018206300A1 (en) | 2017-05-08 | 2018-11-15 | Novozymes A/S | Mannanase variants and polynucleotides encoding same |
WO2018206535A1 (en) | 2017-05-08 | 2018-11-15 | Novozymes A/S | Carbohydrate-binding domain and polynucleotides encoding the same |
CA3058095A1 (en) | 2017-05-08 | 2018-11-15 | Novozymes A/S | Mannanase variants and polynucleotides encoding same |
WO2018224544A1 (en) | 2017-06-08 | 2018-12-13 | Novozymes A/S | Compositions comprising polypeptides having cellulase activity and amylase activity, and uses thereof in cleaning and detergent compositions |
WO2019002356A1 (en) | 2017-06-30 | 2019-01-03 | Novozymes A/S | Enzyme slurry composition |
WO2019008035A1 (en) | 2017-07-07 | 2019-01-10 | Unilever Plc | Laundry cleaning composition |
CN110869480B (en) | 2017-07-07 | 2021-08-13 | 联合利华知识产权控股有限公司 | Whitening composition |
CN111032856A (en) | 2017-08-07 | 2020-04-17 | 诺维信公司 | Use of FCA control based on pH |
AR112778A1 (en) | 2017-08-07 | 2019-12-11 | Novozymes As | FERMENTER EQUIPPED WITH EJECTOR |
MX2020001606A (en) | 2017-08-18 | 2020-08-03 | Danisco Us Inc | Alpha-amylase variants. |
EP3655537A1 (en) | 2017-08-23 | 2020-05-27 | Danisco US Inc. | Methods and compositions for efficient genetic modifications of bacillus licheniformis strains |
WO2019038057A1 (en) | 2017-08-24 | 2019-02-28 | Novozymes A/S | Xanthan lyase variants and polynucleotides encoding same |
US11525128B2 (en) | 2017-08-24 | 2022-12-13 | Novozymes A/S | GH9 endoglucanase variants and polynucleotides encoding same |
EP3673060A1 (en) | 2017-08-24 | 2020-07-01 | Henkel AG & Co. KGaA | Detergent composition comprising xanthan lyase variants ii |
US11624059B2 (en) | 2017-08-24 | 2023-04-11 | Henkel Ag & Co. Kgaa | Detergent compositions comprising GH9 endoglucanase variants II |
EP3682010A1 (en) | 2017-09-13 | 2020-07-22 | Danisco US Inc. | Modified 5'-untranslated region (utr) sequences for increased protein production in bacillus |
US20200277553A1 (en) | 2017-09-20 | 2020-09-03 | Novozymes A/S | Use of Enzymes for Improving Water Absorption And/Or Whiteness |
WO2019057902A1 (en) | 2017-09-22 | 2019-03-28 | Novozymes A/S | Novel polypeptides |
CA3073362A1 (en) | 2017-09-27 | 2019-04-04 | Novozymes A/S | Lipase variants and microcapsule compositions comprising such lipase variants |
WO2019067390A1 (en) | 2017-09-27 | 2019-04-04 | The Procter & Gamble Company | Detergent compositions comprising lipases |
EP3692147A1 (en) | 2017-10-02 | 2020-08-12 | Novozymes A/S | Polypeptides having mannanase activity and polynucleotides encoding same |
WO2019068715A1 (en) | 2017-10-02 | 2019-04-11 | Novozymes A/S | Polypeptides having mannanase activity and polynucleotides encoding same |
WO2019076800A1 (en) | 2017-10-16 | 2019-04-25 | Novozymes A/S | Cleaning compositions and uses thereof |
US20200318037A1 (en) | 2017-10-16 | 2020-10-08 | Novozymes A/S | Low dusting granules |
WO2019076833A1 (en) | 2017-10-16 | 2019-04-25 | Novozymes A/S | Low dusting granules |
US11866748B2 (en) | 2017-10-24 | 2024-01-09 | Novozymes A/S | Compositions comprising polypeptides having mannanase activity |
CN111386340A (en) | 2017-10-27 | 2020-07-07 | 宝洁公司 | Detergent compositions comprising polypeptide variants |
US20230416706A1 (en) | 2017-10-27 | 2023-12-28 | Novozymes A/S | Dnase Variants |
DE102017125559A1 (en) | 2017-11-01 | 2019-05-02 | Henkel Ag & Co. Kgaa | CLEANSING COMPOSITIONS CONTAINING DISPERSINE II |
BR112020008711A2 (en) | 2017-11-01 | 2020-11-10 | Novozymes A/S | polypeptides and compositions comprising such polypeptides |
WO2019086530A1 (en) | 2017-11-01 | 2019-05-09 | Novozymes A/S | Polypeptides and compositions comprising such polypeptides |
US11505767B2 (en) | 2017-11-01 | 2022-11-22 | Novozymes A/S | Methods for cleansing medical devices |
DE102017125558A1 (en) | 2017-11-01 | 2019-05-02 | Henkel Ag & Co. Kgaa | CLEANING COMPOSITIONS CONTAINING DISPERSINE I |
DE102017125560A1 (en) | 2017-11-01 | 2019-05-02 | Henkel Ag & Co. Kgaa | CLEANSING COMPOSITIONS CONTAINING DISPERSINE III |
EP3703661A1 (en) | 2017-11-02 | 2020-09-09 | Danisco US Inc. | Freezing point depressed solid matrix compositions for melt granulation of enzymes |
CN111315879A (en) | 2017-11-09 | 2020-06-19 | 巴斯夫欧洲公司 | Enzyme particle coating comprising organic white pigment |
CN111465680A (en) | 2017-11-29 | 2020-07-28 | 巴斯夫欧洲公司 | Compositions, their preparation and use |
BR112020010648A2 (en) | 2017-11-30 | 2021-02-02 | Unilever N.V. | detergent composition, laundry detergent composition, method to improve enzymatic cleaning in water and use of a protease enzyme |
EP3720954A1 (en) | 2017-12-04 | 2020-10-14 | Novozymes A/S | Lipase variants and polynucleotides encoding same |
FI3735478T3 (en) | 2018-01-03 | 2023-10-26 | Danisco Us Inc | Mutant and genetically modified bacillus cells and methods thereof for increased protein production |
CN111868239A (en) | 2018-02-08 | 2020-10-30 | 诺维信公司 | Lipase, lipase variants and compositions thereof |
WO2019154954A1 (en) | 2018-02-08 | 2019-08-15 | Novozymes A/S | Lipase variants and compositions thereof |
EP3755793A1 (en) | 2018-02-23 | 2020-12-30 | Henkel AG & Co. KGaA | Detergent composition comprising xanthan lyase and endoglucanase variants |
EP3765185B1 (en) | 2018-03-13 | 2023-07-19 | Novozymes A/S | Microencapsulation using amino sugar oligomers |
EP3775190A1 (en) | 2018-03-29 | 2021-02-17 | Novozymes A/S | Mannanase variants and polynucleotides encoding same |
WO2019201793A1 (en) | 2018-04-17 | 2019-10-24 | Novozymes A/S | Polypeptides comprising carbohydrate binding activity in detergent compositions and their use in reducing wrinkles in textile or fabric. |
US11661592B2 (en) | 2018-04-19 | 2023-05-30 | Novozymes A/S | Stabilized endoglucanase variants |
WO2019201785A1 (en) | 2018-04-19 | 2019-10-24 | Novozymes A/S | Stabilized cellulase variants |
EP3784779A1 (en) | 2018-04-26 | 2021-03-03 | Basf Se | Lipase enzymes |
US20210115422A1 (en) | 2018-05-03 | 2021-04-22 | Basf Se | Amylase enzymes |
EP3775127B1 (en) | 2018-05-17 | 2022-07-20 | Unilever IP Holdings B.V. | Cleaning composition |
WO2019238761A1 (en) | 2018-06-15 | 2019-12-19 | Basf Se | Water soluble multilayer films containing wash active chemicals and enzymes |
WO2020002604A1 (en) | 2018-06-28 | 2020-01-02 | Novozymes A/S | Detergent compositions and uses thereof |
EP3814489A1 (en) | 2018-06-29 | 2021-05-05 | Novozymes A/S | Subtilase variants and compositions comprising same |
US20210071116A1 (en) | 2018-06-29 | 2021-03-11 | Novozymes A/S | Detergent Compositions and Uses Thereof |
EP3818139A1 (en) | 2018-07-02 | 2021-05-12 | Novozymes A/S | Cleaning compositions and uses thereof |
EP3818138A1 (en) | 2018-07-03 | 2021-05-12 | Novozymes A/S | Cleaning compositions and uses thereof |
WO2020008024A1 (en) | 2018-07-06 | 2020-01-09 | Novozymes A/S | Cleaning compositions and uses thereof |
EP3818140A1 (en) | 2018-07-06 | 2021-05-12 | Novozymes A/S | Cleaning compositions and uses thereof |
CN112805361A (en) | 2018-07-31 | 2021-05-14 | 丹尼斯科美国公司 | Variant alpha-amylases with amino acid substitutions that reduce PKA of generalized acids |
WO2020030623A1 (en) | 2018-08-10 | 2020-02-13 | Basf Se | Packaging unit comprising a detergent composition containing an enzyme and at least one chelating agent |
CN112703246A (en) | 2018-09-17 | 2021-04-23 | 联合利华知识产权控股有限公司 | Detergent composition |
US20210340466A1 (en) | 2018-10-01 | 2021-11-04 | Novozymes A/S | Detergent compositions and uses thereof |
WO2020070209A1 (en) | 2018-10-02 | 2020-04-09 | Novozymes A/S | Cleaning composition |
CN112969775A (en) | 2018-10-02 | 2021-06-15 | 诺维信公司 | Cleaning composition |
WO2020070014A1 (en) | 2018-10-02 | 2020-04-09 | Novozymes A/S | Cleaning composition comprising anionic surfactant and a polypeptide having rnase activity |
CN113056476A (en) | 2018-10-03 | 2021-06-29 | 诺维信公司 | Polypeptides having alpha-mannan degrading activity and polynucleotides encoding same |
WO2020070249A1 (en) | 2018-10-03 | 2020-04-09 | Novozymes A/S | Cleaning compositions |
WO2020069913A1 (en) | 2018-10-05 | 2020-04-09 | Basf Se | Compounds stabilizing hydrolases in liquids |
EP3677676A1 (en) | 2019-01-03 | 2020-07-08 | Basf Se | Compounds stabilizing amylases in liquids |
EP3861115A1 (en) | 2018-10-05 | 2021-08-11 | Basf Se | Compounds stabilizing hydrolases in liquids |
CN112805377A (en) | 2018-10-05 | 2021-05-14 | 巴斯夫欧洲公司 | Compounds for stabilizing amylases in liquids |
EP3864124A1 (en) | 2018-10-11 | 2021-08-18 | Novozymes A/S | Cleaning compositions and uses thereof |
BR112021006967A2 (en) | 2018-10-12 | 2021-07-13 | Danisco Us Inc. | alpha-amylases with mutations that improve stability in the presence of chelators |
EP3647398A1 (en) | 2018-10-31 | 2020-05-06 | Henkel AG & Co. KGaA | Cleaning compositions containing dispersins v |
EP3647397A1 (en) | 2018-10-31 | 2020-05-06 | Henkel AG & Co. KGaA | Cleaning compositions containing dispersins iv |
WO2020099491A1 (en) | 2018-11-14 | 2020-05-22 | Novozymes A/S | Oral care composition comprising a polypeptide having dnase activity |
WO2020104231A1 (en) | 2018-11-19 | 2020-05-28 | Basf Se | Powders and granules containing a chelating agent and an enzyme |
EP3884023A1 (en) | 2018-11-20 | 2021-09-29 | Unilever Global Ip Limited | Detergent composition |
WO2020104157A1 (en) | 2018-11-20 | 2020-05-28 | Unilever Plc | Detergent composition |
EP3884026A1 (en) | 2018-11-20 | 2021-09-29 | Unilever Global Ip Limited | Detergent composition |
WO2020104158A1 (en) | 2018-11-20 | 2020-05-28 | Unilever Plc | Detergent composition |
JP2022513085A (en) | 2018-11-20 | 2022-02-07 | デュポン ニュートリション バイオサイエンシス エーピーエス | Modified Robust High Tm-Phytase Ramification Group Polypeptide and Fragments thereof |
CN113056549B (en) | 2018-11-20 | 2023-03-10 | 联合利华知识产权控股有限公司 | Detergent composition |
CN113302270A (en) | 2018-12-03 | 2021-08-24 | 诺维信公司 | Low pH powder detergent compositions |
EP3891277A1 (en) | 2018-12-03 | 2021-10-13 | Novozymes A/S | Powder detergent compositions |
EP3898919A1 (en) | 2018-12-21 | 2021-10-27 | Novozymes A/S | Detergent pouch comprising metalloproteases |
WO2020127796A2 (en) | 2018-12-21 | 2020-06-25 | Novozymes A/S | Polypeptides having peptidoglycan degrading activity and polynucleotides encoding same |
US20220186177A1 (en) | 2019-02-20 | 2022-06-16 | Basf Se | Industrial fermentation process for bacillus using defined medium and magnesium feed |
EP3927809A1 (en) | 2019-02-20 | 2021-12-29 | Basf Se | Industrial fermentation process for bacillus using defined medium and trace element feed |
EP3702452A1 (en) | 2019-03-01 | 2020-09-02 | Novozymes A/S | Detergent compositions comprising two proteases |
US20220235341A1 (en) | 2019-03-21 | 2022-07-28 | Novozymes A/S | Alpha-amylase variants and polynucleotides encoding same |
US20220170001A1 (en) | 2019-03-25 | 2022-06-02 | Basf Se | Amylase Enzymes |
EP3947665A2 (en) | 2019-03-25 | 2022-02-09 | Basf Se | Amylase enzymes |
WO2020200198A1 (en) * | 2019-04-02 | 2020-10-08 | Novozymes A/S | Liquid dishwashing detergent compositions |
WO2020201403A1 (en) | 2019-04-03 | 2020-10-08 | Novozymes A/S | Polypeptides having beta-glucanase activity, polynucleotides encoding same and uses thereof in cleaning and detergent compositions |
EP3953462A1 (en) | 2019-04-10 | 2022-02-16 | Novozymes A/S | Polypeptide variants |
BR112021020439A2 (en) | 2019-04-12 | 2022-05-24 | Novozymes As | Stabilized variants of glycoside hydrolase |
WO2020229480A1 (en) | 2019-05-14 | 2020-11-19 | Basf Se | Compounds stabilizing hydrolases in liquids |
BR112021022167A2 (en) | 2019-05-16 | 2022-01-18 | Unilever Ip Holdings B V | Laundry auxiliary composition, method of delivering enzymes to fabrics, method of enhancing the softening benefit of a fabric conditioner, and use of an auxiliary laundry composition |
WO2020249546A1 (en) | 2019-06-13 | 2020-12-17 | Basf Se | Method of recovering a protein from fermentation broth using a divalent cation |
US20220306791A1 (en) | 2019-06-14 | 2022-09-29 | Basf Se | Aqueous polymer dispersions suitable as opacifiers in liquid formulations |
WO2020260006A1 (en) | 2019-06-28 | 2020-12-30 | Unilever Plc | Detergent compositions |
WO2020260038A1 (en) | 2019-06-28 | 2020-12-30 | Unilever Plc | Detergent composition |
US20220372400A1 (en) | 2019-06-28 | 2022-11-24 | Conopco, Inc., D/B/A Unilever | Detergent composition |
WO2020260040A1 (en) | 2019-06-28 | 2020-12-30 | Unilever Plc | Detergent composition |
BR112021025261A2 (en) | 2019-06-28 | 2022-04-26 | Unilever Ip Holdings B V | Detergent composition and household method for treating a fabric |
BR112021023398A2 (en) | 2019-06-28 | 2022-01-04 | Unilever Ip Holdings B V | Detergent composition, home method of treating a textile and use of an ether sulfate alcohol |
JP2022538360A (en) | 2019-07-01 | 2022-09-01 | ビーエーエスエフ ソシエタス・ヨーロピア | Peptide acetals to stabilize enzymes |
EP3994273A1 (en) | 2019-07-02 | 2022-05-11 | Basf Se | Method for preparing a fermentation medium |
WO2021001400A1 (en) | 2019-07-02 | 2021-01-07 | Novozymes A/S | Lipase variants and compositions thereof |
PL3959326T3 (en) | 2019-07-05 | 2023-10-09 | Basf Se | Industrial fermentation process for microbial cells using a fed-batch pre-culture |
CA3146541A1 (en) | 2019-07-09 | 2021-01-14 | Dupont Nutrition Biosciences Aps | Fat coated particulate enzyme compositions |
US20220403298A1 (en) | 2019-07-12 | 2022-12-22 | Novozymes A/S | Enzymatic emulsions for detergents |
CN114615894A (en) | 2019-08-16 | 2022-06-10 | 杜邦营养生物科学有限公司 | Composition for digestive tract health comprising a combination of lactobacillus strains |
JP2022545465A (en) | 2019-08-22 | 2022-10-27 | ビーエーエスエフ ソシエタス・ヨーロピア | amylase variant |
CN114787329A (en) | 2019-08-27 | 2022-07-22 | 诺维信公司 | Detergent composition |
EP4022020A1 (en) | 2019-08-27 | 2022-07-06 | Novozymes A/S | Composition comprising a lipase |
WO2021043764A1 (en) | 2019-09-02 | 2021-03-11 | Unilever Global Ip Limited | Detergent composition |
WO2021046073A1 (en) | 2019-09-05 | 2021-03-11 | Dupont Nutrition Biosciences Aps | Feed composition |
EP4031644A1 (en) | 2019-09-19 | 2022-07-27 | Novozymes A/S | Detergent composition |
CN114423851A (en) | 2019-09-19 | 2022-04-29 | 联合利华知识产权控股有限公司 | Detergent composition |
US20220340843A1 (en) | 2019-10-03 | 2022-10-27 | Novozymes A/S | Polypeptides comprising at least two carbohydrate binding domains |
AR120142A1 (en) | 2019-10-07 | 2022-02-02 | Unilever Nv | DETERGENT COMPOSITION |
WO2021074430A1 (en) | 2019-10-18 | 2021-04-22 | Basf Se | Storage-stable hydrolase containing liquids |
CN114828642A (en) | 2019-10-21 | 2022-07-29 | 杜邦营养生物科学有限公司 | Composition for digestive tract health |
US20220403359A1 (en) | 2019-10-24 | 2022-12-22 | Danisco Us Inc | Variant maltopentaose/maltohexaose-forming alpha-amylases |
US20230009832A1 (en) | 2019-11-20 | 2023-01-12 | Dupont Nutrition Biosciences Aps | Thermostable phytase variants |
CN113891931A (en) | 2019-11-29 | 2022-01-04 | 巴斯夫欧洲公司 | Compositions and polymers useful in such compositions |
WO2021115912A1 (en) | 2019-12-09 | 2021-06-17 | Basf Se | Formulations comprising a hydrophobically modified polyethyleneimine and one or more enzymes |
CN115103602A (en) | 2019-12-19 | 2022-09-23 | 杜邦营养生物科学有限公司 | Daily ration preparation |
WO2021122121A1 (en) | 2019-12-20 | 2021-06-24 | Henkel Ag & Co. Kgaa | Cleaning compositions comprising dispersins ix |
US20220411773A1 (en) | 2019-12-20 | 2022-12-29 | Novozymes A/S | Polypeptides having proteolytic activity and use thereof |
WO2021122118A1 (en) | 2019-12-20 | 2021-06-24 | Henkel Ag & Co. Kgaa | Cleaning compositions comprising dispersins vi |
EP4077617A1 (en) | 2019-12-20 | 2022-10-26 | Novozymes A/S | Stabilized liquid boron-free enzyme compositions |
KR20220121235A (en) | 2019-12-20 | 2022-08-31 | 헨켈 아게 운트 코. 카게아아 | Cleaning Composition Comprising Dispersin and Carbohydrase |
US20230340442A1 (en) | 2020-01-15 | 2023-10-26 | Danisco Us Inc. | Compositions and methods for enhanced protein production in bacillus licheniformis |
US20230407208A1 (en) | 2020-01-29 | 2023-12-21 | Conopco, Inc., D/B/A Unilever | Laundry detergent product |
WO2021152120A1 (en) | 2020-01-31 | 2021-08-05 | Novozymes A/S | Mannanase variants and polynucleotides encoding same |
WO2021152123A1 (en) | 2020-01-31 | 2021-08-05 | Novozymes A/S | Mannanase variants and polynucleotides encoding same |
WO2021158927A1 (en) | 2020-02-07 | 2021-08-12 | Dupont Nutrition Biosciences Aps | Feed compositions for animal health |
WO2021160818A1 (en) | 2020-02-14 | 2021-08-19 | Basf Se | Mannanase variants |
US20230240334A1 (en) | 2020-02-28 | 2023-08-03 | Dupont Nutrition Biosciences Aps | Feed compositions |
EP3892708A1 (en) | 2020-04-06 | 2021-10-13 | Henkel AG & Co. KGaA | Cleaning compositions comprising dispersin variants |
US20230143128A1 (en) | 2020-04-08 | 2023-05-11 | Novozymes A/S | Carbohydrate binding module variants |
WO2021214059A1 (en) | 2020-04-21 | 2021-10-28 | Novozymes A/S | Cleaning compositions comprising polypeptides having fructan degrading activity |
EP3907271A1 (en) | 2020-05-07 | 2021-11-10 | Novozymes A/S | Cleaning composition, use and method of cleaning |
EP4158011A1 (en) | 2020-05-26 | 2023-04-05 | Novozymes A/S | Subtilase variants and compositions comprising same |
CN115698246A (en) | 2020-06-08 | 2023-02-03 | 联合利华知识产权控股有限公司 | Method for increasing protease activity |
JP2023530443A (en) | 2020-06-18 | 2023-07-18 | ビーエーエスエフ ソシエタス・ヨーロピア | Composition and use thereof |
WO2021259099A1 (en) | 2020-06-24 | 2021-12-30 | Novozymes A/S | Use of cellulases for removing dust mite from textile |
EP3936593A1 (en) | 2020-07-08 | 2022-01-12 | Henkel AG & Co. KGaA | Cleaning compositions and uses thereof |
KR20230038177A (en) | 2020-07-09 | 2023-03-17 | 바스프 에스이 | composition and its application |
WO2022008732A1 (en) | 2020-07-10 | 2022-01-13 | Basf Se | Enhancing the activity of antimicrobial preservatives |
WO2022023250A1 (en) | 2020-07-27 | 2022-02-03 | Unilever Ip Holdings B.V. | Use of an enzyme and surfactant for inhibiting microorganisms |
CN116322625A (en) | 2020-08-24 | 2023-06-23 | 诺维信公司 | Oral care compositions comprising levanase |
US20230313165A1 (en) | 2020-08-25 | 2023-10-05 | Novozymes A/S | Variants of a family 44 xyloglucanase |
CN116096845A (en) | 2020-08-28 | 2023-05-09 | 联合利华知识产权控股有限公司 | Detergent composition |
CN116157496A (en) | 2020-08-28 | 2023-05-23 | 联合利华知识产权控股有限公司 | Surfactant and detergent composition |
CA3186910A1 (en) | 2020-08-28 | 2022-03-03 | Rolf Thomas Lenhard | Protease variants with improved solubility |
WO2022043042A1 (en) | 2020-08-28 | 2022-03-03 | Unilever Ip Holdings B.V. | Detergent composition |
US20230303951A1 (en) | 2020-08-28 | 2023-09-28 | Conopco, Inc., D/B/A Unilever | Detergent composition |
EP4204526B1 (en) | 2020-08-28 | 2024-04-24 | Unilever IP Holdings B.V. | Surfactant and detergent composition |
EP4213641A1 (en) | 2020-09-15 | 2023-07-26 | Novozymes A/S | Animal feed comprising insects or insect meal |
BR112023005106A2 (en) | 2020-09-22 | 2023-04-18 | Basf Se | LIQUID COMPOSITION, LIQUID DETERGENT FORMULATION, AND USES OF AT LEAST ONE DIOL (EXCEPT 1,2-PROANODIOL) AND DETERGENT FORMULATIONS |
WO2022074037A2 (en) | 2020-10-07 | 2022-04-14 | Novozymes A/S | Alpha-amylase variants |
CN117241678A (en) | 2020-10-16 | 2023-12-15 | 杜邦营养生物科学有限公司 | Feed composition for animal health |
WO2022083949A1 (en) | 2020-10-20 | 2022-04-28 | Basf Se | Compositions and their use |
EP4232539A2 (en) | 2020-10-20 | 2023-08-30 | Novozymes A/S | Use of polypeptides having dnase activity |
EP4237525A1 (en) | 2020-10-28 | 2023-09-06 | Novozymes A/S | Use of lipoxygenase |
EP4237552A2 (en) | 2020-10-29 | 2023-09-06 | Novozymes A/S | Lipase variants and compositions comprising such lipase variants |
US20230407209A1 (en) | 2020-11-13 | 2023-12-21 | Novozymes A/S | Detergent Composition Comprising a Lipase |
WO2022106400A1 (en) | 2020-11-18 | 2022-05-27 | Novozymes A/S | Combination of immunochemically different proteases |
EP4256020A1 (en) | 2020-12-07 | 2023-10-11 | Unilever IP Holdings B.V. | Detergent compositions |
AU2021394636A1 (en) | 2020-12-07 | 2023-06-08 | Unilever Global Ip Limited | Detergent compositions |
EP4015629A1 (en) | 2020-12-18 | 2022-06-22 | Basf Se | Polymer mixtures for increasing stability and performance of hydrolase-containing detergents |
EP4032966A1 (en) | 2021-01-22 | 2022-07-27 | Novozymes A/S | Liquid enzyme composition with sulfite scavenger |
US20240124805A1 (en) | 2021-01-28 | 2024-04-18 | Novozymes A/S | Lipase with low malodor generation |
WO2022169933A2 (en) | 2021-02-03 | 2022-08-11 | Dupont Nutrition Biosciences Aps | Compositions for gut health |
EP4039806A1 (en) | 2021-02-04 | 2022-08-10 | Henkel AG & Co. KGaA | Detergent composition comprising xanthan lyase and endoglucanase variants with im-proved stability |
WO2022171872A1 (en) | 2021-02-12 | 2022-08-18 | Novozymes A/S | Stabilized biological detergents |
WO2022171780A2 (en) | 2021-02-12 | 2022-08-18 | Novozymes A/S | Alpha-amylase variants |
WO2022189521A1 (en) | 2021-03-12 | 2022-09-15 | Novozymes A/S | Polypeptide variants |
WO2022194673A1 (en) | 2021-03-15 | 2022-09-22 | Novozymes A/S | Dnase variants |
EP4060036A1 (en) | 2021-03-15 | 2022-09-21 | Novozymes A/S | Polypeptide variants |
EP4314222A1 (en) | 2021-03-26 | 2024-02-07 | Novozymes A/S | Detergent composition with reduced polymer content |
WO2022268885A1 (en) | 2021-06-23 | 2022-12-29 | Novozymes A/S | Alpha-amylase polypeptides |
WO2023023644A1 (en) | 2021-08-20 | 2023-02-23 | Danisco Us Inc. | Polynucleotides encoding novel nucleases, compositions thereof and methods thereof for eliminating dna from protein preparations |
WO2023041694A1 (en) | 2021-09-20 | 2023-03-23 | Unilever Ip Holdings B.V. | Detergent composition |
AU2022349014A1 (en) | 2021-09-27 | 2024-04-04 | International N&H Denmark Aps | Feed additive compositions and methods for using the same |
WO2023061827A1 (en) | 2021-10-13 | 2023-04-20 | Basf Se | Compositions comprising polymers, polymers, and their use |
WO2023066741A1 (en) | 2021-10-20 | 2023-04-27 | Basf Se | Phosphate-free composition and methods for their manufacture and use |
WO2023088776A1 (en) | 2021-11-22 | 2023-05-25 | Basf Se | Compositions comprising polymers, polymers, and their use |
WO2023088777A1 (en) | 2021-11-22 | 2023-05-25 | Basf Se | Compositions comprising polymers, polymers, and their use |
WO2023088761A1 (en) | 2021-11-22 | 2023-05-25 | Basf Se | Compositions comprising polymers, polymers, and their use |
WO2023114988A2 (en) | 2021-12-16 | 2023-06-22 | Danisco Us Inc. | Variant maltopentaose/maltohexaose-forming alpha-amylases |
WO2023110599A2 (en) | 2021-12-17 | 2023-06-22 | Basf Se | Compositions and their applications |
WO2023116569A1 (en) | 2021-12-21 | 2023-06-29 | Novozymes A/S | Composition comprising a lipase and a booster |
EP4206309A1 (en) | 2021-12-30 | 2023-07-05 | Novozymes A/S | Protein particles with improved whiteness |
WO2023148086A1 (en) | 2022-02-04 | 2023-08-10 | Basf Se | Compositions comprising polymers, polymers, and their use |
EP4234664A1 (en) | 2022-02-24 | 2023-08-30 | Evonik Operations GmbH | Composition comprising glucolipids and enzymes |
WO2023165507A1 (en) | 2022-03-02 | 2023-09-07 | Novozymes A/S | Use of xyloglucanase for improvement of sustainability of detergents |
WO2023165950A1 (en) | 2022-03-04 | 2023-09-07 | Novozymes A/S | Dnase variants and compositions |
WO2023194204A1 (en) | 2022-04-08 | 2023-10-12 | Novozymes A/S | Hexosaminidase variants and compositions |
WO2023227332A1 (en) | 2022-05-27 | 2023-11-30 | Unilever Ip Holdings B.V. | Laundry liquid composition comprising a surfactant, an alkoxylated zwitterionic polyamine polymer and a protease |
WO2023227331A1 (en) | 2022-05-27 | 2023-11-30 | Unilever Ip Holdings B.V. | Composition comprising a specific methyl ester ethoxylate surfactant and a lipase |
WO2023227421A1 (en) | 2022-05-27 | 2023-11-30 | Unilever Ip Holdings B.V. | Laundry liquid composition comprising a surfactant, an alkoxylated zwitterionic polyamine polymer, and a fragrance |
WO2023227375A1 (en) | 2022-05-27 | 2023-11-30 | Unilever Ip Holdings B.V. | Laundry liquid composition comprising a surfactant, an aminocarboxylate, an organic acid and a fragrance |
WO2023227335A1 (en) | 2022-05-27 | 2023-11-30 | Unilever Ip Holdings B.V. | Liquid composition comprising linear alkyl benzene sulphonate, methyl ester ethoxylate and alkoxylated zwitterionic polyamine polymer |
WO2023227356A1 (en) | 2022-05-27 | 2023-11-30 | Unilever Ip Holdings B.V. | Composition containing enzyme |
CN114836408B (en) * | 2022-05-28 | 2023-09-19 | 湖北大学 | Alkaline protease containing propeptide mutant and application thereof |
WO2023233025A1 (en) | 2022-06-03 | 2023-12-07 | Unilever Ip Holdings B.V. | Liquid detergent product |
WO2023247348A1 (en) | 2022-06-21 | 2023-12-28 | Novozymes A/S | Mannanase variants and polynucleotides encoding same |
WO2023247664A2 (en) | 2022-06-24 | 2023-12-28 | Novozymes A/S | Lipase variants and compositions comprising such lipase variants |
WO2024012894A1 (en) | 2022-07-15 | 2024-01-18 | Basf Se | Alkanolamine formates for enzyme stabilization in liquid formulations |
WO2024056334A1 (en) | 2022-09-13 | 2024-03-21 | Unilever Ip Holdings B.V. | Washing machine and washing method |
WO2024056333A1 (en) | 2022-09-13 | 2024-03-21 | Unilever Ip Holdings B.V. | Washing machine and washing method |
WO2024056332A1 (en) | 2022-09-13 | 2024-03-21 | Unilever Ip Holdings B.V. | Washing machine and washing method |
WO2024056278A1 (en) | 2022-09-13 | 2024-03-21 | Unilever Ip Holdings B.V. | Washing machine and washing method |
EP4349944A1 (en) | 2022-10-05 | 2024-04-10 | Unilever IP Holdings B.V. | Laundry liquid composition |
EP4349948A1 (en) | 2022-10-05 | 2024-04-10 | Unilever IP Holdings B.V. | Laundry liquid composition |
EP4349942A1 (en) | 2022-10-05 | 2024-04-10 | Unilever IP Holdings B.V. | Laundry liquid composition |
EP4349943A1 (en) | 2022-10-05 | 2024-04-10 | Unilever IP Holdings B.V. | Laundry liquid composition |
EP4349946A1 (en) | 2022-10-05 | 2024-04-10 | Unilever IP Holdings B.V. | Unit dose fabric treatment product |
EP4349947A1 (en) | 2022-10-05 | 2024-04-10 | Unilever IP Holdings B.V. | Laundry liquid composition |
EP4349945A1 (en) | 2022-10-05 | 2024-04-10 | Unilever IP Holdings B.V. | Laundry liquid composition |
Citations (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3723250A (en) * | 1967-10-03 | 1973-03-27 | Novo Terapeutisk Labor As | Proteolytic enzymes, their production and use |
US4752585A (en) * | 1985-12-17 | 1988-06-21 | Cetus Corporation | Oxidation-resistant muteins |
US4760025A (en) * | 1984-05-29 | 1988-07-26 | Genencor, Inc. | Modified enzymes and methods for making same |
US4914031A (en) * | 1987-04-10 | 1990-04-03 | Amgen, Inc. | Subtilisin analogs |
US4980288A (en) * | 1986-02-12 | 1990-12-25 | Genex Corporation | Subtilisin with increased thermal stability |
US5116741A (en) * | 1988-04-12 | 1992-05-26 | Genex Corporation | Biosynthetic uses of thermostable proteases |
US5122449A (en) * | 1988-10-07 | 1992-06-16 | Eastman Kodak Company | Use of a protease in the extraction of chlamydial, gonococcal and herpes antigens |
US5208158A (en) * | 1990-04-19 | 1993-05-04 | Novo Nordisk A/S | Oxidation stable detergent enzymes |
US5399283A (en) * | 1986-01-15 | 1995-03-21 | Amgen Inc. | Thermally stable and pH stable subtilisin analogs and method for production thereof |
US5665587A (en) * | 1989-06-26 | 1997-09-09 | Novo Nordisk A/S | Modified subtilisins and detergent compositions containing same |
US5700676A (en) * | 1984-05-29 | 1997-12-23 | Genencor International Inc. | Modified subtilisins having amino acid alterations |
US5741694A (en) * | 1988-01-07 | 1998-04-21 | Novo Nordisk A/S | Useful mutations of bacterial alkaline protease |
US5766898A (en) * | 1990-12-05 | 1998-06-16 | Novo Nordisk A/S | Proteins with changed epitopes and methods for the production thereof |
US5837517A (en) * | 1995-05-05 | 1998-11-17 | Novo Nordisk A/S | Protease variants and compositions |
US5858757A (en) * | 1991-05-01 | 1999-01-12 | Novo Nordisk A/S | Stabilized enzymes and detergent compositions |
US6300116B1 (en) * | 1996-11-04 | 2001-10-09 | Novozymes A/S | Modified protease having improved autoproteolytic stability |
US6555355B1 (en) * | 1997-08-29 | 2003-04-29 | Novozymes, A/S | Protease variants and compositions |
US6558938B1 (en) * | 1997-08-29 | 2003-05-06 | Novozymes, A/S | Protease variants and compositions |
US6605458B1 (en) * | 1997-11-21 | 2003-08-12 | Novozymes A/S | Protease variants and compositions |
US6682924B1 (en) * | 1995-05-05 | 2004-01-27 | Novozymes A/S | Protease variants and compositions |
US20040147008A1 (en) * | 2002-11-06 | 2004-07-29 | Novozymes A/S | Subtilase variants |
US6773907B2 (en) * | 1997-11-21 | 2004-08-10 | Peter Kamp Hansen | Subtilase enzymes |
US6777218B1 (en) * | 2000-03-14 | 2004-08-17 | Novozymes A/S | Subtilase enzymes having an improved wash performance on egg stains |
US6780629B2 (en) * | 1997-11-21 | 2004-08-24 | Novozymes A/S | Subtilase enzymes |
US20040197894A1 (en) * | 2001-07-12 | 2004-10-07 | Fano Tina Sejersgard | Subtilase variants |
US20040203130A1 (en) * | 2000-04-03 | 2004-10-14 | Novozymes A/S | Subtilisin variants |
US20040241820A1 (en) * | 2000-08-21 | 2004-12-02 | Novozymes A/S | Subtilase enzymes |
US20040248273A1 (en) * | 2000-10-13 | 2004-12-09 | Novozymes A/S | Subtilase variants |
US20050181446A1 (en) * | 2000-04-28 | 2005-08-18 | Novozymes A/S | Protein variants having modified immunogenicity |
US20070161531A1 (en) * | 2005-07-08 | 2007-07-12 | Novozymes A/S | Subtilase variants |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3929887A (en) | 1970-05-18 | 1975-12-30 | Endo Lab | Alkylenepoly(aralkylamines) and the salts thereof |
IE81141B1 (en) * | 1983-06-24 | 2000-04-05 | Genencor Int | Procaryotic carbonyl hydrolases |
US5972682A (en) * | 1984-05-29 | 1999-10-26 | Genencor International, Inc. | Enzymatically active modified subtilisins |
US5013657A (en) * | 1988-04-12 | 1991-05-07 | Bryan Philip N | Subtilisin mutations |
EP0260299A4 (en) * | 1986-02-12 | 1988-11-24 | Genex Corp | Mutagenesis and screening method and product. |
US4990452A (en) * | 1986-02-12 | 1991-02-05 | Genex Corporation | Combining mutations for stabilization of subtilisin |
ES2068181T3 (en) * | 1986-04-30 | 1995-04-16 | Genencor Int | MUTANTS OF NON-HUMAN CARBONYL HYDROLASE, DNA SEQUENCES AND VECTORS CODING THEMSELVES AND HOSTS TRANSFORMED WITH THESE VECTORS. |
WO1988006624A2 (en) * | 1987-02-27 | 1988-09-07 | Gist-Brocades N.V. | Molecular cloning and expression of genes encoding proteolytic enzymes |
EP0479396B1 (en) * | 1987-02-27 | 1999-06-09 | Genencor International, Inc. | Transformation of alkalophilic bacillus strains |
JP3155984B2 (en) * | 1987-04-06 | 2001-04-16 | ノヴォザイムズ・アクティーゼルスカブ | Manipulating electrostatic interactions at metal ion binding sites for protein stabilization |
US6799287B1 (en) | 2000-05-01 | 2004-09-28 | Hewlett-Packard Development Company, L.P. | Method and apparatus for verifying error correcting codes |
-
1988
- 1988-01-07 DK DK006488A patent/DK6488D0/en not_active Application Discontinuation
-
1989
- 1989-01-06 EP EP95107678A patent/EP0675196A3/en not_active Ceased
- 1989-01-06 AT AT89901711T patent/ATE136329T1/en not_active IP Right Cessation
- 1989-01-06 WO PCT/DK1989/000002 patent/WO1989006279A1/en active IP Right Grant
- 1989-01-06 EP EP05004172A patent/EP1538204A3/en not_active Withdrawn
- 1989-01-06 JP JP1501511A patent/JPH0675504B2/en not_active Expired - Fee Related
- 1989-01-06 EP EP04025116A patent/EP1498481A1/en not_active Withdrawn
- 1989-01-06 EP EP89901711A patent/EP0396608B1/en not_active Expired - Lifetime
- 1989-01-06 DE DE68926163T patent/DE68926163T2/en not_active Expired - Fee Related
-
1990
- 1990-07-04 DK DK199001612A patent/DK175697B1/en not_active IP Right Cessation
-
1994
- 1994-02-10 JP JP6016202A patent/JP2726799B2/en not_active Expired - Lifetime
-
1995
- 1995-06-07 US US08/486,415 patent/US5741694A/en not_active Expired - Lifetime
- 1995-06-07 US US08/486,846 patent/US6506589B1/en not_active Expired - Lifetime
-
1996
- 1996-03-29 DK DK199600361A patent/DK176102B1/en not_active IP Right Cessation
-
1997
- 1997-10-01 JP JP9268984A patent/JPH10113179A/en active Pending
-
2002
- 2002-11-27 US US10/306,089 patent/US6808913B2/en not_active Expired - Fee Related
- 2002-12-05 US US10/310,730 patent/US6835821B2/en not_active Expired - Fee Related
- 2002-12-06 US US10/313,853 patent/US6908991B2/en not_active Expired - Fee Related
-
2004
- 2004-07-21 US US10/896,177 patent/US20050003986A1/en not_active Abandoned
Patent Citations (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3723250A (en) * | 1967-10-03 | 1973-03-27 | Novo Terapeutisk Labor As | Proteolytic enzymes, their production and use |
US4760025A (en) * | 1984-05-29 | 1988-07-26 | Genencor, Inc. | Modified enzymes and methods for making same |
US5700676A (en) * | 1984-05-29 | 1997-12-23 | Genencor International Inc. | Modified subtilisins having amino acid alterations |
US4752585A (en) * | 1985-12-17 | 1988-06-21 | Cetus Corporation | Oxidation-resistant muteins |
US5399283A (en) * | 1986-01-15 | 1995-03-21 | Amgen Inc. | Thermally stable and pH stable subtilisin analogs and method for production thereof |
US4980288A (en) * | 1986-02-12 | 1990-12-25 | Genex Corporation | Subtilisin with increased thermal stability |
US4914031A (en) * | 1987-04-10 | 1990-04-03 | Amgen, Inc. | Subtilisin analogs |
US5741694A (en) * | 1988-01-07 | 1998-04-21 | Novo Nordisk A/S | Useful mutations of bacterial alkaline protease |
US6808913B2 (en) * | 1988-01-07 | 2004-10-26 | Novozymes A/S | Useful mutations of bacterial alkaline protease |
US6506589B1 (en) * | 1988-01-07 | 2003-01-14 | Novozymes, A/S | Useful mutations of bacterial alkaline protease |
US5116741A (en) * | 1988-04-12 | 1992-05-26 | Genex Corporation | Biosynthetic uses of thermostable proteases |
US5122449A (en) * | 1988-10-07 | 1992-06-16 | Eastman Kodak Company | Use of a protease in the extraction of chlamydial, gonococcal and herpes antigens |
US5665587A (en) * | 1989-06-26 | 1997-09-09 | Novo Nordisk A/S | Modified subtilisins and detergent compositions containing same |
US5208158A (en) * | 1990-04-19 | 1993-05-04 | Novo Nordisk A/S | Oxidation stable detergent enzymes |
US5766898A (en) * | 1990-12-05 | 1998-06-16 | Novo Nordisk A/S | Proteins with changed epitopes and methods for the production thereof |
US5858757A (en) * | 1991-05-01 | 1999-01-12 | Novo Nordisk A/S | Stabilized enzymes and detergent compositions |
US6190900B1 (en) * | 1995-05-05 | 2001-02-20 | Novo Nordisk A/S | Subtilase variants |
US5837517A (en) * | 1995-05-05 | 1998-11-17 | Novo Nordisk A/S | Protease variants and compositions |
US6682924B1 (en) * | 1995-05-05 | 2004-01-27 | Novozymes A/S | Protease variants and compositions |
US20040023355A1 (en) * | 1995-05-05 | 2004-02-05 | Novozymes A/S | Subtilase variants |
US20020102702A1 (en) * | 1996-11-04 | 2002-08-01 | Novozymes A/S | Protease variants and compositions |
US6300116B1 (en) * | 1996-11-04 | 2001-10-09 | Novozymes A/S | Modified protease having improved autoproteolytic stability |
US7098017B2 (en) * | 1996-11-04 | 2006-08-29 | Novozymes A/S | Protease variants and compositions |
US6555355B1 (en) * | 1997-08-29 | 2003-04-29 | Novozymes, A/S | Protease variants and compositions |
US6558938B1 (en) * | 1997-08-29 | 2003-05-06 | Novozymes, A/S | Protease variants and compositions |
US20050239185A1 (en) * | 1997-08-29 | 2005-10-27 | Novozymes A/S | Protease variants and compositions |
US6921657B2 (en) * | 1997-08-29 | 2005-07-26 | Novozymes A/S | Protease variants and compositions |
US20030180933A1 (en) * | 1997-11-21 | 2003-09-25 | Novozymes A/S | Protease variants and compositions |
US6605458B1 (en) * | 1997-11-21 | 2003-08-12 | Novozymes A/S | Protease variants and compositions |
US6780629B2 (en) * | 1997-11-21 | 2004-08-24 | Novozymes A/S | Subtilase enzymes |
US7026153B2 (en) * | 1997-11-21 | 2006-04-11 | Novozymes A/S | Protease variants and compositions |
US6773907B2 (en) * | 1997-11-21 | 2004-08-10 | Peter Kamp Hansen | Subtilase enzymes |
US6777218B1 (en) * | 2000-03-14 | 2004-08-17 | Novozymes A/S | Subtilase enzymes having an improved wash performance on egg stains |
US7220566B2 (en) * | 2000-04-03 | 2007-05-22 | Novozymes A/S | Subtilisin variants |
US20040203130A1 (en) * | 2000-04-03 | 2004-10-14 | Novozymes A/S | Subtilisin variants |
US6902922B2 (en) * | 2000-04-03 | 2005-06-07 | Novozymes A/S | Subtilisin variants |
US20050181446A1 (en) * | 2000-04-28 | 2005-08-18 | Novozymes A/S | Protein variants having modified immunogenicity |
US7109016B2 (en) * | 2000-08-21 | 2006-09-19 | Novozymes A/S | Subtilase enzymes |
US20040241820A1 (en) * | 2000-08-21 | 2004-12-02 | Novozymes A/S | Subtilase enzymes |
US6893855B2 (en) * | 2000-10-13 | 2005-05-17 | Novozymes A/S | Subtilase variants |
US7192757B2 (en) * | 2000-10-13 | 2007-03-20 | Novozymes A/S | Subtilase variants |
US20040248273A1 (en) * | 2000-10-13 | 2004-12-09 | Novozymes A/S | Subtilase variants |
US20040197894A1 (en) * | 2001-07-12 | 2004-10-07 | Fano Tina Sejersgard | Subtilase variants |
US20040147008A1 (en) * | 2002-11-06 | 2004-07-29 | Novozymes A/S | Subtilase variants |
US20070161531A1 (en) * | 2005-07-08 | 2007-07-12 | Novozymes A/S | Subtilase variants |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070270574A1 (en) * | 2000-04-03 | 2007-11-22 | Novozymes A/S | Subtilisin variants |
US7605115B2 (en) * | 2000-04-03 | 2009-10-20 | Novozymas Als | Subtilisin variants |
US20040248273A1 (en) * | 2000-10-13 | 2004-12-09 | Novozymes A/S | Subtilase variants |
US7192757B2 (en) * | 2000-10-13 | 2007-03-20 | Novozymes A/S | Subtilase variants |
US10087401B2 (en) | 2012-03-16 | 2018-10-02 | Monosol, Llc | Water soluble compositions incorporating enzymes, and method of making same |
EP3354716A1 (en) | 2012-03-16 | 2018-08-01 | Monosol, LLC | Water soluble compositions incorporating enzymes, and method of making same |
WO2013138288A1 (en) | 2012-03-16 | 2013-09-19 | Monosol, Llc. | Water soluble compositions incorporating enzymes, and method of making same |
WO2013158364A1 (en) | 2012-04-16 | 2013-10-24 | Monosol, Llc | Powdered pouch and method of making same |
US9394092B2 (en) | 2012-04-16 | 2016-07-19 | Monosol, Llc | Powdered pouch and method of making same |
US9908675B2 (en) | 2012-04-16 | 2018-03-06 | Monosol, Llc | Powdered pouch and method of making same |
US10696460B2 (en) | 2012-04-16 | 2020-06-30 | Monosol, Llc | Powdered pouch and method of making same |
US11753222B2 (en) | 2012-04-16 | 2023-09-12 | Monosol, Llc | Powdered pouch and method of making same |
US11104497B2 (en) | 2014-10-03 | 2021-08-31 | Monosol, Llc | Degradable materials and packaging made from same |
US11884467B2 (en) | 2014-10-03 | 2024-01-30 | Monosol, Llc | Degradable materials and packaging made from same |
Also Published As
Publication number | Publication date |
---|---|
DK176102B1 (en) | 2006-06-12 |
DK175697B1 (en) | 2005-01-24 |
DK36196A (en) | 1996-03-29 |
US20030148495A1 (en) | 2003-08-07 |
US5741694A (en) | 1998-04-21 |
US6808913B2 (en) | 2004-10-26 |
EP0396608B1 (en) | 1996-04-03 |
EP0396608A1 (en) | 1990-11-14 |
DE68926163T2 (en) | 1996-10-02 |
US6506589B1 (en) | 2003-01-14 |
JPH0675504B2 (en) | 1994-09-28 |
EP0675196A2 (en) | 1995-10-04 |
JPH06292577A (en) | 1994-10-21 |
DE68926163D1 (en) | 1996-05-09 |
DK161290D0 (en) | 1990-07-04 |
JP2726799B2 (en) | 1998-03-11 |
EP1498481A1 (en) | 2005-01-19 |
US6908991B2 (en) | 2005-06-21 |
WO1989006279A1 (en) | 1989-07-13 |
ATE136329T1 (en) | 1996-04-15 |
EP1538204A2 (en) | 2005-06-08 |
US20030175933A1 (en) | 2003-09-18 |
JPH03503477A (en) | 1991-08-08 |
DK161290A (en) | 1990-09-07 |
EP0675196A3 (en) | 1995-11-22 |
EP1538204A3 (en) | 2007-07-04 |
US20030186378A1 (en) | 2003-10-02 |
DK6488D0 (en) | 1988-01-07 |
US6835821B2 (en) | 2004-12-28 |
JPH10113179A (en) | 1998-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6808913B2 (en) | Useful mutations of bacterial alkaline protease | |
EP0328229B2 (en) | Novel proteolytic enzymes and their use in detergents | |
JP3471797B2 (en) | Stabilizing enzymes and detergents | |
JP4611531B2 (en) | Subtilase enzyme subgroups I-S1 and I-S2 with additional amino acid residues in the active site loop region | |
JP5603164B2 (en) | Subtilase enzyme subgroups I-S1 and I-S2 with additional amino acid residues in the active site loop region | |
JP4768128B2 (en) | Subtilase enzyme subgroups I-S1 and I-S2 with additional amino acid residues in the active site loop region | |
KR100767710B1 (en) | Subtilase enzymes of the i-s1 and i-s2 sub-groups having at least one additional amino acid residue between positions 97 and 98 | |
JP4611530B2 (en) | Subtilase enzyme subgroups I-S1 and I-S2 with additional amino acid residues in the active site loop region | |
JP4611529B2 (en) | Subtilase enzyme subgroups I-S1 and I-S2 with additional amino acid residues in the active site loop region |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |